

DOCKET NO. : CHIR-0157

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Antonello Covacci, Massimo Bugnoli, John  
Telford, Rino Rappuoli and Giovanni  
Macchia

Serial No.: Unassigned

Group Art Unit: Unassigned

Filing Date: Herewith

Examiner: Unassigned

For: **HELICOBACTER PYLORI CAI ANTIGEN PROTEINS USEFUL FOR  
VACCINES AND DIAGNOSTICS**

EXPRESS MAIL LABEL NO: EL140212350US  
DATE OF DEPOSIT: July 26, 1999

Box ☒ Patent Application  
☐ Provisional ☐ Design ☐ Sequence

Assistant Commissioner for Patents  
Washington DC 20231

Sir:

PATENT APPLICATION TRANSMITTAL LETTER

Transmitted herewith for filing, please find

☒ A Utility Patent Application under 37 C.F.R. 1.53(b).

It is a continuing application, as follows:

☐ continuation ☒ divisional ☐ continuation-in-part of prior application number  
08/471,491.

☐ A Provisional Patent Application under 37 C.F.R. 1.53(c).

☐ A Design Patent Application (submitted in duplicate).

Including the following:

☐ Provisional Application Cover Sheet.

☒ New or Revised Specification, including pages 1 to 66 containing:

☒ Specification

☒ Claims

☐ Abstract

☐ Substitute Specification, including Claims and Abstract.

☐ The present application is a continuation application of Application No. \_\_\_\_\_ filed \_\_\_\_\_. The present application includes the Specification of the parent application which has been revised in accordance with the amendments filed in the parent application. Since none of those amendments incorporate new matter into the parent application, the present revised Specification also does not include new matter.

☐ The present application is a continuation application of Application No. \_\_\_\_\_ filed \_\_\_\_\_, which in turn is a continuation-in-part of Application No. \_\_\_\_\_ filed \_\_\_\_\_. The present application includes the Specification of the parent application which has been revised in accordance with the amendments filed in the parent application. Although the amendments in the parent C-I-P application may have incorporated new matter, since those are the only revisions included in the present application, the present application includes no new matter in relation to the parent application.

☒ A copy of earlier application Serial No. PCT/EP93/00472 Filed March 2, 1993, including Specification, Claims and Abstract (pages 1 - 66), to which no new matter has been added TOGETHER WITH a copy of the executed oath or declaration for such earlier application and all drawings and appendices. Such earlier application is hereby incorporated into the present application by reference.

☒ Please enter the following amendment to the Specification under the Cross-Reference to Related Applications section (or create such a section) : "This Application:

☐ is a continuation of ☒ is a divisional of ☐ claims benefit of U.S. provisional Application Serial No. 08/471,491 filed June 6, 1995, which is a divisional of U.S. application S.N. 08/256,848, filed October 21, 1994, which is a U.S. national phase application of PCT/EP93/00472, filed March 2, 1993 and PCT/EP93/00158, filed January 25, 1993, which two PCT applications claimed priority benefit of Italian application S.N. FI 92 A 000052, filed March 2, 1992.

☐ Signed Statement attached deleting inventor(s) named in the prior application.

☒ A Preliminary Amendment.

☒ 11 Sheets of ☐ Formal ☒ Informal Drawings.

☐ Petition to Accept Photographic Drawings.

☐ Petition Fee

☒ An ☐ Executed ☒ Unexecuted Declaration or Oath and Power of Attorney.

☐ An Associate Power of Attorney.

☐ An ☐ Executed ☐ Copy of Executed Assignment of the Invention to \_\_\_\_\_

☐ A Recordation Form Cover Sheet.

☐ Recordation Fee - \$40.00.

☒ The prior application is assigned of record to Chiron Corporation, Emeryville, CA.

☒ Priority is claimed under 35 U.S.C. § 119 of Patent Application No. FI 92A 000052 filed March 2, 1992 in Italy (country).

☒ A Certified Copy of each of the above applications for which priority is claimed:

☐ is enclosed.

☒ has been filed in prior application Serial No. PCT/EP93/00472 filed March 3, 1992.

- ☐ An ☐ Executed or ☐ Copy of Executed Earlier Statement Claiming Small Entity Status under 37 C.F.R. 1.9 and 1.27  
☐ is enclosed.  
☐ has been filed in prior application Serial No. \_\_\_\_\_ filed \_\_\_\_\_, said status is still proper and desired in present case.
- ☐ Diskette Containing DNA/Amino Acid Sequence Information.
- ☒ Statement to Support Submission of DNA/Amino Acid Sequence Information.
- ☐ The computer readable form in this application \_\_\_\_\_, is identical with that filed in Application Serial Number \_\_\_\_\_, filed \_\_\_\_\_. In accordance with 37 CFR 1.821(e), please use the ☐ first-filed, ☐ last-filed or ☐ only computer readable form filed in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the computer readable form that will be used for the instant application. A paper copy of the Sequence Listing is ☐ included in the originally-filed specification of the instant application, ☐ included in a separately filed preliminary amendment for incorporation into the specification.
- ☐ Information Disclosure Statement.  
☐ Attached Form 1449.  
☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.
- ☐ A copy of Petition for Extension of Time as filed in the prior case.
- ☐ Appended Material as follows: \_\_\_\_\_.
- ☒ Return Receipt Postcard (should be specifically itemized).
- ☒ Other as follows: Sequence Listing (pp. 62 - 83)  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_.



**FEE CALCULATION:**

- ☒ Cancel in this application original claims 1-37 of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)

			SMALL ENTITY		NOT SMALL ENTITY	
			RATE	FEE	RATE	FEE
PROVISIONAL APPLICATION			\$75.00	\$	\$150.00	\$
DESIGN APPLICATION			\$155.00	\$	\$310.00	\$
UTILITY APPLICATIONS BASE FEE			\$380.00	\$	\$760.00	\$760
UTILITY APPLICATION; ALL CLAIMS CALCULATED AFTER ENTRY OF ALL AMENDMENTS						
	No. Filed	No. Extra				
TOTAL CLAIMS	28- 20 =	8	\$9 each	\$	\$18 each	\$144
INDEP. CLAIMS	8- 3 =	5	\$39 each	\$	\$78 each	\$390
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM			\$130	\$	\$260	\$
ADDITIONAL FILING FEE				\$		\$534
TOTAL FILING FEE DUE				\$		\$1,294

- ☒ A Check is enclosed in the amount of \$ 1,294.
- ☒ The Commissioner is authorized to charge payment of the following fees and to refund any overpayment associated with this communication or during the pendency of this application to deposit account 23-3050. This sheet is provided in duplicate.
- ☐ The foregoing amount due.
- ☒ Any additional filing fees required, including fees for the presentation of extra claims under 37 C.F.R. 1.16.
- ☒ Any additional patent application processing fees under 37 C.F.R. 1.17 or 1.20(d).
- ☐ The issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance.
- ☒ The Commissioner is hereby requested to grant an extension of time for the appropriate length of time, should one be necessary, in connection with this filing or

any future filing submitted to the U.S. Patent and Trademark Office in the above-identified application during the pendency of this application. The Commissioner is further authorized to charge any fees related to any such extension of time to deposit account 23-3050. This sheet is provided in duplicate.

**SHOULD ANY DEFICIENCIES APPEAR** with respect to this application, including deficiencies in payment of fees, missing parts of the application or otherwise, the United States Patent and Trademark Office is respectfully requested to promptly notify the undersigned.

Date: July 26, 1999



Francis A. Paintin

Registration No. 19,386

Woodcock Washburn Kurtz  
Mackiewicz & Norris LLP  
One Liberty Place - 46th Floor  
Philadelphia PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT : COVACCI et al.  
SERIAL NO. : Unassigned GROUP: Unassigned  
FILED : Herewith EXAMINER: Unassigned  
TITLE : HELICOBACTER PYLORI CAI ANTIGEN PROTEINS  
USEFUL FOR VACCINES AND DIAGNOSTICS

Assistant Commissioner  
of Patents and Trademarks  
Washington, DC 20231

PRELIMINARY AMENDMENT

Please amend the above-identified application as follows:

In the Specification:

Please insert the enclosed pages 62 through 83 herein  
(containing Sequence Listings 1-7) into the specification after  
page 61 thereof, and renumber original pages 62 to 66 (containing  
the original claims) as pages 84 to 88.

At page 1, line 1, before the first line insert the  
following; -- This application is a divisional of U.S.  
application Serial No. 08/471,491, filed June 6, 1995, which is  
a divisional of U.S. application Serial No. 08/256,848, filed  
October 21, 1994, which is a U.S. national phase application of  
PCT/EP93/00472, filed March 2, 1993 and PCT/EP93/00158, filed  
January 25, 1993, which two PCT applications claimed priority  
benefit of Italian application Serial No. FI 92 A 000052, filed  
March 2, 1992, the entire contents of each application is  
incorporated by reference herein.--

At page 4, at line 26, delete "Fig.1 is" and insert "--Figs. 1A, 1B and 1C (SEQ. ID No.2) comprise--; at line 28, after "Fig.2" insert "--(SEQ ID No.3)--; at line 33, delete "Fig.4 (SEQ. ID No.4) and (SEQ. ID No.5) is" and insert "--Figs. 4A through 4F (SEQ. ID No.4 and SEQ. ID No.5) comprise--; and, at line 34, after "antigen." insert the following:

--The numbers along the left-hand margins of Figs. 4A, 4C and 4E designate the amino acid positions, and the numbers along the right-hand margins of Figs. 4B, 4D and 4F designate the nucleotide positions.--; at page 4, line 35, delete "Fig. 5 is" and insert "--Figs.5A, 5B and 5C (SEQ ID No.7 and SEQ ID No.6) comprise--.

In the Claims:

Cancel claims 1-37 without prejudice and insert the following claims:

-- 38. A purified protein of the *Helicobacter pylori* cytotoxin associated immunodominant (CAI) antigen.

39. The purified protein of claim 38 wherein said protein is recombinantly produced.

40. A purified protein of the *Helicobacter pylori* cytotoxin associated immunodominant (CAI) antigen comprises the amino acid sequence set forth in SEQ ID NO: 5.

41. The purified protein of claim 40 wherein said protein is recombinantly produced.

42. A polypeptide sequence of the *Helicobacter pylori* cytotoxin associated immunodominant (CAI) antigen, which polypeptide sequence: (i) comprises at least five amino acids, (ii) can be used to induce the production of antibodies to Helicobacter pylori, and (iii) exhibits substantially no contribution to toxicity.

43. The polypeptide sequence of claim 42 which comprises at least ten amino acids.

44. The polypeptide sequence of claim 42 which comprises about five to about fifteen amino acids.

45. A polypeptide sequence of the *Helicobacter pylori* cytotoxin associated immunodominant (CAI) antigen amino acid sequence set forth in SEQ ID NO: 5, which polypeptide sequence: (i) comprises at least five amino acids, (ii) can be used to induce the production of antibodies to *Helicobacter pylori*, and (iii) exhibits substantially no contribution to toxicity.

46. The polypeptide sequence of claim 45 which comprises at

least ten amino acids.

47. The polypeptide sequence of claim 45 which comprises about five to about fifteen amino acids.

48. A prophylactic or therapeutic vaccine comprising an effective amount of a polypeptide sequence of the *Helicobacter pylori* cytotoxin associated immunodominant (CAI) antigen, which polypeptide sequence: (i) comprises at least five amino acids, (ii) can be used to induce the production of antibodies to *Helicobacter pylori*, and (iii) exhibits substantially no contribution to toxicity.

49. The vaccine of claim 48 wherein said polypeptide sequence comprises at least ten amino acids.

50. The vaccine of claim 48 wherein said polypeptide sequence comprises about five to about fifteen amino acids.

51. The vaccine of claim 48 which further comprises an effective amount of a second polypeptide sequence of the *Helicobacter pylori* heat shock protein, which second polypeptide sequence: (i) comprises at least five amino acids, (ii) can be used to induce the production of antibodies to *Helicobacter*

*pylori*, and (iii) exhibits substantially no contribution to toxicity.

52. The vaccine of claim 51 wherein said second polypeptide sequence comprises at least ten amino acids.

53. The vaccine of claim 51 wherein said second polypeptide sequence comprises about five to fifteen amino acids.

54. A prophylactic or therapeutic vaccine comprising an effective amount of a polypeptide sequence of the *Helicobacter pylori* cytotoxin associated immunodominant (CAI) antigen amino acid sequence set forth in SEQ ID NO: 5, which polypeptide sequence: (i) comprises at least five amino acids, (ii) can be used to induce the production of antibodies to *Helicobacter pylori*, and (iii) exhibits substantially no contribution to toxicity.

55. The vaccine of claim 54 wherein said polypeptide sequence comprises at least ten amino acids.

56. The vaccine of claim 54 wherein said polypeptide sequence comprises about five to about fifteen amino acids.

57. The vaccine of claim 54 which further comprises an

effective amount of a second polypeptide sequence of the *Helicobacter pylori* heat shock protein amino acid, which second polypeptide sequence: (i) comprises at least five amino acids, (ii) can be used to induce the production of antibodies to *Helicobacter pylori*, and (iii) exhibits substantially no contribution to toxicity.

58. The vaccine of claim 57 wherein said second polypeptide sequence comprises at least ten amino acids.

59. The vaccine of claim 57 wherein said second polypeptide sequence comprises about five to fifteen amino acids.

60. A method of preparation of a prophylactic or therapeutic vaccine which comprises bringing into association:

(1) an effective amount of a polypeptide sequence of the *Helicobacter pylori* cytotoxin associated immunodominant (CAI) antigen, which polypeptide sequence: (i) comprises at least five amino acids, (ii) can be used to induce the production of antibodies to *Helicobacter pylori*, and (iii) exhibits substantially no contribution to toxicity, and

(2) a pharmaceutically acceptable carrier.

61. The method of claim 60 which further comprises adding



an effective amount of a second polypeptide sequence of the *Helicobacter pylori* heat shock protein, which second polypeptide sequence: (i) comprises at least five amino acids, (ii) can be used to induce the production of antibodies to *Helicobacter pylori*, and (iii) exhibits substantially no contribution to toxicity.

62. A method of preparation of a prophylactic or therapeutic vaccine which comprises bringing into association:

(1) an effective amount of a polypeptide sequence of the *Helicobacter pylori* cytotoxin associated immunodominant (CAI) antigen amino acid sequence set forth in SEQ ID NO: 5, which polypeptide sequence: (i) comprises at least five amino acids, (ii) can be used to induce the production of antibodies to *Helicobacter pylori*, and (iii) exhibits substantially no contribution to toxicity, and

(2) a pharmaceutically acceptable carrier.

63. The method of claim 62 which further comprises adding an effective amount of a second polypeptide sequence of the *Helicobacter pylori* heat shock protein, which second polypeptide sequence: (i) comprises at least five amino acids, (ii) can be used to induce the production of antibodies to *Helicobacter*

*pylori*, and (iii) exhibits substantially no contribution to toxicity.

64. A method of treatment of an individual infected with *Helicobacter pylori* comprising administering an effective amount of the vaccine as defined in claim 48.

65. A method of treatment of an individual infected with *Helicobacter pylori* comprising administering an effective amount of the vaccine as defined in claim 51.

#### REMARKS

In applicants' prior filed U.S. application Serial No. 08/471,491, filed June 6, 1995, in an Office Action dated November 26, 1996, the Examiner made a five-part restriction requirement in which Group I included original claims 4-5, 9-15, 17-19, 23-24 and 39, covering claims to the proteins including fragments thereof, vaccines and methods of preparation of vaccines and the proteins.


The claims of this application are solely drawn to the invention of Group I of applicants' 1995 application, which invention was part of the original claims in applicants' PCT/EP93/00472 application and for which applicants' declaration was made in 1994.

For the Examiner's information, applicants made a claim for priority benefit of their Italian application in the declaration of their March 2, 1993 PCT application; a certified copy of said Italian application with a sworn English translation thereof can be found in the file of applicants' PCT application.

An Information Disclosure Statement will be filed in due course. It is likely that the art cited by the Examiner and that included in the Information Disclosure Statement in applicants' parent application Serial No. 08/471,491 are the most pertinent to this invention as well.

Please call applicants' undersigned attorney if he can be of assistance in advancing the prosecution.

Respectfully submitted,

  
Francis A. Paintin  
Registration No.19,386

Date: *July 26, 1999*

WOODCOCK WASHBURN KURTZ  
MACKIEWICZ & NORRIS LLP  
One Liberty Place - 46<sup>th</sup> Floor  
Philadelphia, PA 19103  
(215) 568-3100

HELICOBACTER PYLORI PROTEINS  
USEFUL FOR VACCINES AND DIAGNOSTICS

BACKGROUND OF THE INVENTION

1. Field of the Disclosure

The present invention relates generally to certain  
5 Helicobacter pylori proteins, to the genes which express  
these proteins, and to the use of these proteins for  
diagnostic and vaccine applications.

2. Brief Description of Related Art

Helicobacter pylori is a curved, microaerophilic,  
10 gram negative bacterium that has been isolated for the first  
time in 1982 from stomach biopsies of patients with chronic  
gastritis, Warren et al., Lancet i:1273-75 (1983).  
Originally named Campylobacter pylori, it has been  
recognized to be part of a separate genus named  
15 Helicobacter, Goodwin et al., Int. J. Syst. Bacteriol.  
39:397-405 (1989). The bacterium colonizes the human  
gastric mucosa, and infection can persist for decades.  
During the last few years, the presence of the bacterium has  
been associated with chronic gastritis type B, a condition  
20 that may remain asymptomatic in most infected persons but  
increases considerably the risk of peptic ulcer and gastric  
adenocarcinoma. The most recent studies strongly suggest  
that H. pylori infection may be either a cause or a cofactor  
of type B gastritis, peptic ulcers, and gastric tumors, see  
25 e.g., Blaser, Gastroenterology 93:371-83 (1987); Dooley et  
al., New Engl. J. Med. 321:1562-66 (1989); Parsonnet et  
al., New Engl. J. Med. 325:1127-31 (1991). H. pylori is  
believed to be transmitted by the oral route, Thomas et al.,  
Lancet i:340, 1194 (1992), and the risk of infection  
30 increases with age, Graham et al., Gastroenterology  
100:1495-1501 (1991), and is facilitated by crowding, Drumm  
et al., New Engl. J. Med. 432:359-63 (1990); Blaser, Clin.  
Infect. Dis. 15:386-93 (1992). In developed countries, the  
presence of antibodies against H. pylori antigens increases  
35 from less than 20% to over 50% in people 30 and 60 years old  
respectively, Jones et al., Med. Microbio. 22:57-62 (1986);  
Morris et al., N.Z. Med. J. 99:657-59 (1986), while in

developing countries over 80% of the population are already infected by the age of 20, Graham et al., Digestive Diseases and Sciences 36:1084-88 (1991).

The nature and the role of the virulence factors of H. pylori are still poorly understood. The factors that have been identified so far include the flagella that are probably necessary to move across the mucus layer, see e.g., Leying et al., Mol. Microbiol. 6:2863-74 (1992); the urease that is necessary to neutralize the acidic environment of the stomach and to allow initial colonization, see e.g., Cussac et al., J. Bacteriol. 174:2466-73 (1992); Perez-Perez et al., J. Infect. Immun. 60:3658-3663 (1992); Austin et al., J. Bacteriol. 174:7470-73 (1992); PCT Publ. No. WO 90/04030; and a high molecular weight cytotoxic protein formed by monomers allegedly having a molecular weight of 87 kDa that causes formation of vacuoles in eukaryotic epithelial cells and is produced by H. pylori strains associated with disease, see e.g., Cover et al., J. Bio. Chem. 267:10570-75 (1992) (referencing a "vacuolating toxin" with a specified 23 amino acid N-terminal sequence) ; Cover et al., J. Clin. Invest. 90:913-18 (1992); Leunk, Rev. Infect. Dis. 13:5686-89 (1991). Additionally, the following is also known.

H. pylori culture supernatants have been shown by different authors to contain an antigen with a molecular weight of 120, 128, or 130 kDa, Apel et al., Zentralblatt fur Bakteriologie. Microb. und Hygiene 268:271-76 (1988); Crabtree et al., J. Clin. Pathol 45:733-34 (1992); Cover et al., Infect. Immun. 58:603-10 (1990); Figura et al., H. pylori, gastritis and peptic ulcer (eds. Malfrtheiner et al.), Springer Verlag, Berlin (1990). Whether the difference in size of the antigen described was due to interlaboratory differences in estimating the molecular weight of the same protein, to the size variability of the same antigen, or to actual different proteins was not clear. No nucleotide or amino acid sequence information was given about the protein. This protein is very immunogenic in infected humans because specific antibodies are detected in sera of virtually all patients infected with H. pylori, Gerstenecker et al., Eur.

J. Clin. Microbiol. 11:595-601 (1992).

H. pylori heat shock proteins (hsp) have been described, Evans et al., Infect. Immun. 60:2125-27 (1992) (44 amino acid N-terminal sequence and a molecular weight of about 62 kDa); Dunn et al., Infect. Immun. 60:1946-51 (1992) (33 amino acids found in the N-terminal sequence and a molecular weight of about 54 kDa); Austin et al., J. Bacteriol. 174:7470-73 (1992) (37 amino acids found in the N-terminal sequence and a molecular weight of about 60 kDa). Austin et al. suggest that these are, in fact, the same protein with identical amino acid sequences at their N-terminus.

For examples of diagnostic tests based on H. pylori lysates or semipurified antigens, see Evans et al., Gastroenterology 96:1004-08 (1989); U.S. 4,882,271; PCT Publ. No. WO 89/08843 (all relating to compositions and assays containing the same having high molecular weight antigens (300-700 kDa) from the outer membrane surface with urease activity); EPO Publ. No. 329 570 (relating to antigenic compositions for detecting H. pylori antibodies having fragments of at least one fragment from the group 63, 57, 45, and 31 kDa).

The percentage of people infected by H. pylori, either in a symptomatic or an asymptomatic form, is very high in both developing and developed countries, and the cost of hospitalization and therapy makes desirable the development of both H. pylori vaccines and further diagnostic tests for this disease.

#### SUMMARY OF THE INVENTION

The present invention describes nucleotide and amino acid sequences for three major H. pylori proteins. Specifically, these are the cytotoxin, the "Cytotoxin Associated Immunodominant" (CAI) antigen, and the heat shock protein. None of the complete amino acid sequences for these proteins has been known, nor have their genes been identified. The present invention pertains to not only these purified proteins and their genes, but also recombinant materials associated therewith, such as vectors

and host cells. The understanding at the molecular level of the nature and the role of these proteins and the availability of recombinant production has important implications for the development of new diagnostics for H. pylori and for the design of vaccines that may prevent H. pylori infection and treat disease.

As such, these proteins can be used in both vaccine and diagnostic applications. The present invention includes methods for treating and diagnosing those diseases associated with H. pylori. As H. pylori has been associated with type B gastritis, peptic ulcers, and gastric adenocarcinoma, it is hoped that the present invention will assist in early detection and alleviation of these disease states. Currently, diagnosis relies mostly on endoscopy and histological staining of biopsies; existing immunoassays are based on H. pylori lysates or semi-purified antigens. Given the heterogeneity found in such assays, correlation with disease state is not yet well established. Thus, the potential for recombinant antigen-based immunoassays, as well as nucleic acid assays for disease detection, is great. At present, there is no commercial vaccine for H. pylori infection or treatment. A recombinant vaccine is thus an object of the present invention.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is the nucleotide sequence for the cytotoxin (CT) protein.

Fig. 2 is the amino acid sequence for the cytotoxin (CT) protein.

Fig. 3 is a map of the cai gene for the CAI protein and summary of the clones used to identify and sequence this gene.

Fig. 4 is the nucleotide and amino acid sequences of the CAI antigen.

Fig. 5 is the nucleotide and amino acid sequences of the heat shock protein (hsp).

#### DETAILED DESCRIPTION OF THE INVENTION

##### A. General Methodology

The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature. See e.g., Sambrook, et al., MOLECULAR CLONING; A LABORATORY MANUAL, SECOND EDITION (1989); DNA CLONING, VOLUMES I AND II (D.N Glover ed. 1985); OLIGONUCLEOTIDE SYNTHESIS (M.J. Gait ed, 1984); NUCLEIC ACID HYBRIDIZATION (B.D. Hames & S.J. Higgins eds. 1984); TRANSCRIPTION AND TRANSLATION (B.D. Hames & S.J. Higgins eds. 1984); ANIMAL CELL CULTURE (R.I. Freshney ed. 1986); IMMOBILIZED CELLS AND ENZYMES (IRL Press, 1986); B. Perbal, A PRACTICAL GUIDE TO MOLECULAR CLONING (1984); the series, METHODS IN ENZYMOLOGY (Academic Press, Inc.); GENE TRANSFER VECTORS FOR MAMMALIAN CELLS (J.H. Miller and M.P. Calos eds. 1987, Cold Spring Harbor Laboratory), Methods in Enzymology Vol. 154 and Vol. 155 (Wu and Grossman, and Wu, eds., respectively), Mayer and Walker, eds. (1987), IMMUNOCHEMICAL METHODS IN CELL AND MOLECULAR BIOLOGY (Academic Press, London), Scopes, (1987), PROTEIN PURIFICATION: PRINCIPLES AND PRACTICE, Second Edition (Springer-Verlag, N.Y.), and HANDBOOK OF EXPERIMENTAL IMMUNOLOGY, VOLUMES I-IV (D.M. Weir and C. C. Blackwell eds 1986).

Standard abbreviations for nucleotides and amino acids are used in this specification. All publications, patents, and patent applications cited herein are incorporated by reference.

#### B. Definitions

"Cytotoxin" or "toxin" of H. pylori refers to the protein, and fragments thereof, whose nucleotide sequence and amino acid sequences are shown in Figs. 1 and 2, respectively, and their derivatives, and whose molecular weight is about 140 kDa. This protein serves as a precursor to a protein having an approximate weight of 100 kDa and having cytotoxic activity. The cytotoxin causes vacuolation and death of a number of eukaryotic cell types and has been purified from H. pylori culture supernatants. Additionally,



the cytotoxin is proteinaceous and has an apparent molecular mass determined by gel filtration of approximately 950-972 kDa. Denaturing gel electrophoresis of purified material previously revealed that the principal component of the 950-972 kDa molecule was allegedly a polypeptide of apparent molecular mass of 87 kDa, Cover et al., J. Biol. Chem. 267:10570-75 1992). It is suggested herein, however, that the previously described 87 kDa results from either the further processing of the 100 kDa protein or from proteolytic degradation of a larger protein during purification.

The "Cytotoxin Associated Immunodominant" (CAI) antigen refers to that protein, and fragments thereof, whose amino acid sequence is described in Fig. 4 and derivatives thereof. This is an hydrophilic, surface-exposed protein having a molecular weight of approximately 120-132 kDa, preferably 128-130 kDa, produced by clinical isolates. The size of the gene and of the encoded protein varies in different strains by a mechanism that involves duplication of regions internal to the gene. The clinical isolates that do not produce the CAI antigen, do not have the cai gene, and are also unable to produce an active cytotoxin. The association between the presence of the cai gene and cytotoxicity suggests that the product of the cai gene is necessary for the transcription, folding, export or function of the cytotoxin. Alternatively, both the cytotoxin (CT) and the cai gene are absent in noncytotoxic strains. This would imply some physical linkage between the two genes. A peculiar property of the CAI antigen is the size variability, suggesting that the cai gene is continuously changing. The CAI antigen appears to be associated to the cell surface. This suggests that the release of the antigen in the supernatant may be due to the action of proteases present in the serum that may cleave either the antigen itself, or the complexes that hold the CAI antigen associated to the bacterial surface. Similar processing activities may release the antigen during in vivo growth. The absence of a typical leader peptide sequence suggests the presence of an independent export system.

"Heat shock protein" (hsp) refers to the H. pylori protein, and fragments thereof, whose amino acid sequence is given in Fig. 5 and derivatives thereof, and whose molecular weight is in the range of 54-62 kDa, preferably about 58-60 kDa. This hsp belongs to the group of Gram negative bacteria heat shock proteins, hsp60. In general, hsp are among the most conserved proteins in all living organisms, either prokaryotic and eukaryotic, animals and plants, and the conservation is spread along the whole sequence. This high conservation suggests a participation of the whole sequence at the functional structure of the protein that can be hardly modified without impairing its activity.

Examples of proteins that can be used in the present invention include polypeptides with minor amino acid variations from the natural amino acid sequence of the protein; in particular, conservative amino acid replacements are contemplated. Conservative replacements are those that take place within a family of amino acids that are related in their side chains. Genetically encoded amino acids are generally divided into four families: (1) acidic = aspartate, glutamate; (2) basic = lysine, arginine, histidine; (3) non-polar = alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar = glycine, asparagine, glutamine, cystine, serine, threonine, tyrosine. Phenylalanine, tryptophan, and tyrosine are sometimes classified jointly as aromatic amino acids. For example, it is reasonably predictable that an isolated replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, a threonine with a serine, or a similar conservative replacement of an amino acid with a structurally related amino acid will not have a major effect on the biological activity. Polypeptide molecules having substantially the same amino acid sequence as the protein but possessing minor amino acid substitutions that do not substantially affect the functional aspects are within the definition of the protein.

A significant advantage of producing the protein by recombinant DNA techniques rather than by isolating and

purifying a protein from natural sources is that equivalent quantities of the protein can be produced by using less starting material than would be required for isolating the protein from a natural source. Producing the protein by recombinant techniques also permits the protein to be isolated in the absence of some molecules normally present in cells. Indeed, protein compositions entirely free of any trace of human protein contaminants can readily be produced because the only human protein produced by the recombinant non-human host is the recombinant protein at issue. Potential viral agents from natural sources and viral components pathogenic to humans are also avoided.

The term "recombinant polynucleotide" as used herein intends a polynucleotide of genomic, cDNA, semisynthetic, or synthetic origin which, by virtue of its origin or manipulation: (1) is not associated with all or a portion of a polynucleotide with which it is associated in nature, (2) is linked to a polynucleotide other than that to which it is linked in nature, or (3) does not occur in nature. Thus, this term also encompasses the situation wherein the H. pylori bacterium genome is genetically modified (e.g., through mutagenesis) to produce one or more altered polypeptides.

The term "polynucleotide" as used herein refers to a polymeric form of a nucleotide of any length, preferably deoxyribonucleotides, and is used interchangeably herein with the terms "oligonucleotide" and "oligomer." The term refers only to the primary structure of the molecule. Thus, this term includes double- and single-stranded DNA, as well as antisense polynucleotides. It also includes known types of modifications, for example, the presence of labels which are known in the art, methylation, end "caps," substitution of one or more of the naturally occurring nucleotides with an analog, internucleotide modifications such as, for example, replacement with certain types of uncharged linkages (e.g., methyl phosphonates, phosphotriesters, phosphoamidates, carbamates, etc.) or charged linkages (e.g., phosphorothioates, phosphorodithioates, etc.), introduction of pendant moieties, such as, for example,

proteins (including nucleases, toxins, antibodies, signal peptides, poly-L-lysine, etc.), intercalators (e.g., acridine, psoralen, etc.), chelators (e.g., metals, radioactive species, boron, oxidative moieties, etc.),  
5 alkylators (e.g., alpha anomeric nucleic acids, etc.).

By "genomic" is meant a collection or library of DNA molecules which are derived from restriction fragments that have been cloned in vectors. This may include all or part of the genetic material of an organism.

10 By "cDNA" is meant a complimentary mRNA sequence that hybridizes to a complimentary strand of mRNA.

As used herein, the term "oligomer" refers to both primers and probes and is used interchangeably herein with the term "polynucleotide." The term oligomer does not  
15 connote the size of the molecule. However, typically oligomers are no greater than 1000 nucleotides, more typically are no greater than 500 nucleotides, even more typically are no greater than 250 nucleotides; they may be no greater than 100 nucleotides, and may be no greater than 75 nucleotides,  
20 and also may be no greater than 50 nucleotides in length.

The term "primer" as used herein refers to an oligomer which is capable of acting as a point of initiation of synthesis of a polynucleotide strand when used under appropriate conditions. The primer will be completely or  
25 substantially complementary to a region of the polynucleotide strand to be copied. Thus, under conditions conducive to hybridization, the primer will anneal to the complementary region of the analyte strand. Upon addition of suitable reactants, (e.g., a polymerase, nucleotide triphosphates, and the like), the primer will be extended by  
30 the polymerizing agent to form a copy of the analyte strand. The primer may be single-stranded or alternatively may be partially or fully double-stranded.

The terms "analyte polynucleotide" and "analyte strand" refer to a single- or double-stranded nucleic acid  
35 molecule which is suspected of containing a target sequence, and which may be present in a biological sample.

As used herein, the term "probe" refers to a structure comprised of a polynucleotide which forms a hybrid

structure with a target sequence, due to complementarity of at least one sequence in the probe with a sequence in the target region. The polynucleotide regions of probes may be composed of DNA, and/or RNA, and/or synthetic nucleotide analogs. Included within probes are "capture probes" and "label probes".

As used herein, the term "target region" refers to a region of the nucleic acid which is to be amplified and/or detected. The term "target sequence" refers to a sequence with which a probe or primer will form a stable hybrid under desired conditions.

The term "capture probe" as used herein refers to a polynucleotide probe comprised of a single-stranded polynucleotide coupled to a binding partner. The single-stranded polynucleotide is comprised of a targeting polynucleotide sequence, which is complementary to a target sequence in a target region to be detected in the analyte polynucleotide. This complementary region is of sufficient length and complementarity to the target sequence to afford a duplex of stability which is sufficient to immobilize the analyte polynucleotide to a solid surface (via the binding partners). The binding partner is specific for a second binding partner; the second binding partner can be bound to the surface of a solid support, or may be linked indirectly via other structures or binding partners to a solid support.

The term "targeting polynucleotide sequence" as used herein refers to a polynucleotide sequence which is comprised of nucleotides which are complementary to a target nucleotide sequence; the sequence is of sufficient length and complementarity with the target sequence to form a duplex which has sufficient stability for the purpose intended.

The term "binding partner" as used herein refers to a molecule capable of binding a ligand molecule with high specificity, as for example an antigen and an antibody specific therefor. In general, the specific binding partners must bind with sufficient affinity to immobilize the analyte copy/complementary strand duplex (in the case of

capture probes) under the isolation conditions. Specific binding partners are known in the art, and include, for example, biotin and avidin or streptavidin, IgG and protein A, the numerous known receptor-ligand couples, and  
5 complementary polynucleotide strands. In the case of complementary polynucleotide binding partners, the partners are normally at least about 15 bases in length, and may be at least 40 bases in length; in addition, they have a content of Gs and Cs of at least about 40% and as much as  
10 about 60%. The polynucleotides may be composed of DNA, RNA, or synthetic nucleotide analogs.

The term "coupled" as used herein refers to attachment by covalent bonds or by strong non-covalent interactions (e.g., hydrophobic interactions, hydrogen  
15 bonds, etc.). Covalent bonds may be, for example, ester, ether, phosphoester, amide, peptide, imide, carbon-sulfur bonds, carbon-phosphorus bonds, and the like.

The term "support" refers to any solid or semi-solid surface to which a desired binding partner may be anchored. Suitable supports include glass, plastic, metal,  
20 polymer gels, and the like, and may take the form of beads, wells, dipsticks, membranes, and the like.

The term "label" as used herein refers to any atom or moiety which can be used to provide a detectable  
25 (preferably quantifiable) signal, and which can be attached to a polynucleotide or polypeptide.

As used herein, the term "label probe" refers to a polynucleotide probe which is comprised of a targeting polynucleotide sequence which is complementary to a target  
30 sequence to be detected in the analyte polynucleotide. This complementary region is of sufficient length and complementarily to the target sequence to afford a duplex comprised of the "label probe" and the "target sequence" to be detected by the label. The label probe is coupled to a  
35 label either directly, or indirectly via a set of ligand molecules with high specificity for each other, including multimers.

The term "multimer," as used herein, refers to linear or branched polymers of the same repeating

single-stranded polynucleotide unit or different single-stranded polynucleotide units. At least one of the units has a sequence, length, and composition that permits it to hybridize specifically to a first single-stranded nucleotide sequence of interest, typically an analyte or a polynucleotide probe (e.g., a label probe) bound to an analyte. In order to achieve such specificity and stability, this unit will normally be at least about 15 nucleotides in length, typically no more than about 50 nucleotides in length, and preferably about 30 nucleotides in length; moreover, the content of Gs and Cs will normally be at least about 40%, and at most about 60%. In addition to such unit(s), the multimer includes a multiplicity of units that are capable of hybridizing specifically and stably to a second single-stranded nucleotide of interest, typically a labeled polynucleotide or another multimer. These units are generally about the same size and composition as the multimers discussed above. When a multimer is designed to be hybridized to another multimer, the first and second oligonucleotide units are heterogeneous (different), and do not hybridize with each other under the conditions of the selected assay. Thus, multimers may be label probes, or may be ligands which couple the label to the probe.

A "replicon" is any genetic element, e.g., a plasmid, a chromosome, a virus, a cosmid, etc. that behaves as an autonomous unit of polynucleotide replication within a cell; i.e., capable of replication under its own control. This may include selectable markers.

"PCR" refers to the technique of polymerase chain reaction as described in Saiki, et al., Nature 324:163 (1986); and Scharf et al., Science (1986) 233:1076-1078; and U.S. 4,683,195; and U.S. 4,683,202.

As used herein, x is "heterologous" with respect to y if x is not naturally associated with y in the identical manner; i.e., x is not associated with y in nature or x is not associated with y in the same manner as is found in nature.

"Homology" refers to the degree of similarity

between x and y. The correspondence between the sequence from one form to another can be determined by techniques known in the art. For example, they can be determined by a direct comparison of the sequence information of the polynucleotide. Alternatively, homology can be determined by hybridization of the polynucleotides under conditions which form stable duplexes between homologous regions (for example, those which would be used prior to  $S_1$  digestion), followed by digestion with single-stranded specific nuclease(s), followed by size determination of the digested fragments.

A "vector" is a replicon in which another polynucleotide segment is attached, so as to bring about the replication and/or expression of the attached segment.

"Control sequence" refers to polynucleotide sequences which are necessary to effect the expression of coding sequences to which they are ligated. The nature of such control sequences differs depending upon the host organism; in prokaryotes, such control sequences generally include promoter, ribosomal binding site, and transcription termination sequence; in eukaryotes, generally, such control sequences include promoters and transcription termination sequence. The term "control sequences" is intended to include, at a minimum, all components whose presence is necessary for expression, and may also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences.

"Operably linked" refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner. A control sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.

An "open reading frame" (ORF) is a region of a polynucleotide sequence which encodes a polypeptide; this region may represent a portion of a coding sequence or a total coding sequence.

A "coding sequence" is a polynucleotide sequence



which is translated into a polypeptide, usually via mRNA, when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a translation start codon at the 5'-terminus and a translation stop codon at the 3'-terminus. A coding sequence can include, but is not limited to, cDNA, and recombinant polynucleotide sequences.

As used herein, the term "polypeptide" refers to a polymer of amino acids and does not refer to a specific length of the product; thus, peptides, oligopeptides, and proteins are included within the definition of polypeptide. This term also does not refer to or exclude post expression modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations and the like. Included within the definition are, for example, polypeptides containing one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), polypeptides with substituted linkages, as well as other modifications known in the art, both naturally occurring and non-naturally occurring.

A polypeptide or amino acid sequence "derived from" a designated nucleic acid sequence refers to a polypeptide having an amino acid sequence identical to that of a polypeptide encoded in the sequence, or a portion thereof wherein the portion consists of at least 3-5 amino acids, and more preferably at least 8-10 amino acids, and even more preferably at least 11-15 amino acids, or which is immunologically identifiable with a polypeptide encoded in the sequence. This terminology also includes a polypeptide expressed from a designated nucleic acid sequence.

"Immunogenic" refers to the ability of a polypeptide to cause a humoral and/or cellular immune response, whether alone or when linked to a carrier, in the presence or absence of an adjuvant. "Neutralization" refers to an immune response that blocks the infectivity, either partially or fully, of an infectious agent.

"Epitope" refers to an antigenic determinant of a peptide, polypeptide, or protein; an epitope can comprise 3 or more amino acids in a spatial conformation unique to the

epitope. Generally, an epitope consists of at least 5 such amino acids and, more usually, consists of at least 8-10 such amino acids. Methods of determining spatial conformation of amino acids are known in the art and  
5 include, for example, x-ray crystallography and 2-dimensional nuclear magnetic resonance. Antibodies that recognize the same epitope can be identified in a simple immunoassay showing the ability of one antibody to block the binding of another antibody to a target antigen.

10 "Treatment," as used herein, refers to prophylaxis and/or therapy (i.e., the modulation of any disease symptoms). An "individual" indicates an animal that is susceptible to infection by H. pylori and includes, but is not limited to, primates, including humans. A "vaccine" is  
15 an immunogenic, or otherwise capable of eliciting protection against H. pylori, whether partial or complete, composition useful for treatment of an individual.

The H. pylori proteins may be used for producing antibodies, either monoclonal or polyclonal, specific to the  
20 proteins. The methods for producing these antibodies are known in the art.

"Recombinant host cells", "host cells," "cells," "cell cultures," and other such terms denote, for example, microorganisms, insect cells, and mammalian cells, that can  
25 be, or have been, used as recipients for recombinant vector or other transfer DNA, and include the progeny of the original cell which has been transformed. It is understood that the progeny of a single parental cell may not necessarily be completely identical in morphology or in  
30 genomic or total DNA complement as the original parent, due to natural, accidental, or deliberate mutation. Examples for mammalian host cells include Chinese hamster ovary (CHO) and monkey kidney (COS) cells.

Specifically, as used herein, "cell line," refers  
35 to a population of cells capable of continuous or prolonged growth and division in vitro. Often, cell lines are clonal populations derived from a single progenitor cell. It is further known in the art that spontaneous or induced changes can occur in karyotype during storage or transfer of such

clonal populations. Therefore, cells derived from the cell line referred to may not be precisely identical to the ancestral cells or cultures, and the cell line referred to includes such variants. The term "cell lines" also includes  
5 immortalized cells. Preferably, cell lines include nonhybrid cell lines or hybridomas to only two cell types.

As used herein, the term "microorganism" includes prokaryotic and eukaryotic microbial species such as bacteria and fungi, the latter including yeast and  
10 filamentous fungi.

"Transformation", as used herein, refers to the insertion of an exogenous polynucleotide into a host cell, irrespective of the method used for the insertion, for example, direct uptake, transduction, f-mating or  
15 electroporation. The exogenous polynucleotide may be maintained as a non-integrated vector, for example, a plasmid, or alternatively, may be integrated into the host genome.

By "purified" and "isolated" is meant, when  
20 referring to a polypeptide or nucleotide sequence, that the indicated molecule is present in the substantial absence of other biological macromolecules of the same type. The term "purified" as used herein preferably means at least 75% by weight, more preferably at least 85% by weight, more  
25 preferably still at least 95% by weight, and most preferably at least 98% by weight, of biological macromolecules of the same type present (but water, buffers, and other small molecules, especially molecules having a molecular weight of less than 1000, can be present).

### 30 C. Nucleic Acid Assays

Using as a basis the genome of H. pylori, polynucleotide probes of approximately 8 nucleotides or more can be prepared which hybridize with the positive strand(s) of the RNA or its complement, as well as to cDNAs. These  
35 polynucleotides serve as probes for the detection, isolation and/or labeling of polynucleotides which contain nucleotide sequences, and/or as primers for the transcription and/or replication of the targeted sequences. Each probe contains a targeting polynucleotide sequence, which is comprised of

nucleotides which are complementary to a target nucleotide sequence; the sequence is of sufficient length and complementarily with the sequence to form a duplex which has sufficient stability for the purpose intended. For example, if the purpose is the isolation, via immobilization, of an analyte containing a target sequence, the probes will contain a polynucleotide region which is of sufficient length and complementarily to the targeted sequence to afford sufficient duplex stability to immobilize the analyte on a solid surface under the isolation conditions. For example, also, if the polynucleotide probes are to serve as primers for the transcription and/or replication of target sequences, the probes will contain a polynucleotide region of sufficient length and complementarily to the targeted sequence to allow for replication. For example, also, if the polynucleotide probes are to be used as label probes, or are to bind to multimers, the targeting polynucleotide region would be of sufficient length and complementarily to form stable hybrid duplex structures with the label probes and/or multimers to allow detection of the duplex. The probes may contain a minimum of about 4 contiguous nucleotides which are complementary to the targeted sequence; usually the oligomers will contain a minimum of about 8 continuous nucleotides which are complementary to the targeted sequence, and preferably will contain a minimum of about 14 contiguous nucleotides which are complementary to the targeted sequence.

The probes, however, need not consist only of the sequence which is complementary to the targeted sequence. They may contain additional nucleotide sequences or other moieties. For example, if the probes are to be used as primers for the amplification of sequences via PCR, they may contain sequences which, when in duplex, form restriction enzyme sites which facilitate the cloning of the amplified sequences. For example, also, if the probes are to be used as "capture probes" in hybridization assays, they will be coupled to a "binding partner" as defined above. Preparation of the probes is by means known in the art, including, for example, by methods which include excision,

transcription or chemical synthesis.

#### D. Expression Systems

Once the appropriate H. pylori coding sequence is isolated, it can be expressed in a variety of different expression systems; for example those used with mammalian cells, baculoviruses, bacteria, and yeast.

##### i. Mammalian Systems

Mammalian expression systems are known in the art. A mammalian promoter is any DNA sequence capable of binding mammalian RNA polymerase and initiating the downstream (3') transcription of a coding sequence (e.g. structural gene) into mRNA. A promoter will have a transcription initiating region, which is usually placed proximal to the 5' end of the coding sequence, and a TATA box, usually located 25-30 base pairs (bp) upstream of the transcription initiation site. The TATA box is thought to direct RNA polymerase II to begin RNA synthesis at the correct site. A mammalian promoter will also contain an upstream promoter element, usually located within 100 to 200 bp upstream of the TATA box. An upstream promoter element determines the rate at which transcription is initiated and can act in either orientation, Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd ed (1989).

Mammalian viral genes are often highly expressed and have a broad host range; therefore sequences encoding mammalian viral genes provide particularly useful promoter sequences. Examples include the SV40 early promoter, mouse mammary tumor virus LTR promoter, adenovirus major late promoter (Ad-MLP), and herpes simplex virus promoter. In addition, sequences derived from non-viral genes, such as the murine metallothionein gene, also provide useful promoter sequences. Expression may be either constitutive or regulated (inducible), depending on the promoter can be induced with glucocorticoid in hormone-responsive cells.

The presence of an enhancer element (enhancer), combined with the promoter elements described above, will usually increase expression levels. An enhancer is a regulatory DNA sequence that can stimulate transcription up to 1000-fold when linked to homologous or heterologous

promoters, with synthesis beginning at the normal RNA start site. Enhancers are also active when they are placed upstream or downstream from the transcription initiation site, in either normal or flipped orientation, or at a distance of more than 1000 nucleotides from the promoter, Maniatis et al., Science 236:1237 (1989); Alberts et al. Molecular Biology of the Cell, 2nd ed (1989). Enhancer elements derived from viruses may be particularly useful, because they usually have a broader host range. Examples include the SV40 early gene enhancer, Dijkema et al (1985) EMBO J. 4:761, and the enhancer/promoters derived from the long terminal repeat (LTR) of the Rous Sarcoma Virus, Gorman et al. (1982) Proc. Natl. Acad. Sci. 79:6777, and from human cytomegalovirus, Boshart et al. (1985) Cell 41:5221. Additionally, some enhancers are regulatable and become active only in the presence of an inducer, such as a hormone or metal ion, Sassone-Corsi et al. (1986) Trends Genet. 2:215; Maniatis et al. (1987) Science 236:1237.

A DNA molecule may be expressed intracellularly in mammalian cells. A promoter sequence may be directly linked with the DNA molecule, in which case the first amino acid at the N-terminus of the recombinant protein will always be a methionine, which is encoded by the ATG start codon. If desired, the N-terminus may be cleaved from the protein by in vitro incubation with cyanogen bromide.

Alternatively, foreign proteins can also be secreted from the cell into the growth media by creating chimeric DNA molecules that encode a fusion protein comprised of a leader sequence fragment that provides for secretion of the foreign protein in mammalian cells. Preferably, there are processing sites encoded between the leader fragment and the foreign gene that can be cleaved either in vivo or in vitro. The leader sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell. The adenovirus tripartite leader is an example of a leader sequence that provides for secretion of a foreign protein in mammalian cells.

Usually, transcription termination and

polyadenylation sequences recognized by mammalian cells are regulatory regions located 3' to the translation stop codon and thus, together with the promoter elements, flank the coding sequence. The 3' terminus of the mature mRNA is formed by site-specific post-transcriptional cleavage and polyadenylation, Birnstiel et al. (1985) Cell 41:349; Proudfoot and Whitelaw (1988) "Termination and 3' end processing of eukaryotic RNA. In Transcription and splicing (ed. B.D. Hames and D.M. Glover); Proudfoot (1989) Trends Biochem. Sci. 14:105. These sequences direct the transcription of an mRNA which can be translated into the polypeptide encoded by the DNA. Examples of transcription terminator/polyadenylation signals include those derived from SV40, Sambrook et al (1989), Molecular Cloning: A Laboratory Manual.

Some genes may be expressed more efficiently when introns (also called intervening sequences) are present. Several cDNAs, however, have been efficiently expressed from vectors that lack splicing signals (also called splice donor and acceptor sites), see e.g., Gething and Sambrook (1981) Nature 293:620. Introns are intervening noncoding sequences within a coding sequence that contain splice donor and acceptor sites. They are removed by a process called "splicing," following polyadenylation of the primary transcript, Nevins (1983) Annu. Rev. Biochem. 52:441; Green (1986) Annu. Rev. Genet. 20:671; Padgett et al. (1986) Annu. Rev. Biochem. 55:1119; Krainer and Maniatis (1988) "RNA splicing," In Transcription and splicing (ed. B.D. Hames and D.M. Glover):

Usually, the above-described components, comprising a promoter, polyadenylation signal, and transcription termination sequence are put together into expression constructs. Enhancers, introns with functional splice donor and acceptor sites, and leader sequences may also be included in an expression construct, if desired. Expression constructs are often maintained in a replicon, such as an extrachromosomal element (e.g., plasmids) capable of stable maintenance in a host, such as mammalian cells or bacteria. Mammalian replication systems include those

derived from animal viruses, which require trans-acting factors to replicate. For example, plasmids containing the replication systems of papovaviruses, such as SV40, Gluzman (1981) Cell 23:175, or polyomavirus, replicate to extremely high copy number in the presence of the appropriate viral T antigen. Additional examples of mammalian replicons include those derived from bovine papillomavirus and Epstein-Barr virus. Additionally, the replicon may have two replication systems, thus allowing it to be maintained, for example, in mammalian cells for expression and in a procaryotic host for cloning and amplification. Examples of such mammalian-bacteria shuttle vectors include pMT2, Kaufman et al. (1989) Mol. Cell. Biol. 9:946, and pHEBO, Shimizu et al. (1986) Mol. Cell. Biol. 6:1074.

The transformation procedure used depends upon the host to be transformed. Methods for introduction of heterologous polynucleotides into mammalian cells are known in the art and include dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei.

Mammalian cell lines available as hosts for expression are known in the art and include many immortalized cell lines available from the American Type Culture Collection (ATCC), including but not limited to, Chinese hamster ovary (CHO) cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (e.g., Hep G2), and a number of other cell lines.

#### ii. Baculovirus Systems

The polynucleotide encoding the protein can also be inserted into a suitable insect expression vector, and is operably linked to the control elements within that vector. Vector construction employs techniques which are known in the art.

Generally, the components of the expression system include a transfer vector, usually a bacterial plasmid, which contains both a fragment of the baculovirus genome,



and a convenient restriction site for insertion of the heterologous gene or genes to be expressed; a wild type baculovirus with a sequence homologous to the baculovirus-specific fragment in the transfer vector (this allows for the homologous recombination of the heterologous gene in to the baculovirus genome); and appropriate insect host cells and growth media.

After inserting the DNA sequence encoding the protein into the transfer vector, the vector and the wild type viral genome are transfected into an insect host cell where the vector and viral genome are allowed to recombine. The packaged recombinant virus is expressed and recombinant plaques are identified and purified. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, inter alia, Invitrogen, San Diego CA ("MaxBac" kit). These techniques are generally known to those skilled in the art and fully described in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987) (hereinafter "Summers and Smith").

Prior to inserting the DNA sequence encoding the protein into the baculovirus genome, the above-described components, comprising a promoter, leader (if desired), coding sequence of interest, and transcription termination sequence, are usually assembled into an intermediate transplacement construct (transfer vector). This construct may contain a single gene and operably linked regulatory elements; multiple genes, each with its owned set of operably linked regulatory elements; or multiple genes, regulated by the same set of regulatory elements. Intermediate transplacement constructs are often maintained in a replicon, such as an extrachromosomal element (e.g., plasmids) capable of stable maintenance in a host, such as a bacterium. The replicon will have a replication system, thus allowing it to be maintained in a suitable host for cloning and amplification.

Currently, the most commonly used transfer vector for introducing foreign genes into AcNPV is pAc373. Many other vectors, known to those of skill in the art, have also

been designed. These include, for example, pVL985 (which alters the polyhedrin start codon from ATG to ATT, and which introduces a BamHI cloning site 32 basepairs downstream from the ATT; see Luckow and Summers, Virology (1989) 17:31.

5           The plasmid usually also contains the polyhedron polyadenylation signal (Miller et al. (1988) Ann. Rev. Microbiol., 42:177) and a procaryotic ampicillin-resistance (amp) gene and origin of replication for selection and propagation in E. coli.

10           Baculovirus transfer vectors usually contain a baculovirus promoter. A baculovirus promoter is any DNA sequence capable of binding a baculovirus RNA polymerase and initiating the downstream (5' to 3') transcription of a coding sequence (e.g. structural gene) into mRNA. A  
15           promoter will have a transcription initiation region which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region usually includes an RNA polymerase binding site and a transcription initiation site. A baculovirus transfer vector may also  
20           have a second domain called an enhancer, which, if present, is usually distal to the structural gene. Expression may be either regulated or constitutive.

          Structural genes, abundantly transcribed at late times in a viral infection cycle, provide particularly  
25           useful promoter sequences. Examples include sequences derived from the gene encoding the viral polyhedron protein, Friesen et al., (1986) "The Regulation of Baculovirus Gene Expression," in: The Molecular Biology of Baculoviruses (ed. Walter Doerfler); EPO Publ. Nos. 127 839 and 155 476; and  
30           the gene encoding the p10 protein, Vlak et al., (1988), J. Gen. Virol. 69:765.

          DNA encoding suitable signal sequences can be derived from genes for secreted insect or baculovirus proteins, such as the baculovirus polyhedrin gene (Carbonell  
35           et al. (1988) Gene, 73:409). Alternatively, since the signals for mammalian cell posttranslational modifications (such as signal peptide cleavage, proteolytic cleavage, and phosphorylation) appear to be recognized by insect cells, and the signals required for secretion and nuclear

accumulation also appear to be conserved between the invertebrate cells and vertebrate cells, leaders of non-insect origin, such as those derived from genes encoding human  $\alpha$ -interferon, Maeda et al., (1985), Nature 315:592; human gastrin-releasing peptide, Lebacqz-Verheyden et al., (1988), Molec. Cell. Biol. 8:3129; human IL-2, Smith et al., (1985) Proc. Nat'l Acad. Sci. USA, 82:8404; mouse IL-3, (Miyajima et al., (1987) Gene 58:273; and human glucocerebrosidase, Martin et al. (1988) DNA 7:99, can also be used to provide for secretion in insects.

A recombinant polypeptide or polyprotein may be expressed intracellularly or, if it is expressed with the proper regulatory sequences, it can be secreted. Good intracellular expression of nonfused foreign proteins usually requires heterologous genes that ideally have a short leader sequence containing suitable translation initiation signals preceding an ATG start signal. If desired, methionine at the N-terminus may be cleaved from the mature protein by in vitro incubation with cyanogen bromide.

Alternatively, recombinant polyproteins or proteins which are not naturally secreted can be secreted from the insect cell by creating chimeric DNA molecules that encode a fusion protein comprised of a leader sequence fragment that provides for secretion of the foreign protein in insects. The leader sequence fragment usually encodes a signal peptide comprised of hydrophobic amino acids which direct the translocation of the protein into the endoplasmic reticulum.

After insertion of the DNA sequence and/or the gene encoding the expression product precursor of the protein, an insect cell host is co-transformed with the heterologous DNA of the transfer vector and the genomic DNA of wild type baculovirus -- usually by co-transfection. The promoter and transcription termination sequence of the construct will usually comprise a 2-5kb section of the baculovirus genome. Methods for introducing heterologous DNA into the desired site in the baculovirus virus are known in the art. (See Summers and Smith; Ju et al. (1987); Smith

et al., Mol. Cell. Biol. (1983) 3:2156; and Luckow and Summers (1989)). For example, the insertion can be into a gene such as the polyhedrin gene, by homologous double crossover recombination; insertion can also be into a restriction enzyme site engineered into the desired baculovirus gene. Miller et al., (1989), Bioessays 4:91.

The DNA sequence, when cloned in place of the polyhedrin gene in the expression vector, is flanked both 5' and 3' by polyhedrin-specific sequences and is positioned downstream of the polyhedrin promoter.

The newly formed baculovirus expression vector is subsequently packaged into an infectious recombinant baculovirus. Homologous recombination occurs at low frequency (between about 1% and about 5%); thus, the majority of the virus produced after cotransfection is still wild-type virus. Therefore, a method is necessary to identify recombinant viruses. An advantage of the expression system is a visual screen allowing recombinant viruses to be distinguished. The polyhedrin protein, which is produced by the native virus, is produced at very high levels in the nuclei of infected cells at late times after viral infection. Accumulated polyhedrin protein forms occlusion bodies that also contain embedded particles. These occlusion bodies, up to 15  $\mu$ m in size, are highly refractile, giving them a bright shiny appearance that is readily visualized under the light microscope. Cells infected with recombinant viruses lack occlusion bodies. To distinguish recombinant virus from wild-type virus, the transfection supernatant is plaqued onto a monolayer of insect cells by techniques known to those skilled in the art. Namely, the plaques are screened under the light microscope for the presence (indicative of wild-type virus) or absence (indicative of recombinant virus) of occlusion bodies. "Current Protocols in Microbiology" Vol. 2 (Ausubel et al. eds) at 16.8 (Supp. 10, 1990); Summers and Smith; Miller et al. (1989).

Recombinant baculovirus expression vectors have been developed for infection into several insect cells. For example, recombinant baculoviruses have been developed for,

inter alia: Aedes aegypti , Autographa californica, Bombyx mori, Drosophila melanogaster, Spodoptera frugiperda, and Trichoplusia ni (PCT Pub. No. WO 89/046699; Carbonell et al., (1985) J. Virol. 56:153; Wright (1986) Nature 321:718; 5 Smith et al., (1983) Mol. Cell. Biol. 3:2156; and see generally, Fraser, et al. (1989) In Vitro Cell. Dev. Biol. 25:225).

Cells and cell culture media are commercially available for both direct and fusion expression of 10 heterologous polypeptides in a baculovirus/expression system; cell culture technology is generally known to those skilled in the art. See, e.g., Summers and Smith.

The modified insect cells may then be grown in an appropriate nutrient medium, which allows for stable 15 maintenance of the plasmid(s) present in the modified insect host. Where the expression product gene is under inducible control, the host may be grown to high density, and expression induced. Alternatively, where expression is constitutive, the product will be continuously expressed 20 into the medium and the nutrient medium must be continuously circulated, while removing the product of interest and augmenting depleted nutrients. The product may be purified by such techniques as chromatography, e.g., HPLC, affinity chromatography, ion exchange chromatography, etc.; 25 electrophoresis; density gradient centrifugation; solvent extraction, or the like. As appropriate, the product may be further purified, as required, so as to remove substantially any insect proteins which are also secreted in the medium or result from lysis of insect cells, so as to provide a 30 product which is at least substantially free of host debris, e.g., proteins, lipids and polysaccharides.

In order to obtain protein expression, recombinant host cells derived from the transformants are incubated under conditions which allow expression of the recombinant 35 protein encoding sequence. These conditions will vary, dependent upon the host cell selected. However, the conditions are readily ascertainable to those of ordinary skill in the art, based upon what is known in the art.

### iii. Bacterial Systems

Bacterial expression techniques are known in the art. A bacterial promoter is any DNA sequence capable of binding bacterial RNA polymerase and initiating the downstream (3') transcription of a coding sequence (e.g. structural gene) into mRNA. A promoter will have a transcription initiation region which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region usually includes an RNA polymerase binding site and a transcription initiation site.

5 A bacterial promoter may also have a second domain called an operator, that may overlap an adjacent RNA polymerase binding site at which RNA synthesis begins. The operator permits negative regulated (inducible) transcription, as a gene repressor protein may bind the operator and thereby inhibit transcription of a specific gene. Constitutive expression may occur in the absence of negative regulatory elements, such as the operator. In addition, positive regulation may be achieved by a gene activator protein binding sequence, which, if present is usually proximal (5')

10 to the RNA polymerase binding sequence. An example of a gene activator protein is the catabolite activator protein (CAP), which helps initiate transcription of the lac operon in *E. coli*, Raibaud et al. (1984) Annu. Rev. Genet. 18:173. Regulated expression may therefore be either positive or negative, thereby either enhancing or reducing transcription.

15 20 25

Sequences encoding metabolic pathway enzymes provide particularly useful promoter sequences. Examples include promoter sequences derived from sugar metabolizing enzymes, such as galactose, lactose (lac), Chang et al. (1977) Nature 198:1056, and maltose. Additional examples include promoter sequences derived from biosynthetic enzymes such as tryptophan (trp), Goeddel et al. (1980) Nuc. Acids Res. 8:4057; Yelverton et al. (1981) Nucl. Acids Res. 9:731; U.S. 4,738,921; EPO Publ. Nos. 036 776 and 121 775. The g-

30 35

laotamase (bla) promoter system, Weissmann (1981) "The cloning of interferon and other mistakes." In Interferon 3 (ed. I. Gresser), bacteriophage lambda PL, Shimatake et al. (1981) Nature 292:128, and T5, U.S. 4,689,406, promoter

systems also provide useful promoter sequences.

In addition, synthetic promoters which do not occur in nature also function as bacterial promoters. For example, transcription activation sequences of one bacterial or bacteriophage promoter may be joined with the operon sequences of another bacterial or bacteriophage promoter, creating a synthetic hybrid promoter, U.S. 4,551,433. For example, the tac promoter is a hybrid trp-lac promoter comprised of both trp promoter and lac operon sequences that is regulated by the lac repressor, Amann et al. (1983) Gene 25:167; de Boer et al. (1983) Proc. Natl. Acad. Sci. 80:21. Furthermore, a bacterial promoter can include naturally occurring promoters of non-bacterial origin that have the ability to bind bacterial RNA polymerase and initiate transcription. A naturally occurring promoter of non-bacterial origin can also be coupled with a compatible RNA polymerase to produce high levels of expression of some genes in prokaryotes. The bacteriophage T7 RNA polymerase/promoter system is an example of a coupled promoter system, Studier et al. (1986) J. Mol. Biol. 189:113; Tabor et al. (1985) Proc Natl. Acad. Sci. 82:1074. In addition, a hybrid promoter can also be comprised of a bacteriophage promoter and an E. coli operator region (EPO Publ. No. 267 851).

In addition to a functioning promoter sequence, an efficient ribosome binding site is also useful for the expression of foreign genes in prokaryotes. In E. coli, the ribosome binding site is called the Shine-Dalgarno (SD) sequence and includes an initiation codon (ATG) and a sequence 3-9 nucleotides in length located 3-11 nucleotides upstream of the initiation codon, Shine et al. (1975) Nature 254:34. The SD sequence is thought to promote binding of mRNA to the ribosome by the pairing of bases between the SD sequence and the 3' end of E. coli 16S rRNA, Steitz et al. (1979) "Genetic signals and nucleotide sequences in messenger RNA." In Biological Regulation and Development: Gene Expression (ed. R.F. Goldberger). To express eukaryotic genes and prokaryotic genes with weak ribosome-binding site, Sambrook et al. (1989), Molecular Cloning: A

Laboratory Manual.

A DNA molecule may be expressed intracellularly. A promoter sequence may be directly linked with the DNA molecule, in which case the first amino acid at the N-terminus will always be a methionine, which is encoded by the ATG start codon. If desired, methionine at the N-terminus may be cleaved from the protein by in vitro incubation with cyanogen bromide or by either in vivo or in vitro incubation with a bacterial methionine N-terminal peptidase (EPO Publ. No. 219 237).

Fusion proteins provide an alternative to direct expression. Usually, a DNA sequence encoding the N-terminal portion of an endogenous bacterial protein, or other stable protein, is fused to the 5' end of heterologous coding sequences. Upon expression, this construct will provide a fusion of the two amino acid sequences. For example, the bacteriophage lambda cell gene can be linked at the 5' terminus of a foreign gene and expressed in bacteria. The resulting fusion protein preferably retains a site for a processing enzyme (factor Xa) to cleave the bacteriophage protein from the foreign gene, Nagai et al. (1984) Nature 309:810. Fusion proteins can also be made with sequences from the lacZ, Jia et al. (1987) Gene 60:197, trpE, Allen et al. (1987) J. Biotechnol. 5:93; Makoff et al. (1989) J. Gen. Microbiol. 135:11, and EPO Publ. No. 324 647, genes. The DNA sequence at the junction of the two amino acid sequences may or may not encode a cleavable site. Another example is a ubiquitin fusion protein. Such a fusion protein is made with the ubiquitin region that preferably retains a site for a processing enzyme (e.g. ubiquitin specific processing-protease) to cleave the ubiquitin from the foreign protein. Through this method, native foreign protein can be isolated. Miller et al. (1989) Bio/Technology 7:698.

Alternatively, foreign proteins can also be secreted from the cell by creating chimeric DNA molecules that encode a fusion protein comprised of a signal peptide sequence fragment that provides for secretion of the foreign protein in bacteria, U.S. 4,336,336. The signal sequence fragment usually encodes a signal peptide comprised of



hydrophobic amino acids which direct the secretion of the protein from the cell. The protein is either secreted into the growth media (gram-positive bacteria) or into the periplasmic space, located between the inner and outer membrane of the cell (gram-negative bacteria). Preferably there are processing sites, which can be cleaved either in vivo or in vitro encoded between the signal peptide fragment and the foreign gene.

DNA encoding suitable signal sequences can be derived from genes for secreted bacterial proteins, such as the E. coli outer membrane protein gene (ompA). Masui et al. (1983), in: Experimental Manipulation of Gene Expression; Ghrayeb et al. (1984) EMBO J. 3:2437 and the E. coli alkaline phosphatase signal sequence (phoA), Oka et al. (1985) Proc. Natl. Acad. Sci. 82:7212. As an additional example, the signal sequence of the alpha-amylase gene from various Bacillus strains can be used to secrete heterologous proteins from B. subtilis. Palva et al. (1982) Proc. Natl. Acad. Sci. USA 79:5582; EPO Publ. No. 244 042.

Usually, transcription termination sequences recognized by bacteria are regulatory regions located 3' to the translation stop codon, and thus together with the promoter flank the coding sequence. These sequences direct the transcription of an mRNA which can be translated into the polypeptide encoded by the DNA. Transcription termination sequences frequently include DNA sequences of about 50 nucleotides capable of forming stem loop structures that aid in terminating transcription. Examples include transcription termination sequences derived from genes with strong promoters, such as the trp gene in E. coli as well as other biosynthetic genes.

Usually, the above-described components, comprising a promoter, signal sequence (if desired), coding sequence of interest, and transcription termination sequence, are put together into expression constructs. Expression constructs are often maintained in a replicon, such as an extrachromosomal element (e.g., plasmids) capable of stable maintenance in a host, such as bacteria. The replicon will have a replication system, thus allowing it to

be maintained in a procaryotic host either for expression or for cloning and amplification. In addition, a replicon may be either a high or low copy number plasmid. A high copy number plasmid will generally have a copy number ranging from about 5 to about 200, and usually about 10 to about 150. A host containing a high copy number plasmid will preferably contain at least about 10, and more preferably at least about 20 plasmids. Either a high or low copy number vector may be selected, depending upon the effect of the vector and the foreign protein on the host.

Alternatively, the expression constructs can be integrated into the bacterial genome with an integrating vector. Integrating vectors usually contain at least one sequence homologous to the bacterial chromosome that allows the vector to integrate. Integrations appear to result from recombinations between homologous DNA in the vector and the bacterial chromosome. For example, integrating vectors constructed with DNA from various *Bacillus* strains integrate into the *Bacillus* chromosome (EPO Publ. No. 127 328). Integrating vectors may also be comprised of bacteriophage or transposon sequences.

Usually, extrachromosomal and integrating expression constructs may contain selectable markers to allow for the selection of bacterial strains that have been transformed. Selectable markers can be expressed in the bacterial host and may include genes which render bacteria resistant to drugs such as ampicillin, chloramphenicol, erythromycin, kanamycin (neomycin), and tetracycline. Davies et al. (1978) *Annu. Rev. Microbiol.* 32:469. Selectable markers may also include biosynthetic genes, such as those in the histidine, tryptophan, and leucine biosynthetic pathways.

Alternatively, some of the above-described components can be put together in transformation vectors. Transformation vectors are usually comprised of a selectable marker that is either maintained in a replicon or developed into an integrating vector.

Expression and transformation vectors, either extra-chromosomal replicons or integrating vectors, have

been developed for transformation into many bacteria. For example, expression vectors have been developed for, inter alia, the following bacteria: Bacillus subtilis, Palv et al. (1982) Proc. Natl. Acad. Sci. USA 79:5582; EPO Publ. Nos. 036 259 and 063 953; PCT Publ. No. WO 84/04541; E. coli, Shimatake et al. (1981) Nature 292:128; Amann et al. (1985) Gene 40:183; Studier et al. (1986) J. Mol. Biol. 189:113; EPO Publ. Nos. 036 776, 136 829 and 136 907; Streptococcus cremoris, Powell et al. (1988) Appl. Environ. Microbiol. 54:655; Streptococcus lividans, Powell et al. (1988) Appl. Environ. Microbiol. 54:655; and Streptomyces lividans, U.S. 4,745,056.

Methods of introducing exogenous DNA into bacterial hosts are well-known in the art, and usually include either the transformation of bacteria treated with  $\text{CaCl}_2$  or other agents, such as divalent cations and DMSO. DNA can also be introduced into bacterial cells by electroporation. Transformation procedures usually vary with the bacterial species to be transformed. See, e.g., Masson et al. (1989) FEMS Microbiol. Lett. 60:273; Palva et al. (1982) Proc. Natl. Acad. Sci. USA 79:5582; EPO Publ. Nos. 036 259 and 063 953; PCT Publ. No. WO 84/04541, for Bacillus; Miller et al. (1988) Proc. Natl. Acad. Sci. 85:856; Wang et al. (1990) J. Bacteriol. 172:949, for Campylobacter; Cohen et al. (1973) Proc. Natl. Acad. Sci. 69:2110; Dower et al. (1988) Nucleic Acids Res. 16:6127; Kushner (1978) "An improved method for transformation of E. coli with ColEI-derived plasmids," In Genetic Engineering: Proceedings of the International Symposium on Genetic Engineering (eds. H.W. Boyer and S. Nicosia); Mandel et al. (1970) J. Mol. Biol. 53:159; Taketo (1988) Biochim. Biophys. Acta 949:318, for Escherichia; Chassy et al. (1987) FEMS Microbiol. Lett. 44:173, for Lactobacillus; Fiedler et al. (1988) Anal. Biochem 170:38, for Pseudomonas; Augustin et al. (1990) FEMS Microbiol. Lett. 66:203, for Staphylococcus; Barany et al. (1980) J. Bacteriol. 144:698; Harlander (1987) "Transformation of Streptococcus lactis by electroporation, in: Streptococcal Genetics (ed. J. Ferretti and R. Curtiss III); Perry et al. (1981) Infec. Immun. 32:1295; Powell et

al. (1988) Appl. Environ. Microbiol. 54:655; Somkuti et al. (1987) Proc. 4th Evr. Cong. Biotechnology 1:412, for Streptococcus.

#### iv. Yeast Expression

5 Yeast expression systems are also known to one of ordinary skill in the art. A yeast promoter is any DNA sequence capable of binding yeast RNA polymerase and initiating the downstream (3') transcription of a coding sequence (e.g. structural gene) into mRNA. A promoter will  
10 have a transcription initiation region which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region usually includes an RNA polymerase binding site (the "TATA Box") and a transcription initiation site. A yeast promoter may also have a second  
15 domain called an upstream activator sequence (UAS), which, if present, is usually distal to the structural gene. The UAS permits regulated (inducible) expression. Constitutive expression occurs in the absence of a UAS. Regulated expression may be either positive or negative, thereby  
20 either enhancing or reducing transcription.

Yeast is a fermenting organism with an active metabolic pathway, therefore sequences encoding enzymes in the metabolic pathway provide particularly useful promoter sequences. Examples include alcohol dehydrogenase (ADH)  
25 (EPO Publ. No. 284 044), enolase, glucokinase, glucose-6-phosphate isomerase, glyceraldehyde-3-phosphate-dehydrogenase (GAP or GAPDH), hexokinase, phosphofructokinase, 3-phosphoglycerate mutase, and pyruvate kinase (PyK) (EPO Publ. No. 329 203). The yeast PHO5 gene,  
30 encoding acid phosphatase, also provides useful promoter sequences, Myanohara et al. (1983) Proc. Natl. Acad. Sci. USA 80:1.

In addition, synthetic promoters which do not occur in nature also function as yeast promoters. For  
35 example, UAS sequences of one yeast promoter may be joined with the transcription activation region of another yeast promoter, creating a synthetic hybrid promoter. Examples of such hybrid promoters include the ADH regulatory sequence linked to the GAP transcription activation region (U.S.

4,876,197 and U.S. 4,880,734). Other examples of hybrid promoters include promoters which consist of the regulatory sequences of either the ADH2, GAL4, GAL10, or PHO5 genes, combined with the transcriptional activation region of a glycolytic enzyme gene such as GAP or PyK (EPO Publ. No. 164 556). Furthermore, a yeast promoter can include naturally occurring promoters of non-yeast origin that have the ability to bind yeast RNA polymerase and initiate transcription. Examples of such promoters include, inter alia, Cohen et al. (1980) Proc. Natl. Acad. Sci. USA 77:1078; Henikoff et al. (1981) Nature 283:835; Hollenberg et al. (1981) Curr. Topics Microbiol. Immunol. 96:119; Hollenberg et al. (1979) "The Expression of Bacterial Antibiotic Resistance Genes in the Yeast *Saccharomyces cerevisiae*," in: Plasmids of Medical, Environmental and Commercial Importance (eds. K.N. Timmis and A. Puhler); Mercerau-Puigalon et al. (1980) Gene 11:163; Panthier et al. (1980) Curr. Genet. 2:109.

A DNA molecule may be expressed intracellularly in yeast. A promoter sequence may be directly linked with the DNA molecule, in which case the first amino acid at the N-terminus of the recombinant protein will always be a methionine, which is encoded by the ATG start codon. If desired, methionine at the N-terminus may be cleaved from the protein by in vitro incubation with cyanogen bromide.

Fusion proteins provide an alternative for yeast expression systems, as well as in mammalian, baculovirus, and bacterial expression systems. Usually, a DNA sequence encoding the N-terminal portion of an endogenous yeast protein, or other stable protein, is fused to the 5' end of heterologous coding sequences. Upon expression, this construct will provide a fusion of the two amino acid sequences. For example, the yeast or human superoxide dismutase (SOD) gene, can be linked at the 5' terminus of a foreign gene and expressed in yeast. The DNA sequence at the junction of the two amino acid sequences may or may not encode a cleavable site. See e.g., EPO Publ. No. 196 056. Another example is a ubiquitin fusion protein. Such a fusion protein is made with the ubiquitin region that

preferably retains a site for a processing enzyme (e.g. ubiquitin-specific processing protease) to cleave the ubiquitin from the foreign protein. Through this method, therefore, native foreign protein can be isolated (see, 5 e.g., PCT Publ. No. WO 88/024066).

Alternatively, foreign proteins can also be secreted from the cell into the growth media by creating chimeric DNA molecules that encode a fusion protein comprised of a leader sequence fragment that provide for 10 secretion in yeast of the foreign protein. Preferably, there are processing sites encoded between the leader fragment and the foreign gene that can be cleaved either in vivo or in vitro. The leader sequence fragment usually encodes a signal peptide comprised of hydrophobic amino 15 acids which direct the secretion of the protein from the cell.

DNA encoding suitable signal sequences can be derived from genes for secreted yeast proteins, such as the yeast invertase gene (EPO Publ. No. 012 873; JPO Publ. No. 20 62,096,086) and the A-factor gene (U.S. 4,588,684). Alternatively, leaders of non-yeast origin, such as an interferon leader, exist that also provide for secretion in yeast (EPO Publ. No. 060 057).

A preferred class of secretion leaders are those 25 that employ a fragment of the yeast alpha-factor gene, which contains both a "pre" signal sequence, and a "pro" region. The types of alpha-factor fragments that can be employed include the full-length pre-pro alpha factor leader (about 83 amino acid residues) as well as truncated alpha-factor 30 leaders (usually about 25 to about 50 amino acid residues) (U.S. 4,546,083 and U.S. 4,870,008; EPO Publ. No. 324 274). Additional leaders employing an alpha-factor leader fragment that provides for secretion include hybrid alpha-factor leaders made with a presequence of a first yeast, but a pro- 35 region from a second yeast alphafactor. (See e.g., PCT Publ. No. WO 89/02463.)

Usually, transcription termination sequences recognized by yeast are regulatory regions located 3' to the translation stop codon, and thus together with the promoter

flank the coding sequence. These sequences direct the transcription of an mRNA which can be translated into the polypeptide encoded by the DNA. Examples of transcription terminator sequence and other yeast-recognized termination sequences, such as those coding for glycolytic enzymes.

Usually, the above-described components, comprising a promoter, leader (if desired), coding sequence of interest, and transcription termination sequence, are put together into expression constructs. Expression constructs are often maintained in a replicon, such as an extrachromosomal element (e.g., plasmids) capable of stable maintenance in a host, such as yeast or bacteria. The replicon may have two replication systems, thus allowing it to be maintained, for example, in yeast for expression and in a procaryotic host for cloning and amplification. Examples of such yeast-bacteria shuttle vectors include YEp24, Botstein et al. (1979) Gene 8:17-24; pCl/1, Brake et al. (1984) Proc. Natl. Acad. Sci USA 81:4642-4646; and YRp17, Stinchcomb et al. (1982) J. Mol. Biol. 158:157. In addition, a replicon may be either a high or low copy number plasmid. A high copy number plasmid will generally have a copy number ranging from about 5 to about 200, and usually about 10 to about 150. A host containing a high copy number plasmid will preferably have at least about 10, and more preferably at least about 20. A high or low copy number vector may be selected, depending upon the effect of the vector and the foreign protein on the host.

Alternatively, the expression constructs can be integrated into the yeast genome with an integrating vector. Integrating vectors usually contain at least one sequence homologous to a yeast chromosome that allows the vector to integrate, and preferably contain two homologous sequences flanking the expression construct. Integrations appear to result from recombinations between homologous DNA in the vector and the yeast chromosome, Orr-Weaver et al. (1983) Methods in Enzymol. 101:228-245. An integrating vector may be directed to a specific locus in yeast by selecting the appropriate homologous sequence for inclusion in the vector. One or more expression construct may integrate, possibly

affecting levels of recombinant protein produced, Rine et al. (1983) Proc. Natl. Acad. Sci. USA 80:6750. The chromosomal sequences included in the vector can occur either as a single segment in the vector, which results in the integration of the entire vector, or two segments homologous to adjacent segments in the chromosome and flanking the expression construct in the vector, which can result in the stable integration of only the expression construct.

Usually, extrachromosomal and integrating expression constructs may contain selectable markers to allow for the selection of yeast strains that have been transformed. Selectable markers may include biosynthetic genes that can be expressed in the yeast host, such as ADE2, HIS4, LEU2, TRP1, and ALG7, and the G418 resistance gene, which confer resistance in yeast cells to tunicamycin and G418, respectively. In addition, a suitable selectable marker may also provide yeast with the ability to grow in the presence of toxic compounds, such as metal. For example, the presence of CUP1 allows yeast to grow in the presence of copper ions. Butt et al. (1987) Microbiol. Rev. 51:351.

Alternatively, some of the above-described components can be put together into transformation vectors. Transformation vectors are usually comprised of a selectable marker that is either maintained in a replicon or developed into an integrating vector.

Expression and transformation vectors, either extrachromosomal replicons or integrating vectors, have been developed for transformation into many yeasts. For example, expression vectors have been developed for, inter alia, the following yeasts: Candida albicans, Kurtz, et al. (1986) Mol. Cell. Biol. 6:142; Candida maltosa, Kunze, et al. (1985) J. Basic Microbiol. 25:141; Hansenula polymorpha, Gleeson, et al. (1986) J. Gen. Microbiol. 132:3459; Roggenkamp et al. (1986) Mol. Gen. Genet. 202:302; Kluyveromyces fragilis, Das, et al. (1984) J. Bacteriol. 158:1165; Kluyveromyces lactis, De Louvencourt et al. (1983) J. Bacteriol. 154:737; Van den Berg et al. (1990)



- Bio/Technology 8:135; Pichia guillerimondii, Kunze et al. (1985) J. Basic Microbiol. 25:141; Pichia pastoris, Cregg, et al. (1985) Mol. Cell. Biol. 5:3376; U.S. 4,837,148 and U.S. 4,929,555; Saccharomyces cerevisiae, Hinnen et al. (1978) Proc. Natl. Acad. Sci. USA 75:1929; Ito et al. (1983) J. Bacteriol. 153:163; Schizosaccharomyces pombe, Beach et al. (1981) Nature 300:706; and Yarrowia lipolytica, Davidow, et al. (1985) Curr. Genet. 10:380471 Gaillardin, et al. (1985) Curr. Genet. 10:49.
- 10               Methods of introducing exogenous DNA into yeast hosts are well-known in the art, and usually include either the transformation of spheroplasts or of intact yeast cells treated with alkali cations. Transformation procedures usually vary with the yeast species to be transformed. See
- 15 e.g., Kurtz et al. (1986) Mol. Cell. Biol. 6:142; Kunze et al. (1985) J. Basic Microbiol. 25:141, for Candida; Gleeson et al. (1986) J. Gen. Microbiol. 132:3459; Roggenkamp et al. (1986) Mol. Gen. Genet. 202:302, for Hansenula; Das et al. (1984) J. Bacteriol. 158:1165; De Louvencourt et al. (1983)
- 20 J. Bacteriol. 154:1165; Van den Berg et al. (1990) Bio/Technology 8:135, for Kluyveromyces; Cregg et al. (1985) Mol. Cell. Biol. 5:3376; Kunze et al. (1985) J. Basic Microbiol. 25:141; U.S. 4,837,148 and U.S. 4,929,555, for Pichia; Hinnen et al. (1978) Proc. Natl. Acad. Sci. USA
- 25 75:1929; Ito et al. (1983) J. Bacteriol. 153:163, for Saccharomyces; Beach et al. (1981) Nature 300:706, for Schizosaccharomyces; Davidow et al. (1985) Curr. Genet. 10:39; Gaillardin et al. (1985) Curr. Genet. 10:49, for Yarrowia.

30

#### E. Vaccines

- Each of the H. pylori proteins discussed herein may be used as a sole vaccine candidate or in combination with one or more other antigens, the latter either from H.
- 35 pylori or other pathogenic sources. Preferred are "cocktail" vaccines comprising, for example, the cytotoxin (CT) antigen, the CAI protein, and the urease. Additionally, the hsp can be added to one or more of these components. These vaccines may either be prophylactic (to

prevent infection) or therapeutic (to treat disease after infection).

Such vaccines comprise H. pylori antigen or antigens, usually in combination with "pharmaceutically acceptable carriers", which include any carrier that does not itself induce the production of antibodies harmful to the individual receiving the composition. Suitable carriers are typically large, slowly metabolized macromolecules such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, lipid aggregates (such as oil droplets or liposomes), and inactive virus particles. Such carriers are well known to those of ordinary skill in the art. Additionally, these carriers may function as immunostimulating agents ("adjuvants"). Furthermore, the antigen may be conjugated to a bacterial toxoid, such as a toxoid from diphtheria, tetanus, cholera, H. pylori, etc. pathogens.

Preferred adjuvants to enhance effectiveness of the composition include, but are not limited to: (1) aluminum salts (alum), such as aluminum hydroxide, aluminum phosphate, aluminum sulfate, etc; (2) oil-in-water emulsion formulations (with or without other specific immunostimulating agents such as muramyl peptides (see below) or bacterial cell wall components), such as for example (a) MF59 (PCT Publ. No. WO 90/14837), containing 5% Squalene, 0.5% Tween 80, and 0.5% Span 85 (optionally containing various amounts of MTP-PE (see below), although not required) formulated into submicron particles using a microfluidizer such as Model 110Y microfluidizer (Microfluidics, Newton, MA), (b) SAF, containing 10% Squalene, 0.4% Tween 80, 5% pluronic-blocked polymer L121, and thr-MDP (see below) either microfluidized into a submicron emulsion or vortexed to generate a larger particle size emulsion, and (c) Ribi<sup>TM</sup> adjuvant system (RAS), (Ribi Immunochem, Hamilton, MT) containing 2% Squalene, 0.2% Tween 80, and one or more bacterial cell wall components from the group consisting of monophosphorylipid A (MPL), trehalose dimycolate (TDM), and cell wall skeleton (CWS), preferably MPL + CWS (Detox<sup>TM</sup>); (3) saponin adjuvants, such as

Stimulon™ (Cambridge Bioscience, Worcester, MA) may be used or particles generated therefrom such as ISCOMs (immunostimulating complexes); (4) Complete Freund's Adjuvant (CFA) and Incomplete Freund's Adjuvant (IFA); (5) cytokines, such as interleukins (IL-1, IL-2, etc.), macrophage colony stimulating factor (M-CSF), tumor necrosis factor (TNF), etc; and (6) other substances that act as immunostimulating agents to enhance the effectiveness of the composition. Alum and MF59 are preferred.

As mentioned above, muramyl peptides include, but are not limited to, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-normuramyl-L-alanyl-D-isoglutamine (nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine (MTP-PE), etc.

The immunogenic compositions (e.g., the antigen, pharmaceutically acceptable carrier, and adjuvant) typically will contain diluents, such as water, saline, glycerol, ethanol, etc. Additionally, auxiliary substances, such as wetting or emulsifying agents, pH buffering substances, and the like, may be present in such vehicles.

Typically, the immunogenic compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared. The preparation also may be emulsified or encapsulated in liposomes for enhanced adjuvant effect, as discussed above under pharmaceutically acceptable carriers.

Immunogenic compositions used as vaccines comprise an immunologically effective amount of the antigenic polypeptides, as well as any other of the above-mentioned components, as needed. By "immunologically effective amount", it is meant that the administration of that amount to an individual, either in a single dose or as part of a series, is effective for treatment or prevention. This amount varies depending upon the health and physical condition of the individual to be treated, the taxonomic group of individual to be treated (e.g., nonhuman primate,

primate, etc.), the capacity of the individual's immune system to synthesize antibodies, the degree of protection desired, the formulation of the vaccine, the treating doctor's assessment of the medical situation, and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials.

The immunogenic compositions are conventionally administered parenterally, e.g., by injection, either subcutaneously or intramuscularly. Additional formulations suitable for other modes of administration include oral and pulmonary formulations, suppositories, and transdermal applications. Oral formulations are most preferred for the H. pylori proteins. Dosage treatment may be a single dose schedule or a multiple dose schedule. The vaccine may be administered in conjunction with other immunoregulatory agents.

#### F. Immunodiagnostic Assays

H. pylori antigens can be used in immunoassays to detect antibody levels (or conversely H. pylori antibodies can be used to detect antigen levels) and correlation can be made with gastroduodenal disease and with duodenal ulcer in particular. Immunoassays based on well defined, recombinant antigens can be developed to replace the invasive diagnostics methods that are used today. Antibodies to H. pylori proteins within biological samples, including for example, blood or serum samples, can be detected. Design of the immunoassays is subject to a great deal of variation, and a variety of these are known in the art. Protocols for the immunoassay may be based, for example, upon competition, or direct reaction, or sandwich type assays. Protocols may also, for example, use solid supports, or may be by immunoprecipitation. Most assays involve the use of labeled antibody or polypeptide; the labels may be, for example, fluorescent, chemiluminescent, radioactive, or dye molecules. Assays which amplify the signals from the probe are also known; examples of which are assays which utilize biotin and avidin, and enzyme-labeled and mediated immunoassays, such as ELISA assays.

Kits suitable for immunodiagnosis and containing the appropriate labeled reagents are constructed by packaging the appropriate materials, including the compositions of the invention, in suitable containers, along with the remaining reagents and materials (for example, suitable buffers, salt solutions, etc.) required for the conduct of the assay, as well as suitable set of assay instructions.

#### G. Examples

The examples presented below are provided as a further guide to the practitioner of ordinary skill in the art and are not to be construed as limiting the invention in any way.

##### i. H. pylori cytotoxin (CT) antigen

#### 1. Materials and methods

For general materials and methods relating to H. pylori growth and DNA isolation, see sections ii and iii below, relating to CAI antigen and hsp, respectively.

##### a. Cloning

Two mixtures of degenerate oligonucleotides were synthesized using an Applied Biosystems model 380B DNA synthesizer. These mixtures were used at a concentration of 4 micromolar in a 100 microliter polymerase chain reaction with 200 nanograms of purified DNA using the Genamp PCR kit according to the manufacturers instructions. The reaction was incubated for 1 minute at 94 degrees centigrade, 2 minutes at 48 degrees centigrade and 2 minutes at 56 degrees centigrade. The reaction mix was subjected to 30 cycles of these conditions.

Analysis of the products of this reaction by agarose gel electrophoresis revealed a prominent approximately 87 bp DNA fragment. After digestion with the restriction enzymes XbaI and EcoRI, the fragment was ligated to the Bluescript SK+ (Stratgene) plasmid which had previously also been digested with XbaI and EcoRI. The ligation mixture was used to transform competent E. coli by electroporation at 2000V and 25 microfarads using (200  $\Omega$ ) a BioRad Gene Pulser (California). Transformed E. coli were selected for growth on L-agar plates containing 100

micrograms per milliliter ampicillin. Plasmid DNA was extracted from positive E.coli isolates and subjected to sequence analysis using the Sequenase 2 (United States Biochemical Corporation) DNA sequencing kit according to the manufacturers instructions.

b. Preparation of libraries

(1) Library of HindIII fragments

Seven micrograms of purified DNA were digested to completion with the restriction enzyme HindII. Three micrograms of Bluescript SK+ plasmid DNA were digested to completion with HindIII then treated with calf intestinal phosphatase. Both DNA mixtures were purified by agitation with a water saturated phenol then precipitated by addition of ethyl alcohol to 67% V/V. Both DNAs were resuspended in 50 microliters of water. 0.7 micrograms of DNA fragments were mixed with 0.3 micrograms of Bluescript DNA in 50 microliters of a solution containing 25 mM Tris ph 7.5, 10mM MgCl<sub>2</sub> and 5 units of T4 DNA ligase. This mix was incubated at 15 deg. centigrade for 20 hours after which the DNA was extracted with water saturated phenol and precipitated from ethyl alcohol. The DNA was subsequently resuspended in 50 microL. of water. Introduction of 1 microL of this DNA into E.coli by eletroporation resulted in approximately 3000-10,000 ampicillin resistant bacterial colonies.

2) Library of EcoRI fragments.

About 0.7 microg. of EcoRI digested DNA was purified and mixed with 0.45 micrograms of Bluescript SK+ plasmid which had been previously digested with EcoRI and treated with calf intestinal phosphatase. The fragments were ligated in 50 microL of solution. After purification and precipitation, the DNA was resuspended in 50 microL of water. Electroporation of E. coli with 1 microL of this solution resulted in approximately 200 ampicillin resistant bacterial colonies.

In order to identify suitable restriction fragments from the genome for further cloning, the plasmid was uniformly labeled with 32p and used as a probe to analyze DNA from the strain CCUG digested with various restriction enzymes, separated on agarose gel

electrophoresis and transferred to nitrocellulose filter. The probe revealed a unique approximately 3.5kb HindIII restriction fragment. A library of HindIII digested DNA fragments was prepared and cloned in the Bluescript plasmid vector. This library was screened with 32p labeled DNA corresponding to the 87 bp fragment previously cloned. Two clones containing identical approximately 3.3 kbp hindIII fragments were identified. DNA sequencing of these HindIII fragments revealed sequences capable of coding for the 23 amino acids corresponding to the amino terminus of the previously described 87 kDa cytotoxin. These sequences comprised part of an open reading frame of approximately 300 nucleotides which terminated at the extremity of the fragment delimited by a HindIII restriction site. The sequence also revealed the existence of an EcoRI restriction site within the putative open reading frame 120 bp away from the HindIII site.

A 32p labeled probe corresponding to the sequences between the EcoRI site and the HindIII site was used to screen a library of EcoR fragments from DNA cloned in the Bluescript SK vector. This probe revealed two clones containing approximately 7.3 kbp fragments. DNA sequencing of these fragments revealed a continuous open reading frame which overlapped with the sequences determined from the 3.2 kbp HindIII fragments. The DNA sequence of these overlapping fragments and the conceptual translation of the single long open reading frame contained are shown in Figs. 1 and 2, respectively.

It should be noted that these clones were found to be extremely unstable. The initial colonies identified in the screening were so small as to be difficult to detect. Expansion of these clones by traditional methods of subculturing for 16-18 hours resulted in very heterogeneous populations of plasmids due to DNA rearrangement and deletion. Sufficient quantities of these clones were grown by subculturing for 8-10 hours in the absence of antibiotic selection. In this fashion, although yields of plasmid were relatively low, selection and outgrowth of bacteria containing viable rearranged plasmid were avoided.

c. Screening of DNA libraries

The product of the PCR reaction which contained the predominant 87 bp fragment was labeled with 32p by the random priming method using the Prime-a-gene kit (Promega).  
5 This labeled probe was used in a hybridization reaction with DNA from approximately 3000 bacterial clones immobilized on nitrocellulose filters. The hybridization reaction was carried out at 60 degrees centigrade in a solution of 0.3M NaCl. A positive bacterial clone was expanded and plasmid  
10 DNA was prepared. The plasmid contained an insert of approximately 3.3kb of DNA and was designated TOXHH1.

A 120 bp fragment containing the sequences between position 292 and 410 shown in Fig. 1 was derived from the plasmid TOXHH1 and used to screen approximately 400 colonies  
15 of the library of EcoRI fragments. A positive clone was isolated which contained approximately 7.3kb of DNA sequences and was designated TOXEE1.

The nucleotide sequence shown in Fig. 1 was derived from the clones TOXHH1 and TOXEE1 using the Sequenase 2 sequencing kit. The nucleotides between position  
20 1 and 410 in Fig. 1 were derived from TOXHH1 and those between 291 and 3507 were derived from TOXEE1. E. coli containing plasmids TOXHH1 and TOXEE1 have been deposited with the American Type Culture Collection, see below.

25 d. Preparation of antisera against the cytotoxin

A DNA fragment corresponding to nucleotides 116-413 of the sequence shown in Fig. 1 was cloned into the bacterial expression vector pex 34 A, such that on induction of the bacterial promoter, a fusion protein was produced  
30 which contained a part of the MS2 polymerase polypeptide fused to the amino acids of the cytotoxin polypeptide and including the 23 amino acids previously identified. Approximately 200 micrograms of this fusion protein were partially purified by acrylamide gel electrophoresis and  
35 used to immunize rabbits by standard procedures.

Antisera from these rabbits taken after 3 immunizations spaced 1 month apart was used to probe protein extracts from a cytotoxin positive and a cytotoxin negative strain of H. pylori in standard immunoblotting experiments.



The antisera revealed a polypeptide which migrated on denaturing polyacrylamide gel electrophoresis with an apparent molecular mass of 100 kDa. This polypeptide was detected in protein extracts of the cytotoxin positive but not the cytotoxin negative strain. Serum collected prior to immunization did not react with this polypeptide.

e. Partial purification of vacuolating activity

Total H. pylori membranes at a concentration of 6 mg/ml were solubilized in a solution of 1% CHAPS, 0.5 M NaCl, 10 mM Hepes pH 7.4, 2.5 mM EDTA, 20% sucrose for 1 hour at 4°C. This mixture was then applied to a discontinuous sucrose gradient containing steps of 30%, 35%, 40% and 55% sucrose and subjected to ultracentrifugation for 17 hours at 20000 x g. The gradient was fractionated and each fraction was tested for vacuolating activity and for urease activity. Vacuolating activity associated with urease activity was found in several fractions of the gradient. A peak of vacuolating activity was also found in the topmost fractions of the gradient and these fractions were essentially free of urease activity.

This urease-independent vacuolating activity was further fractionated by stepwise precipitation with ammonium sulphate between concentrations of 20% to 34%. Denaturing polyacrylamide gel electrophoresis of the proteins precipitated at different concentrations of ammonium sulphate revealed a predominant polypeptide of about 100 kDa which copurified with the vacuolating activity. This polypeptide was recognised by the rabbit antisera raised against the recombinant fusion protein described above.

2. Results

Two overlapping fragments corresponding to about 10 kbp of the H. pylori genome have been cloned. These clones contain a gene consisting of 3960 bp (shown in Fig.1) which is capable of coding for a polypeptide of 1296 amino acids (shown in Fig.2). The molecular weight of this putative polypeptide is 139.8 kd. The nucleotide sequence AGGAAG 9 bp upstream of the methionine codon at position 18 in Fig.1 resembles closely the consensus Shine-Dalgarno sequence and supports the hypothesis that this methionine

represents the initiator methionine for synthesis of the polypeptide. A 30 bp nucleotide sequence which begins 10 bp downstream of the putative stop codon at position 3906 in Fig. 1 resembles closely the structure of prokaryotic transcription terminators and is likely to represent the end of the messenger RNA coding sequences.

The cytotoxin gene is defined as coding for a polypeptide precursor of the H. pylori vacuolating activity by the following criteria:

(i) The putative polypeptide contains the 23 amino acid sequence (Fig. 2, positions 34-56) identified as the amino terminus of the previously described 87 kDa vacuolating protein, Clover et al., J. Biol. Chem. 267:10570-75 (1992). This sequence is preceded by 33 amino acids which resemble prokaryotic leader sequences; thus, this sequence is likely to represent the amino terminus of a mature protein;

(ii) Rabbit antisera specific for a 100 amino acid fragment of the putative polypeptide containing the proposed amino terminus recognized a 100 kDa polypeptide in a cytotoxin positive but not a cytotoxin negative strain of H. pylori. This 100 kDa polypeptide copurifies with vacuolating activity from H. pylori membranes.

In sum, the gene described herein codes for an approximately 140 kDa polypeptide which is processed to a 100 kDa polypeptide involved in H. pylori cytotoxic activity. The 87 kDa polypeptide previously described must result from either further processing of the 100 kDa polypeptide or from proteolytic degradation during purification.

#### ii. H. pylori CAI antigen

##### 1. Materials and methods

###### a. Origin of materials

Clones A1, 64/4, G5, A17, 24 and 57/D were obtained from the lambda gt11 library. Clone B1 was obtained from a genomic plasmid library of HindIII fragments. 007 was obtained by PCR. The H. pylori strains producing the cytotoxin were: G10, G27, G29, G32, G33, G39, G56, G65, G105, G113A. The noncytotoxic strains were: G12, G21, G25,

G47, G50, G204. They were isolated from endoscopy biopsy specimens at the Grosseto Hospital, (Tuscany, Italy). The strain CCUG 17874 (cytotoxin positive), was obtained from the Culture Collection of the University of Gotheborg. The noncytotoxic strains Pylo 2U+ (urease positive) and Pylo 2U- (urease negative) were obtained from F. Megraud, Centre Hospitalier, Bordeaux (France). E. coli strains DH10B (Bethesda Research Laboratories), TG1, K12 delta H1 delta trp, Y1088, Y1089, Y1090 are known in the art. Plasmid Bluescript SK+ (Stratagene, La Jolla, CA) was used as a cloning vector. The pEx34 a, b, c plasmids for the expression of MS2 fusion proteins have been previously described. The lambda gt11 phage vector used for the expression library is from the lambda gt11 cloning system kit (Bethesda Research Laboratories). E. coli strains were cultured in LB medium (24). H. pylori strains were plated onto selective media (5% horse blood, Columbia agar base with Dent or Skirrow's antibiotic supplement, 0.2% cyclodextrin) or in Brucella broth liquid medium containing 5% fetal bovine serum (6) or 0.2% cyclodextrin (25).

b. Growth of H. pylori and DNA isolation

H. pylori strains were cultured in solid or liquid media for 3 days at 37 °C, both in microaerophilic atmosphere using Oxoid (Basingstoke, England) or Becton and Dickinson (Cockeysville, MD) gas pack generators or in an incubator containing air supplemented with 5% CO<sub>2</sub>, (26). The bacteria were harvested and resuspended in STE (NaCl 0.1M, Tris-HCl 10mM pH 8, EDTA 1 mM pH 8) containing lysozyme at a final concentration of 100 micrograms/ml and incubated at room temperature for 5 min. To lyse the bacteria SDS was added to a final concentration 1% and heated at 65 °C. After the addition of proteinase K at final concentration of 25 micrograms/ml the solution was incubated at 50° for 2 hours. The DNA was purified by CsCl gradient in the presence of ethidium bromide, precipitated with 77% ethanol and recovered with a sealed glass capillary.

c. Construction and screening of a lambda gt11 expression library

To generate the lambda gt11 expression library,

genomic DNA from the CCUG 17874 strain partially digested with the restriction enzymes HaeIII and AluI was used. After fractionation on 0.8% agarose gel, the DNA between 0.6 and 8 Kb in size was eluted using a Costar Spin-X (0.22 micron) microcentrifuge filter. The products from each digestion were combined, and used to construct the expression library, using the lambda gt11 cloning system kit (Bethesda Research Laboratories) and the Gigapack II Gold packaging kit (Stratagene, La Jolla, CA). The library that contained  $0.8-1 \times 10^6$  recombinant phages was amplified in *E. coli* Y1088, obtaining 150 ml of a lysate with a titer of  $10^9$  phages/ml, 85% of which were recombinant and had an average insert size of 900 base pairs,. Immunological screening was performed by standard procedures, using the Protoblot system (Promega, Madison, WI).

d. Construction of plasmid libraries

Attempts to make complete genomic libraries of partially digested chromosomal DNA, using standard vectors such as EMBL4 or lambda Dash encountered the difficulties described also by many authors in cloning *H. pylori* DNA and failed to give satisfactory libraries. Therefore, partial libraries were obtained using genomic DNA from strains CCUG 17874, G39 and G50 digested with the restriction enzyme HindIII, cloned in the Bluescript SK+. DNA ligation, electroporation of *E. coli* DH 10B, screening, and library amplification have been performed. Libraries ranging from 70000 to 85000 colonies with a background not exceeding the 10% were obtained.

e. DNA manipulation and nucleotide sequencing

DNA manipulation was performed using standard procedures. DNA sequencing was performed using Sequenase 2.0 (USB) and the DNA fragments shown in Fig. 3 subcloned in Bluescript KS+. Each strand was sequenced at least three times. The region between nucleotides 1533 and 2289, for which a DNA clone was not available, was amplified by PCR and sequenced using asymmetric PCR, and direct sequencing of amplified products. The overlapping of this region, was confirmed by one and double side anchored PCR: an external universal anchor (5'-GCAAGCTTATCGATGTCGACTCGAGCT-3'/ 5'-

GACTCGAGTCGACATCGA-3') containing a protruding 5' HindIII sequence, and the recognition sites of ClaI, SalI, XhoI, was ligated to primer-extended DNA and amplified. A second round of PCR using nested primers was then used to obtain  
5 fragments of DNA suitable for cloning and sequencing. DNA sequence data were assembled and analyzed with the GCG package (Genetics Computer Group, Inc., Madison, WI) running on a VAX 3900 under VMS. The GenBank and EMBL databases were examined using the EMBL VAXcluster.

10 f. Protein preparation and ELISA

Protein extracts were obtained by treating H. pylori pellets with 6 M guanidine. Western blotting, SDS-PAGE, electroelution were performed by standard procedures. Fusion proteins were induced and purified by electrocution  
15 or by ion exchange chromatography. Purified proteins were used to immunize rabbits and to coat microtiter plates for ELISA assays. Sera from people with normal mucosa, blood donors and patients were obtained from A. Ponzetto (Torino, Italy). Clinical diagnosis was based on histology of gastric  
20 biopsies. Vacuolating activity of samples was tested on HeLa cells as described by Cover et al. Infect. Immun. 59:1264-70 (1991).

2. Results

a. Immunodominance and cytotoxicity

25 Western blots of H. pylori guanidine extracts probed with sera from patients with gastroduodenal disease showed that a protein of 130 kDa that is a minor component in the Coomassie blue stained gel was strongly recognized by all sera tested. The CAI protein was electroeluted and used  
30 to raise a mouse serum that in a Western blot recognized only this protein. This serum was then used to detect by Western blotting the CAI protein in extracts of the H. pylori strains. The antigen was present in the all 10 strains that had vacuolizing activity on HeLa cells while it  
35 was absent in the eight strains that did not have such activity; in addition, the size of the protein varied slightly among the strains. The CAI antigen was not detected by western blotting in the other species tested such as Campylobacter jejuni, Helicobacter mustelae, E. coli, and

Bordetella pertussis.b. Structure of the cai gene

10<sup>6</sup> clones of the lambda gt11 expression library were screened using the mouse serum specific for the CAI antigen and with a pool of sera from patients with gastroduodenal diseases. The mouse serum detected positive clones at a frequency of  $3 \times 10^{-3}$ . Sequence analysis of 8 clones revealed that they were all partially overlapping with clone A1 shown in Fig. 3. The pool of human sera identified many clones containing different regions of the cai gene, including clones 57/D, 64/4 and 24 and several clones overlapping clone A1.

In Fig. 3, clones A1, 64/4, G5, A17, 24, and 57/D were obtained from the lambda gt11 library. Clone B1 was obtained from a plasmid library of HindIII fragments. E. coli containing plasmids 57/D, 64/4, B1 (B/1), and P1-24 (the latter most plasmid from nucleotide 2150 to 2650) have been deposited with the American Type Culture Collection (ATCC), see below. 007 was obtained by PCR. The open-reading frame is shown at the bottom of Fig. 3. Arrows indicate the position and direction of the synthetic oligonucleotides used as primers for sequencing, and the position of insertion of the repeated sequence of G39 is shown. The nucleotide and amino acid sequence of one of the repeated sequences found in strain G39 is also shown. The capital letters indicate the sequences D1, D2, and D3 duplicated from the cai gene, the small letters indicate the nucleotide and amino acid linkers, P=promoter, and T=terminator.

The nucleotide sequence of the entire region was determined using the clones derived from the lambda gt11 library, the clone B1 isolated from the HindIII plasmid library, and the fragment 007 that was obtained by PCR of the chromosomal DNA. Computer analysis of the 5925 nucleotide sequence revealed a long open reading frame spanning nucleotides 535 to 3977 that was in frame with the fusion proteins deriving from the lambda gt11 clones 64/4, 24 and A1 and A17. Clone 57/D contained an open reading frame only in the 3' end of cloned fragment and therefore

could not make a gene fusion with the beta galactosidase gene of lambda gt11. The presence of an immunoreactive protein in the lambda gt11 clone 57/D could only be explained by the presence of an endogenous promoter driving the expression of a non fused protein. This hypothesis was proven to be true by subcloning in both direction the insert 57/4 into the Bluescript plasmid vector and showing that an immunoreactive protein was obtained in both cases. A conclusive evidence that the gene identified was indeed coding for the CAI antigen was obtained by subcloning the inserts A17 and 64/4 in the pEx 34B plasmid vectors to obtain fusion proteins that were purified and used to immunize rabbits. The sera obtained, recognized specifically the CAI antigen band in cytotoxic H. pylori strains.

The cai gene coded for a putative protein of 1147 amino acids, with predicted molecular weight of 128012.73 Daltons and an isoelectric point of 9.72. The basic properties of the purified protein were confirmed by two dimensional gel electrophoresis. The codon usage and the GC content (37%) of the gene were similar to that described for other H. pylori genes (13,26). A putative ribosome binding site: AGGAG, was identified 5 base pairs upstream from the proposed ATG starting codon. Computer search for promoter sequences of the region upstream from the ATG start codon, identified sequences resembling either -10 or -35 regions, however, a region with good consensus to an E. coli promoter, or resembling published H. pylori promoter sequences was not found. Primer extension analysis of purified H. pylori RNA showed that 104 and 214 base pairs upstream from the ATG start codon there are two transcriptional start sites. Canonical promoters could not be identified upstream from either transcriptional initiation sites. The expression of a portion of the CAI antigen by clone 57/D suggests that E. coli is also recognizing a promoter in this region, however, it is not clear whether E. coli recognizes the same promoters of H. pylori or whether the H. pylori DNA that is rich in A-T provides E. coli with regions that may act as promoters. A rho independent terminator was identified downstream from

the stop codon. In Fig. 4, the AGGAG ribosome binding site and terminator are underlined, and the repeated sequence and motif containing 6 asparagines are boxed. The CAI antigen was very hydrophilic, and did not show obvious leader peptide or transmembrane sequences. The most hydrophilic region was from amino acids 600 to 900, where also a number of unusual features can be observed: the repetition of the sequences EFKNGKNKDFSK and EPYIA, and the presence of a stretch of six contiguous asparagines (boxed in Fig. 4).

10 c. Diversity of the cai gene

Diversity of the gene appears to be generated by internal duplications. To find out the mechanism of size heterogeneity of the CAI proteins in different strains, the structure of one of the strains with a larger CAI protein (G39) was analyzed using Southern blotting, PCR and DNA sequencing. The results showed that the cai gene of G39 and CCUG 17874 were identical in size until position 3406, where the G39 strain was found to contain an insertion of 204 base pairs, made by two identical repeats of 102 base pairs. Each repeat was found to contain sequences deriving from the duplication of 3 segments of DNA (sequences D1, D2 and D3 in Fig. 3) coming from the same region of the cai gene and connected by small linker sequences. A schematic representation of the region where the insertion occurred and of the insertion itself is shown in Fig. 3.

25 d. cai gene absent in noncytotoxic strains

To investigate why the CAI antigen was absent in the noncytotoxic strains, DNA from two of them (G50 and G21), was digested with EcoRI, HindIII and HaeIII restriction enzymes, and tested by Southern blotting using two probes internal to the cai gene, spanning nucleotides 520-1840 and 2850-4331 respectively. Both probes recognized strongly hybridizing bands in strains CCUG 17874 and G39. The bands varied in size in the two strains, in agreement with the gene diversity. However, neither probe hybridized the G50 and G21 DNA. This showed that the noncytotoxic strains tested do not contain the cai gene.

35 e. Serum antibodies

The presence of serum antibodies against the CAI



antigen correlated with gastroduodenal diseases. To study the quantitative antibody response to the CAI antigen, the fusion protein produced by the A17 fragment subcloned in pEx34 was purified to homogeneity and used to coat microtiter plates for an ELISA test. In this assay, the patients with gastroduodenal pathologies had an average ELISA titer that was significantly higher than that found in randomly selected blood donors and people with normal gastric mucosa. To evaluate whether the antibody titer correlated with a particular gastroduodenal disease, the sera from patients with known histological diagnosis were tested in the ELISA assay. Patients with duodenal ulcer had an average antibody titer significantly higher than all the other diseases. Altogether, the ELISA was found to be able to predict 75.3% of the patients with any gastroduodenal disease and 100% of the patients with duodenal ulcer.

In one particular ELISA, a recombinant protein containing 230 amino acids deriving from CAI antigen was identified by screening an expression library of H. pylori DNA using an antiserum specific for the protein. The recombinant antigen was expressed as a fusion protein in E. coli, purified to homogeneity, and used to coat microtiter plates. The plates were then incubated for 90 minutes with a 1/2000 dilution of goat anti-human IgG alkaline phosphatase conjugate. Following washing, the enzyme substrate was added to the plates and the optical density at 405 nm was read 30 minutes later. The cutoff level was determined by the mean absorbance plus two standard deviations, using sera from 20 individuals that had neither gastric disease nor detectable anti-H. pylori antibodies in Western blotting. The ELISA assay was tested on the peripheral blood samples of eighty-two dyspeptic patients (mean age 50.6±13.4 years, ranging from 28 to 80) undergoing routine upper gastrointestinal endoscopy examination. The gastric antral mucosa of patients was obtained for histology and Giemsa stain. Twenty of the patients had duodenal ulcer, 5 had gastric ulcer, 43 had chronic active gastritis type B, 8 had duodenitis and 6 had a normal histology of gastric mucosa. All of the patients with duodenal ulcer had

an optical density value above the cutoff level. The patients with duodenitis, gastric ulcer, and chronic gastritis, had a positive ELISA value in 75%, 80% and 53.9% of the cases, respectively. The agreement between ELISA and  
5 histological Giemsa staining was 95% in duodenal ulcer, 98% in duodenitis, 80% in gastric ulcer and 55.8% in chronic gastritis. This assay gives an excellent correlation with duodenal ulcer disease ( $p < 0.0005$ ).

iii. Heat shock protein (hsp)

10 1. Materials and methods

a. H. pylori strains and growth conditions

H. pylori strains used were: CCUG 17874, G39 and G33 (isolated from gastric biopsies in the hospital of Grosseto, Italy), Pylo 2U+ and Pylo 2U- (provided by F.  
15 Megraud, hospital Pellegrin, Bordeaux, France), BA96 (isolated by gastric biopsies at the University of Siena, Italy). Strain Pylo 2U+ is noncytotoxic; strain Pylo 2U- is noncytotoxic and urease-negative. All strains were routinely grown on Columbia agar containing 0.2% of  
20 cyclodextrin, 5µg/ml of cefsulodin and 5µg/ml of amphotericin B under microaerophilic conditions for 5-6 days at 37°C°. Cells were harvested and washed with PBS. The pellets were resuspended in Laemmli sample buffer and lysed by boiling.

25 Sera of patients affected by gastritis and ulcers (provided by A. Ponzetto, hospital "Le Molinette", Torino, Italy) and sera of patients with gastric carcinoma (provided by F. Roviello, University of Siena, Italy) were used.

b. Immunoscreening of the library

30 Five hundred thousand plaques of a λgt11 H. pylori DNA expression library were mixed with 5 ml of a suspension of E. coli strain Y1090 grown O/N in LB with 0.2% Maltose and 10mM MgSO<sub>4</sub>, and resuspended in 10mM MgSO<sub>4</sub> at 0.5 O.D. After 10 minutes incubation at 37°C, 75 ml of melted  
35 TopAgarose were poured in the bacterial/phage mix and the whole was plated on BBL plates (50,000 plaques/plate). After 3.5 hrs incubation of the plated library at 42°C, nitrocellulose filters (Schleicher and Schuell, Dassel, Germany), previously wet with 10mM IPTG, were set on plates

and incubation was prolonged for 3.5 hrs at 37°C and then O/N at 4°C. Lifted filters with lambda proteins were rinse in PBS, and saturated in 5% nonfat dried milk dissolved in TBST (10mM TRIS pH 8, 100mM NaCl, 5M MgCl<sub>2</sub>) for 20'. The first hybridization step was performed with the sera of patients; to develop and visualize positive plaques we used an anti human Ig antibody alkaline phosphatase conjugated (Cappel, West Chester, PA) and the NBT/BCIP kit (Promega, Madison, WI) in AP buffer (100mM Tris pH 9.5, 100mM NaCl, 5mM MgCl<sub>2</sub>) according to the manufacturer instructions.

c. Recombinant DNA procedures

Reagents and restriction enzymes used were from Sigma (St. Louis, MO) and Boehringer (Mannheim, Germany). Standard techniques were used for molecular cloning, single-stranded DNA purification, transformation in E. coli, radioactive labeling of probes, colony screening of the H. pylori DNA genomic library, Southern blot analysis, PAGE and Western blot analysis.

d. DNA sequence analysis

The DNA fragments were subcloned in Bluescript SK+ (Stratagene, San Diego, CA). Single-stranded DNA sequencing was performed by using [<sup>32</sup>P]dATP (New England Nuclear, Boston, MA) and the Sequenase kit (U.S. Biochemical Corp., Cleveland, OH) according to the manufacturer instructions. The sequence was determined in both strands and each strand was sequenced, on average, twice. Computer sequence analysis was performed using the GCG package.

e. Recombinant proteins

MS2 polymerase fusion proteins were produced using the vector pEX34A, a derivative of pEX31. Insert Hp67 (from nucleotide 445 to nucleotide 1402 in Fig. 5), and the EcoRI linkers were cloned in frame into the EcoRI site of the vector. In order to confirm the location of the stop codon, the HpG3' HindIII fragment was cloned in frame into the HindIII site of pEX34A. Recombinant plasmids were transformed in E. coli K12 [H1 Δtrp. In both cases after induction, a fusion protein of the expected molecular weight was produced. In the case of the EcoRI/EcoRI fragment, the fusion protein obtain after induction was electroeluted to

immunize rabbits using standard protocols.

## 2. Results

### a. Screening of an expression library and cloning of H. pylori hsp

5                   In order to find a serum suitable for the screening of an H. pylori DNA expression library, sonicated extracts of H. pylori strain CCUG 17874 were tested in Western blot analysis against sera of patients affected by different forms of gastritis. The pattern of antigen  
10 recognition by different sera was variable, probably due to differences in the individual immune response as well as to the differences in the antigens expressed by the strains involved in the infection.

                  Serum N°19 was selected to screen a  $\lambda$ gt11 H. pylori DNA expression library to identify H. pylori specific  
15 antigens, expressed in vivo during bacterial growth. Following screening of the library with this serum, many positive clones were isolated and characterized. The nucleotide sequence of one of these, called Hp67, revealed  
20 an open-reading frame of 958 base-pairs, coding for a protein with high homology to the hsp60 family of heat-shock proteins, Ellis, Nature 358:191-92 (1992). In order to obtain the entire coding region, we used fragment Hp67 as a probe on Southern blot analysis of H. pylori DNA digested  
25 with different restriction enzymes. Probe Hp67 recognized two HindIII bands of approximately 800 and 1000 base-pairs, respectively. A genomic H. pylori library of HindIII-digested DNA was screened with probe Hp67 and two positive clones (HpG5' and HpG3') of the expected molecular weight  
30 were obtained. E. coli containing plasmids pHp60G2 (approximately nucleotides 1 to 829) and pHp60G5 (approximately nucleotides 824 to 1838) were deposited with the American Type Culture Collection (ATCC).

### b. Sequence analysis

35                   The nucleotide sequence analysis revealed an open-reading frame of 1638 base-pairs, with a putative ribosome binding site 6 base-pairs upstream the starting ATG. Fig. 5 shows the nucleotide and amino acid sequences of H. pylori hsp. The putative ribosome-binding and the internal HindIII

site are underlined. Cytosine in position 445 and guanine in position 1402 are the first and last nucleotide, respectively, in fragment Hp67. Thymine 1772 was identified as the last putative nucleotide transcribed using an algorithm for the localization of factor-independent terminator regions. The open-reading frame encoded for a protein of 546 amino acids, with a predicted molecular weight of 58.3 KDa and a predicted pI of 5.37. The codon preference of this gene is in agreement with the H. pylori codon usage.

The analysis of the hydrophobicity profiles revealed a protein mostly hydrophilic, without a predicted leader peptide or other transmembrane domains. The amino terminal sequence showed 100% homology to the sequence of 30 amino acids determined by Dunn et al., Infect. Immun. 60:1946-51 (1992) on the purified protein and differed by only one residue (Ser42 instead of Lys) from the sequence of 44 amino acids published by Evans et al., Infect. Immun. 60:2125-27 (1992). (Evans et al., 1992). The N-terminal sequence of the mature hsp protein did not contain the starting methionine, indicating that this had been removed after translation.

c. Homology with hsp60 family

The amino acid sequence analysis showed a very strong homology with the family of heat-shock proteins hsp60, whose members are present in every living organism. Based on the degree of homology between hsp60 proteins of different species, H. pylori hsp belongs to the subgroup of hsp60 proteins of Gram negative bacteria; however, the degree of homology to the other proteins of the hsp60 family is very high (at least 54% identity).

d. Expression of recombinant proteins and production of a polyclonal antiserum

The inserts of clone Hp67 and of clone HpG3' were subcloned in the expression vector pEX34A in order to express these open-reading frames fused to the aminotermus of the MS2 polymerase. The clones produced recombinant proteins of the expected size and were recognized by the human serum used for the initial screening. The fused

protein derived from clone Hp67 was electroeluted and used to immunize rabbits in order to obtain anti-hsp specific polyclonal antisera. The antiserum obtained recognized both fusion proteins, and a protein of 58 KDa on whole-cell  
5 extracts of several strains of H. pylori tested, including a urease-negative strain and noncytotoxic strains.

Hsp has been shown to be expressed by all the H. pylori strains tested and its expression is not associated with the presence of the urease or with the cytotoxicity.  
10 The protein recognized by the anti-hsp antiserum was found in the water soluble extracts of H. pylori and copurified with the urease subunits. This suggests a weak association of this protein with the outer bacterial membrane. Thus, hsp can be described as urease-associated and surface  
15 exposed. The cellular surface localization is surprising as most of the hsp homologous proteins are localized in the cytoplasm or in mitochondria and plastids. The absence of a leader peptide in hsp suggests that this is either exported to the membrane by a peculiar export system, or  
20 that the protein is released from the cytoplasm and is passively adsorbed by the bacterial membrane after death of the bacterium.

Hsp60 proteins have been shown to act as molecular chaperons assisting the correct folding, assembly and  
25 translocation of either oligomeric or multimeric proteins. The cellular localization of H. pylori hsp and its weak association with urease suggest that hsp may play a role in assisting the folding and/or assembly of proteins exposed on the membrane surface and composed of multiple subunits such  
30 as the urease, whose final quaternary structure is  $A_6B_6$ . Austin et al., J. Bacteriol. 174:7470-73 (1992) showed that the H. pylori hsp ultrastructure is composed of seven subunits assembled in a disk-shaped particle that further stack side by side in groups of four. This structure  
35 resembles the shape and dimension of the urease macromolecule and this could explain the common properties of these two macromolecules that lead to their copurification. H. pylori hsp gene, however, is not part of the urease operon. In agreement with the gene structure of

other bacterial hsp60 proteins, it should be part of a dicistronic operon.

e. Presence of anti-hsp antibodies in patients with gastroduodenal diseases

5           The purified fusion protein was tested by Western blot using sera of patients infected by H. pylori and affected by atrophic and superficial gastritis, and patients with duodenal and gastric ulcers: most of the sera recognized the recombinant protein. However, the degree of  
10 recognition greatly varied between different individuals and the antibody levels did not show any obvious correlation with the type of disease. In addition, antibodies against H. pylori antigens and in particular against hsp protein were found in most of the 12 sera of patients affected by  
15 gastric carcinoma that were tested. Although H. pylori hsp recognition could not be put in relation with a particular clinical state of the disease given the high conservation between H. pylori hsp and its human homolog, it is possible that this protein may induce autoimmune antibodies cross-reacting with the human counterpart. This class of homologous proteins has been implicated in the induction of autoimmune disorders in different systems. Then present of high titers of anti-H. pylori hsp antibodies, potentially cross-reacting with the human homolog in dyspeptic patients,  
20 suggests that this protein has a role in gastroduodenal disease. This autoreactivity could play a role in the tissue damage that occurs in H. pylori-induced gastritis, thus increasing the pathogenic mechanisms involved in the infection of this bacterium.

30           The high levels of antibodies against such a conserved protein is somewhat unusual; due to the high homology between members of the hsp60 family, including the human one, this protein should be very well tolerated by the host immune system. The strong immune response observed in  
35 many patients may be explained in two different ways: (1) the immune response is directed only against epitopes specific for H. pylori hsp; (2) the immune response is directed against epitopes which are in common between H. pylori hsp and human homolog.

H. Deposit of Biological Materials

The following materials were deposited on December 15, 1992 and January 22, 1993 by Biocine Sclavo, S.p.A., the assignee of the present invention, with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland, phone (301) 231-5519, under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for Purposes of Patent Procedure. For the cytotoxin protein (CT):

- 10 ATCC No. 69157 E. coli TG1 containing the plasmid TOXHH1  
ATCC No. n/a E. coli TG1 containing the plasmid TOXEE1

For the CAI protein:

- ATCC No. 69158 E. coli TG1 containing the plasmid 57/D  
ATCC No. 69159 E. coli TG1 containing the plasmid 64/4  
15 ATCC No. 69160 E. coli TG1 containing the plasmid P1-24  
ATCC No. 69161 E. coli TG1 containing the plasmid B/1 For the heat shock protein (hsp):

- ATCC No. 69155 E. coli TG1 containing the plasmid pHp60G2  
ATCC No. 69156 E. coli TG1 containing the plasmid pHp605

- 20 These deposits are provided as convenience to those of skill in the art, and are not an admission that a deposit is required under 35 U.S.C. §112. The nucleic acid sequences of these deposits, as well as the amino acid sequences of the polypeptides encoded thereby, are  
25 incorporated herein by reference and should be referred to in the event of any error in the sequences described herein as compared with the sequences of the deposits. A license may be required to make, use, or sell the deposited materials, and no such license is granted hereby.

30



## CLAIMS

What is claimed is:

1. A recombinant Helicobacter pylori protein, or  
5 a derivative or fragment thereof.

2. The recombinant protein according to claim 1  
wherein the protein is a Helicobacter pylori cytotoxin or a  
precursor, derivative or fragment thereof.

10 3. The recombinant protein according to claim 2  
wherein the cytotoxin, precursor, derivative or fragment  
thereof has the amino acid sequence of Figure 2, or a  
portion thereof.

15 4. The recombinant protein according to claim 1  
wherein the protein is a Helicobacter pylori cytotoxin  
associated immunodominant antigen, or a derivative or  
fragment thereof.

20 5. The recombinant protein according to claim 4  
wherein the cytotoxin associated immunodominant antigen,  
derivative or fragment has the amino acid sequence of Figure  
4, or a portion thereof.

25 6. The recombinant protein according to claim 1  
wherein the protein is a Helicobacter pylori heat shock  
protein, or a derivative or fragment thereof.

30 7. The recombinant protein according to claim 6,  
wherein the heat shock protein, derivative or fragment has  
the amino acid sequence of Figure 5 or a portion thereof.

35 8. The recombinant protein according to claim 2  
or 3 wherein the recombinant protein exhibits substantially  
no toxicity, or substantially reduced toxicity.

9. The recombinant protein according to any one  
of claims 4 to 7 wherein the recombinant protein is

immunogenic and exhibits no functional contribution to toxicity, or a substantially reduced functional contribution to toxicity.

5                   10. The recombinant protein according to claim 8 or 9 wherein the recombinant protein is chemically modified to reduce or abolish toxicity or functional contribution to toxicity.

10                   11. The recombinant protein according to claim 8 or 9 wherein the recombinant protein contains one or more amino acid substitutions or deletions.

15                   12. The recombinant protein according to any one of the preceding claims which is labelled or coupled to a solid support.

20                   13. The recombinant protein according to any one of claims 1 to 11 for use in the treatment of Helicobacter pylori infection.

14. The recombinant protein according to any one of claims 1 to 11 for use as a vaccine.

25                   15. A vaccine or therapeutic composition comprising a recombinant protein according to any one of claims 1 to 11 and a pharmaceutically acceptable carrier.

30                   16. The vaccine or therapeutic composition according to claim 15 comprising two or more recombinant proteins according to any one claims 1 to 11.

35                   17. The vaccine or therapeutic composition according to claim 16 comprising, in combination, two or more of

i) a recombinant Helicobacter pylori cytotoxic protein precursor, derivative or fragment thereof,

ii) a Helicobacter pylori recombinant cytotoxin

associated immunodominant antigen, or a derivative or fragment thereof,

iii) Helicobacter pylori recombinant heat shock protein or a derivative or fragment thereof and/or

5 iv) a Helicobacter pylori urease.

18. The vaccine or therapeutic composition according to any one of claims 15 to 17 comprising an adjuvant.

10

19. A method for the preparation of a vaccine or therapeutic composition according to any one of claims 15 or 18 comprising bringing one or more recombinant proteins according to any one of claims 1 to 11 into association with  
15 a pharmaceutically acceptable carrier and optionally an adjuvant.

20. An immunodiagnostic assay comprising at least one step involving as at least one binding partner, a  
20 recombinant protein according to any one of claims 1 to 12, optionally labelled or coupled to a solid support.

21. An immunodiagnosis kit for performing an assay according to claim 20, comprising at least one  
25 recombinant protein according to any one of claims 1 to 20.

22. Use of one or more recombinant proteins according to any one of claims 1 to 11 for the manufacture of a medicament for the treatment of Helicobacter pylori  
30 infection.

23. A method of treatment of an individual infected with Helicobacter pylori comprising administering an effective amount of a recombinant protein according to 1  
35 to 11.

24. The method of treatment according to claim 23 comprising administering an effective amount of, in combination, two or more of

- i) a recombinant Helicobacter pylori cytotoxic protein precursor, derivative or fragment thereof,
- ii) a Helicobacter pylori recombinant cytotoxin associated immunodominant antigen, or a derivative or fragment thereof,
- 5      iii) a Helicobacter pylori recombinant heat shock protein or a derivative or fragment thereof and/or
- iv) a Helicobacter pylori urease.

10                    25.      A method of vaccination comprising administering an immunologically effective amount of, in combination, two or more of

- i) a recombinant Helicobacter pylori cytotoxic protein precursor, derivative or fragment thereof,
- 15                    ii) a Helicobacter pylori recombinant cytotoxin associated immunodominant antigen, or a derivative or fragment thereof,
- iii) a Helicobacter pylori recombinant heat shock protein or a derivative or fragment thereof and/or
- 20                    iv) a Helicobacter pylori urease.

26.      A recombinant polynucleotide encoding a recombinant protein according to any one of claims 1 to 11.

27.      A recombinant polynucleotide encoding a Helicobacter pylori cytotoxic protein or a derivative or fragment thereof comprising all or part of the nucleotide sequence of Figure 1.

28.      A recombinant polynucleotide encoding a Helicobacter pylori recombinant cytotoxin associated immunodominant antigen or a derivative or fragment thereof comprising all or a part of the nucleotide sequence of Figure 4.

29.      A recombinant polynucleotide encoding a Helicobacter pylori recombinant heat shock protein or a derivative or fragment thereof comprising all or a part of

the nucleotide sequence of Figure 5.

5           30. A polynucleotide probe comprising all or part of the recombinant polynucleotide according to any one of claims 26 to 29.

          31. A nucleic acid assay wherein in at least one step involves a polynucleotide probe according to claim 30.

10           32. A kit for performing a nucleic acid assay comprising at least one polynucleotide probe according to claim 30.

15           33. A polynucleotide amplification process employing a polynucleotide primer wherein in at least one primer is a recombinant polynucleotide comprising all or part of the recombinant polynucleotide according to any one of claims 26 to 29.

20           34. A kit for performing a polynucleotide amplification process employing a polynucleotide primer wherein in at least one primer is a recombinant polynucleotide comprising all or part of the recombinant polynucleotide according to any one of claims 26 to 29.

25           35. A vector comprising a recombinant polynucleotide according to any one of claims 26 to 29.

30           36. A host cell transformed with a vector according to claim 35.

35           37. A method for the production of a recombinant polypeptide according to any one of claims 1 to 11, comprising culturing a host cell according to claim 36 and isolating the recombinant polypeptide.

1 / 14

1 AAAAAGAAAG GAAGAAAATG GAAATACAAC AAACACACCG CAAAATCAAT  
51 CGCCCTCTGG TTTCTCTCGC TTTAGTAGGA GCATTAGTCA GCATCACACC  
101 GCAACAAAGT CATGCCGCCT TTTTCACAAC CGTGATCATT CCAGCCATTG  
151 TTGGGGGTAT CGCTACAGGC ACCGCTGTAG GAACGGTCTC AGGGCTTCTT  
201 AGCTGGGGGC TCAAACAAGC CGAAGAAGCC AATAAAACCC CAGATAAACC  
251 CGATAAAGTT TGGCGCATT C AAGCAGGAAA AGGCTTTAAT GAATTCCCTA  
301 ACAAGGAATA CGACTTATAC AGATCCCTTT TATCCAGTAA GATTGATGGA  
351 GGTGTTGGGATT GGGGGAATGC CGCTAGGCAT TATTGGGTCA AAGGCGGGCA  
401 ACAGAATAAG CTTGAAGTGG ATATGAAAGA CGCTGTAGGG ACTTATACCT  
451 TATCAGGGCT TAGAACTTT ACTGGTGGGG ATTTAGATGT CAATATGCAA  
501 AAAGCCACTT TACGCTTGGG CCAATTCAAT GGCAATTCTT TTACAAGCTA  
551 TAAGGATAGT GCTGATCGCA CCACGAGAGT GATTTCAACG CTAAAAATAT  
601 CTCAATTGAT AATTTTGCAG AAATCAACAA CTCGTGTGGG TTCTGGAGCC  
651 GGGAGGAAAG CCAGCTCTAC GGTTTTGACT TTGCAAGCTT CAGAAGGGAT  
701 CACTAGCGAT AAAAACGCTG AAATTTCTCT TTATGATGGT GCCACGCTCA  
751 ATTTGGCTTC AAGCAGCGTT AAATTAATGG GTAATGTGTG GATGGGCCGT  
801 TTGCAATACG TGGGAGCGTA TTTGGCCCCT TCATACAGCA CGATAAACAC  
851 TTCAAAAGTA ACAGGGGAAG TGAATTTTAA CCACCTCACT GTTGGCGATA  
901 AAAACGCCGC TCAAGCGGGC ATTATCGCTA ATAAAAAGAC TAATATTGGC  
951 AACTGGATT TGTGGCAAAG CGCCGGGTTA AACATTATCG CTCCTCCAGA  
1001 AGGTGGCTAT AAGGATAAAC CCAATAATAC CCCTTCTCAA AGTGGTGCTA  
1051 AAAACGACAA AAATGAAAGC GCTAAAAACG ACAAACAAGA GAGCAGTCAA  
1101 AATAATAGTA AACTCAGGT CATTAAACCA CCAATAGTG CGCAAAAAAC  
1151 AGAAGTTCAA CCCACGCAAG TCATTGATGG GCCTTTTGC GGC GGCAAAG  
1201 ACACGGTTGT CAATATCAAC CGCATCAACA CTAACGCTGA TGGCAGGATT  
1251 AGAGTGGGAG GGTTTAAAGC TTCTCTTACC ACCAATGCGG CTCATTTGCA  
1301 TATCGGCAAA GGC GG GTGTCA ATCTGTCCAA TCAAGCGAGC GGGCGCTCTC

FIG. 1A

ERSATZBLATT

2 / 14

1351 TTATAGTGGA AAATCTAACT GGGAATATCA CCGTTGATGG GCCTTTAAGA  
1401 GTGAATAATC AAGTGGGTGG CTATGCTTTG GCAGGATCAA GCGCGAATTT  
1451 TGAGTTTAAAG GCTGGTACGG ATACCAAAAA CGGCACAGCC ACTTTTAATA  
1501 ACGATATTAG TCTGGGAAGA TTTGTGAATT TAAAGGTGGA TGCTCATACA  
1551 GCTAATTTTA AAGGTATTGA TACGGGTAAT GGTGGTTTCA ACACCTTAGA  
1601 TTTTAGTGGC GTTACAGACA AAGTCAATAT CAACAAGCTC ATTACGGCTT  
1651 CCACTAATGT GGCCGTAAAA AACTTCAACA TTAATGAATT GATTGTAAAA  
1701 ACCAATGGGA TAAGTGTGGG GGAATATACT CATTTTAGCG AAGATATAGG  
1751 CAGTCAATCG CGCATCAATA CCGTGCGTTT GGAAACTGGC ACTAGGTCAC  
1801 TTTTCTCTGG GGGTGTAAAA TTAAAGGTG GCGAAAAATT GGTATAGAT  
1851 GAGTTTTACT ATAGCCCTTG GAATTATTTT GACGCTAGAA ATATTAATAA  
1901 TGTTGAAATC ACCAATAAAC TTGCTTTTGG ACCTCAAGGA AGTCCTTGGG  
1951 GCACATCAAA ACTTATGTTT AATAATCTAA CCCTAGGTCA AAATGCGGTC  
2001 ATGGATTATA GCCAATTTTT AAATTTAACC ATTCAAGGGG ATTTTCATCA  
2051 CAATCAAGGC ACTATCAACT ATCTGGTCCG AGGTGGGAAA GTGGCAACCT  
2101 TAAGCGTAGG CAATGCAGCA GCTATGATGT TTAATAATGA TATAGACAGC  
2151 GCGACCGGAT TTTACAAACC GCTCATCAAG ATTAACAGCG CTCAAGATCT  
2201 CATTAAAAAT ACAGAACATG TTTTATTGAA AGCGAAAATC ATTGTTATG  
2251 GTAATGTTTC TACAGGTACC AATGGCATTG GTAATGTTAA TCTAGAAGAG  
2301 CAATTCAAAG AGCGCCTAGC CCTTTATAAC AACAATAACC GCATGGATAC  
2351 TTGTGTGGTG CGAAATACTG ATGACATTAA AGCATGCGGT ATGGCTATCG  
2401 GCGATCAAAG CATGGTGAAC AACCTGACA ATTACAAGTA TCTTATCGGT  
2451 AAGGCATGGA AAAATATAGG GATCAGCAAA ACAGCTAATG GCTCTAAAT  
2501 TTCGGTGTAT TATTTAGGCA ATTCTACGCC TACTGAGAAT GGTGGCAATA  
2551 CCACAAATTT ACCCACAAC ACCACTAGCA ATGCACGTTC TGCCAACAAC  
2601 GCCCTTGCAC AAAACGCTCC TTTCGCTCAA CCTAGTGCTA CTCCTAATTT  
2651 AGTCGCTATC AATCAGCATG ATTTTGGCAC TATTGAAAGC GTGTTTGAAT

FIG. 1B

ERSATZBLATT

3 / 14

2701 TGGCTAACCG CTCTAAAGAT ATTGACACGC TTTATGCTAA CTCAGGCGCT  
2751 CAAGGCAGGG ATCTCTTACA AACCTTATTG ATTGATAGCC ATGATGCGGG  
2801 TTATGCCAGA AAAATGATTG ATGCTACAAG CGCTAATGAA ATCACCAAGC  
2851 AATTGAATAC GGCCACTACC ACTTTAAACA ACATAGCCAG TTTAGAGCAT  
2901 AAAACCAGCG GCTTACAAAC TTTGAGCTTG AGTAATGCGA TGATTTTAAA  
2951 TTCTCGTTTA GTCAATCTCT CCAGGAGACA CACCAACCAT ATTGACTCGT  
3001 TCGCCAAACG CTTACAAGCT TTAAGAGACC AAAAATTCGC TTCTTTAGAA  
3051 AGCGCGGCAG AAGTGTTGTA TCAATTTGCC CCTAAATATG AAAAACCTAC  
3101 CAATGTTTGG GCTAACGCTA TTGGGGGAAC GAGCTTGAAT AATGGCTCTA  
3151 ACGCTTCATT GTATGGCACA AGCGCGGGCG TAGACGCTTA CCTTAACGGG  
3201 CAAGTGGAAG CCATTGTGGG CGGTTTTGGA AGCTATGGTT ATAGCTCTTT  
3251 TAATAATCGT GCGAACTCCC TTAAGTCTGG GGCCAATAAC ACTAATTTTG  
3301 GCGTGTATAG CCGTATTTTA ACCAACCAGC ATGAATTTGA CTTTGAAGCT  
3351 CAAGGGGCAC TAGGGAGCGA TCAATCAAGC TTGAATTTCA AAAGCGCTCT  
3401 ATTACAAGAT TTGAATCAAA GCTATCATT CTTAGCCTAT AGCGCTGCAA  
3451 CAAGAGCGAG CTATGGTTAT GACTTCGCGT TTTTtaggaa CGCTTTAGTG  
3501 TTAAGAACCA GCGTGGGTGT GAGCTATAAC CATTTAGGTT CAACCAACTT  
3551 TAAAGCAAC AGCACCAATC AAGTGGCTTT GAAAAATGGC TCTAGCAGTC  
3601 AGCATTTATT CAACGCTAGC GCTAATGTGG AAGCGCGCTA TTATTATGGG  
3651 GACACTTCAT ACTTCTACAT GAATGCTGGA GTTTTACAAG AGTTCGCTCA  
3701 TGTTGGCTCT AATAACGCCG CGTCTTTAAA CACCTTTAAA GTGAATGCCG  
3751 CTCGCAACCC TTAAATACC CATGCCAGAG TGATGATGGG TGGGGAATTA  
3801 AAATTAGCTA AAGAAGTGTT TTTGAATTTG GCGGTTGTTT ATTTGCACAA  
3851 TTTGATTTCC AATATAGGCC ATTTGCTTTC CAATTTAGGA ATGAGGTATA  
3901 GTTTCTAAAT ACCGCTCTTA AACCCATGCT CAAAGCATGG GTTTGAAATC  
3951 TTACAAAACA

FIG. 1C

ERSAT7RI ATT





4 / 14

1 MEIQQTHRKI NRPLVSLALV GALVSITPQQ SHAAFFTTVI IPAIVGGIAT  
51 GTAVGTVSGL LSWGLKQAE E ANKTPDKPDK VWRIQAGKGF NEFPNKEYDL  
101 YRSLSSKID GGWDWGNAAR HYWVKGGQQN KLEVDMKDAV GTYTL SGLRN  
151 FTGGDL DVNM QKATLRLGQF NGNSFTSYKD SADRTTRVIS TLKISQLIIL  
201 QKSTTRVGSG AGRKASSTVL TLQASEGITS DKNAEISLYD GATLNLASSS  
251 VKLMGNVWMG RLQYVGAYLA PSYSTINTSK VTGEVNFNHL TVGDKNAAQA  
301 GIIANKKTNI GTLDLWQSAG LNIIAPPEGG YKDKPNNTPS QSGAKNDKNE  
351 SAKNDKQESS QNNSNTQVIN PPNSAQKTEV QPTQVIDGPF AGGKDTV VNI  
401 NRINTNADGT IRVGGFKASL TTNA AHLHIG KGGVNLSNQA SGRSLIVENL  
451 TGNITVDGPL RVNNQVGGYA LAGSSANFEE KAGTDTKNGT ATFNNDISLG  
501 RFVNLKVD AH TANFKGIDTG NGGFNTLDFS GVTDKVNINK LITASTNVAV  
551 KNFNINELIV KTNGISVGEY THFSEDIGSQ SRINTVRLET GTRSLFSGGV  
601 KFKGGEK LVI DEFYYSPWNY FDARNIKNVE ITNKLAFGPQ GSPWGTSKLM  
651 FNNLT LGQNA VMDYSQFLNL TIQGDFINNQ GTINYLV RGG KVATLSVGNA  
701 AAMMFNNDID SATGFYKPLI KINSAQDLIK NTEHVLLKAK IIGYGNVSTG  
751 TNGISNVNLE EQFKERLALY NNNNRMDTCV VRNTDDIKAC GMAIGDQSMV  
801 NNP DNYKYLI GKAWKNIGIS KTANGSKISV YYLGNSTPTE NGGNTTNLPT  
851 NTTSNARSAN NALAQNAPFA QPSATPNLVA INQHDFGTIE SVFELANRSK  
901 DIDTLYANS G AQGRDLLQTL LIDSHDAGYA RKMIDATSAN EITKQLNTAT  
951 TTLNNIASLE HKTSG LQTLS LSNAMILNSR LVNLSRRHTN HIDSFAKRLQ  
1001 ALKDQKFASL ESAAEVLYQF APKYEKPTNV WANAIGGTSL NNGSNASLYG  
1051 TSAGVDAYLN GQVEAIVGGF GSYGYSSFNN RANSLNSGAN NTNFGVYSRI  
1101 LTNQHEFD FE AQGALGSDQS SLNFKSALLQ DLNQSYHYLA YSAATRASYG  
1151 YDFAFFRNAL VLKPSVGVS Y NHLGSTNFKS NSTNQVALKN GSSSQHLFNA  
1201 SANVEARYYY GDTSYFYMNA GVLQEF AHVG SNNAASLNTF KVNAARNPLN  
1251 THARVMMGGE LKLAKEVFLN LGVVYLHNLI SNIGHFASNL GMRYSF

FIG. 2

FIG. 3



ERSATZBLATT

CTCCATTTAAGCAACTCCATAGACCACCTAAAGAAACCTTTTTTTGAGGCTATCTTTGAA  
 GCTTAATTATACATGCTATAGTAGCATGACACACAAACCAACTATTTTTAGAACGCTT  
 TCAAAAGATTCAITTTCTTATTTCTTGTTCTTATTAAAGTCTTCTTCAATTTTAGCAATTT  
 CTTTTTCAATATTAAATAGTTAATGAAAAAATAAATGCTTGATATTGTTGAT  
 TTGACACTACAAAGATACCGATAGGTATGAACTAGGTATAGTAAGGAGAACAACTGACT  
 M T  
 AATAATCTTCAAGTAGCTTTTCTTAAAGTTGATAACGCTGTCGCTTCATACGATCTCGAT  
 23 N N L Q V A F L K V D N A V A S Y D P D  
 CAATTAAGGGAAGAACTACTCCAATAAGCGATCAAAATCCTACCAAAAAGAACTAGTAT  
 63 Q L R E E Y S N K A I K N P T K K N Q Y  
 GAATCTTCCACAAGAGCTTTTCAGAAATTTGGGATCAGCGTTACCGAAATTTTCAAGT  
 103 E S S T K S F Q K F G D Q R Y R I F T S  
 GAAATATCATACAACCCCTATCTTGATGATAAGAGAAAGCGGAGTTTTTGAATCT  
 143 E N I I Q P I L D D K E K A E F L K S  
 ATGGCGTGTGTTGATGAGTCTTGAAGAAAGGCAAGAGCAAGAAAAAATGGAGGCT  
 183 M G V F D E S L K E R Q E A E K N G E P  
 GATGCAAGAGCAATCAATCAAGAACCGATTCCCATGTCCCAACGAGATATAGCCACT  
 223 D V K E A I N Q E P V P H V Q P D I A T  
 AATTTTCTAAATTCACCTTTGGCGATATGGAAATGTTAGATGTTGAGGAGTCCCTGAC  
 263 N F S K F T L G D M E M L D V E G V A D  
 TTAATGGGAGTCATAATGGCATAGAACCTGAAAAGTTTTCATTGTTGTATGGGGCAAT  
 303 L M G S H N G I E P E K V S L L Y G G N  
 AACAATGGCTACATAATTAATGTCATATGAAAACGGCAGTGGCTTAGTCATAGCA  
 343 N N V A T I I N V H M K N G S G L V I A  
 GGCTCAACAGGACATTAAGTCAAGAGAGATCCAAACAAATAGATTTCATGGAATTT  
 383 G S Q R A L S Q E E I Q N K I D F M E F  
 ACTGAGATTAAAGATTTCCAAAAGACTTAAGGCTTATTAGACGCCCTTAGGGAATGAT  
 423 T E I K D F Q K D S K A Y L D A L G N D  
 AATGGGATTTGAGCTACACTCTCAAGATTATGGAAAAAGCAGATAAGCTTTAGAT  
 463 N G D L S Y T L K D Y G K K A D K A L D  
 TATTCTAATTTCAATACACCAACGCTCCCAAGATCCCAATAGGGGTAGGGGTTACG

FIG. 4 A

ERSATZBLATT

ATCTGCTTATGATTGTTTTCATTTTGTTCCTCCATGCGATCTTTGCGATCACAAC 120  
 CATGTGCTCACCTTGACTAACCATTCTCCACCATTACTTTASCCTTGATTGTTCT 240  
 TTGTAATTTGGGTAAAAATGTAATCGTCTAGCTTTAGACGGCTGCAACGATCGG 360  
 AATGAGAATGTTCAAGACATGAATGACTACTCAAGCGTGTAGCGATTTTTCAGTCT 480  
 AACGAAACCATTTGACCAACCAACCAACCGAGCGCTTTTAAACCCGACGAATTTATC 600  
 N E T I D Q Q P Q T E A A F N P Q Q F I  
 CAAAACCAATCGTTGATAAGAACGATAGGATAACAGGCAAGCTTTTGAAGGAATCTCG 720  
 Q K P I V D K N D R D N R Q A F E G I S  
 TTTTCAGACTTATCAATAAGAGCAATGATTAAATCAACAAGAGCAATCTCATTGATGA 840  
 F S D G F I N K S N D L I N K D N L I D V  
 TGGGTGTCCTCAAAACGATCCGCTCAAATCAACACCCGATCGATCCGAAATTTTATG 960  
 W V S H Q N D P S K I N T R S I R N F M  
 GCCAAACAATCTTTTCAGGGAATCATATAGGGAATCAATCCGACCGGATCAAAAGTTC 1080  
 A K Q S F A G I I I G N Q I R T D Q K F  
 ACTGGTGGGATTTGGTGGATATTTTCTCTCATTTATTTTGACAAAAACAATCTTCT 1200  
 T G G D W L D I F L S F I F D K K Q S S  
 ACCACCACGACATACAAGGCTTACCGCCTGAAGCTAGAGATTTACTTGATGAAGGGGT 1320  
 T T T D I Q G L P P E A R D L L D E R G  
 ATTGATCCCAATTACAGTTCAATCAATTTATTGATTCAATAACGCTCTGCTTCTGTG 1440  
 I D P N Y K F N Q L L I H N N A L S V  
 GGTGCTCTGGAGCTAGGATGATTGGAAGCCCGCTGTTGTTATAAGACCAACAAGGC 1560  
 G G P G A R H D W N A T V G Y K D Q Q G  
 GGTGGTGAAGAGGATTACAAACCTTAGTTTATCTCTACAAAGAGACCAACTCACA 1680  
 G G E K G I N N P S F Y L Y K E D Q L T  
 CTTGCACAAATAATGCTAATTAGACAACCTTGACGAGAGAGAGAGAGAGAGAGAGAG 1800  
 L A Q N N A K L D N L S E K E K E K F R  
 CGTATTGCTTTTGTCTTAAAAAGACACAAAAACATTTCAGCTTTTAAATGAGTTTGGT 1920  
 R I A F V S K K D T K H S A L I T E F G  
 AGGGAGAAAAATGTTACTCTTCAAGGTAGCTTAACACATGATGGCGTGTGTTTGTGAT 2040  
 R E K N V T L Q G S L K H D G V M F V D  
 AATGGCGTTTCCCATTTAGAGTAGGCTTTTAAACAGGTAGCTATCTTTAATTTGCTGAT 2160

FIG. 4 B

ERSATZBLATT

503 Y S N F K Y T N A S K N P N K G V G V T  
 TTAATAATCTCGTATCACTAGTTTCGTAGGGGAATTTAGAGGATAAACTAACCACT  
 543 L N N L A I T S F V R R N L E D K L T T  
 GAATTGGTTGGAAAACTTTAACTTCAATAAAGCTGTAGCTGACGCTAAACACAGGC  
 583 E L V G K T L N F N K A V A D A K N T G  
 CATTAGAGAAAGAGTAGAGAAAAAATTGGAGAGCAAAAGCGGCAACAAAAATAAATG  
 623 H L E K E V E K K L E S K S G N K N K M  
 GCTAATAGAGACCAAGAGCAATCGCTTACGCTCAGATCTTAAGGCGATCAAAAGGAA  
 663 A N R D A R A I A Y A Q N L K G I K R E  
 GAATTCAAAAATGGCAAAATAAGGATTTACGCAAGGCGAGAGAACACTAAAAGCCCTT  
 703 E F K N G K N K D F S K A E E T L K A L  
 AATGCAGCTTTGAATGAATTCAAAAATGGCAAAATAAGGATTTACGCAAGGTAACGCA  
 743 N A A L N E F K N G K N K D F S K V T Q  
 AAAGTTGATAATCTCAATCAAGCGGTATCAGTGGCTAAAGCAACGGGTGATTTTCAGTAGG  
 783 K V D N L N Q A V S V A K A T G D F S R  
 CAAAAAATGAAGTCTCAATGCTAGAAAAAATCTGAATATATCAATCCGTTAAGAT  
 823 Q K N E S L N A R K K S E I Y Q S V K N  
 AAAAACTTTTCGGACATCAAGAAAGAGTTGAATGCAAACTTGAAATTTCAATAACAA  
 863 K N F S D I K K E L N A K L G N F N N N  
 CAAGCAGCTAGCTTGAAGAACCCCTTACGCTCAAGTTGCTAAAAAGGTAATGCAAAA  
 903 Q A A S L E E P I Y A Q V A K K V N A K  
 CCTTTGAAAAAGGCATGAATAAGTTGATCTCAGTAAGGTAGGCTTTCAAGGAATCAA  
 943 P L K R H D K V D D L S K V G L S R N Q  
 TTTGGCAATCTAGACCAACGATAGACAAAGCTCAAGATTTCTACAAAAACACAACTCCCATG  
 983 F G N L E Q T I D K L K D S T K H N P M  
 TACGCTACTAACAGCCACATACGCATTAAATAGCAATATCAAAATGGAACCAATCAATGAA

FIG.4C

ERSATZBLATT

N G V S H L E V G F N K V A I F N L P D  
 AAAGGATTGCCCCACAGAAGCTAATAAGCTTATCAAGATTTTTTTGAGCAGCAACAAA 2280  
 K G L S P Q E A N K L I K D F L S S N K  
 AATTATGATGAAGTGAATAAAGCTCAGAAGATCTTGAAAAATCTCTAAGGAAACGAGAG 2400  
 N Y D E V K K A Q K D L E K S L R K R E  
 GAACCAAAAGCTCAAGCTAACAGCCAAAGAGATGAGATTTTTTGGTTGATCAATAAGAG 2520  
 E A K A Q A N S Q K D E I F A L I N K E  
 TTGTCTGATAAACTTGAATAATGTCAACAAGAATTTGAAGAGCTTTGATAAATCTTTTAT 2640  
 L S D K L E N V N K N L K D F D K S F D  
 AAAGTTGGTGAAAGATTAGGTATCAATCAATCAGAAATGGATTTCAAAAGTTGAAAACCTT 2760  
 K G S V K D L G I N P E W I S K V E N L  
 GCAAAAAGCGAGCTTGAAAAATCCGTTAAAGATGTGATCATCAATCAAAAGGTAACGGAT 2880  
 A K S D L E N S V K D V I I N Q K V T D  
 GTAGAGCAAGCGTTAGCGGATCTCAAAAATTTCTCAAAAGGAGCAATTTGGCCCAACAGCT 3000  
 V E Q A L A D L K N F S K E Q L A Q Q A  
 GGTGTGAATGGAACCCCTAGTCGGTAATGGGTTATCTCAAGCAGAGCCACAACTCTTTCT 3120  
 G V N G T L V G N G L S Q A E A T T L S  
 AACAAATGGAATCAAAAACGAACCCCATTTATGCTAAAGTTAATAAAAAGAAAGCAGGG 3240  
N N N G L K N E P I Y A K V N K K A G  
 ATTGACCGACTCAATCAATAAGTGGTTTGGGTTGTAGGGCAAGCAGCGGGCTTC 3360  
 I D R L N Q I A S G L G V V G Q A A G F  
 GAATTGGCTCAGAAAAATTGACAACTCTCAATCAAGCGGTATCAGAAGCTAAAGCAGGTTT 3480  
 E L A Q K I D N L N Q A V S E A K A G F  
 AATCTATGGTTGAAAGTGCAAAAAAGTACCTGCTAGTTTGTTCAGCGAACTAGACAAT 3600  
 N L W V E S A K K V P A S L S A K L D N  
 AAAGCGACCGGATGCTAACGCCAAAAAACCCCTGAGTGGCTCAAGCTCGTGAATGATAAG 3720

FIG.4D

ERSATZBLATT

1023 Y A T N S H I R I N S N I K N G A I N  
 ATAGTTGCGCATAATGTAGGAGCGTTCTTTGTGAGAGTATGATAAAATTGGCTTC  
 1063 I V A H N V G S V P L S E Y D K I G F  
 GTAAAGACACTAATTCTGGCTTTACGCAATTTTAAACCAATGATTTTCTACAGCA  
 1103 V K D T N S G F T Q F L T N A F S T A  
 GGTTCCAAAATCTTAAAGGATTAGGAATACCAAAACGCAAAACCCACCTTGT  
 1143 G F Q K S  
 TGAATGCTACCAATTCATGGTATCATATCCCCATACATTCTGTATCTAGCGTAGGAAG  
 AACTCTGTAAATCCCTATTATAGGGACACAGAGTGAGAACCAACTCTCCCTACGG  
 GACAGACACTAACGAAAGGCTTGTCTTTAAAGTCTGCATGGATATTTCTTACCCC  
 CGAAATTAATTAAAGGTTATAAGAGAGCATAACTAGAAACCAAGTAGCTATA  
 GAAAAATCAGAAAAACCATAGGAATTATCACACCTTATAATGCCCAAAAAAGACGCT  
 ATGCCTTTCAAGGTGAGAGGCAGATATTATTATTTCCACCGTGAAAACTTTGTG  
 ATCTCATTTTGTGGGTAAAAAGCTTTCTTTGAGAAATTTATGAAGCGATGAGAAGA  
 CATTCTTCGCTTCAAAACGCTTTCATAATCTCTAAAGCGCTTTATAATCAACAC  
 TTATTAGCGTTACAAATTTGAGCCATCTTTAGCTTGTTTTCTAGCCAGATCACATC  
 CTGCAAAATATCCTACAATAGCATCGCCCGAATGGATGAGTAGGGGGGTTTGAAG  
 TAAATAATCACTTCGGGAAATCTTTAAGGGAGTGAAATAATAACGCATGCAAGTT  
 TCGGAAACATTCAATAGCTTGTGTTTCAGGGCATTGTCTAAGCGTTGGATTGG  
 GCTAAATGCTTGGCTCAATCAGCCCCACAATAGGGATTTTGGAAATGCTTTTGCATC  
 TTGAAAAATCCAAAGCCTCTAAGCCCAATTTGCTTGATCGTAGTGGGGCTTTTAGTG  
 AGGCTTTTAAACGCTAAACCCCTCCACACCGCTATCAAAAACGCTATTTTTCATG  
 TCTTCATGTGCTTAGTTTGTGCAATTTTAGAATAGACAAAGCTT 5925

FIG. 4E

ERSATZBLATT

E K A T G M L T Q K N P E W L K L V N D K  
 AACCAAGAAGATATGAAGATTATTCTGATTCGTTCAAGTTTCCACCAGTTGAACAATGCT  
 3840 N Q K N M K D Y S D S F K F S T K L N N A  
 TCTTATTACTGCTTGGCGAGAGAAAAATCGGGAGCATGGAAATCAAGAACGTTAATACAAAAGGT  
 3960 S Y Y C L A R E N A E H G I K N V N T K G  
 CIAAAGCGAGGGGTTTTTAAATACCTCTTAGCAGAAATCCCAATCGTCTTAGTATTGGGA  
 4080  
 TGTGCAAGTTACGCCCTTTGGAGATATGATGTGAGACCTGTAGGGAATGCGTTGGAGCTCA  
 4200 GCAACATCAGCCTAGGAAGCCCAATCGTCTTTAGCGGTGGGCACCTTCACCTTAAATATCCC  
 4320 AAAAGACCTTAACCCCTTGTCTTAAATTAAGTTGATTGTGCTAGTGGGTTCTGCTATAGTG  
 4440 ACAAGATCAAGTTCAAAAAATCATAGAGCTTTAGAGCAAAATTGATCGGCTCTTAACCAAA  
 4560 TCGCATCAGAAAGTGGAAAAATACGGCTTCAAGAAATTTTGATGAGCTCAAAATAGACACTGTGG  
 4680 GTAATCTTTCTTCTTCTGTAGATTCTAAACGCTTGAATGTGGCTATTTCTAGGCAAAAGAAA  
 4800 ATATCTTTAGCGCTATTTTGAAGTCTGTAGATAGGTAATCTTTTCCAAAGATATCATTAGA  
 4920 AATACCTTATAGTGTGAGCTATAGCCCTTTTGGGAATGAGTATTTTGAAGGCGTATTTTG  
 5040 GCCGCTCGCATGAAATTCACCTTTAGGGAATGCGTGTGCAATTTTTTAAAGGCGTATTTTG  
 5160 GGCAAAATGCTCCATAAAATAGCCCTCAATTTTTGAGCGATTAAAGGGAATGCGTGAACC  
 5280 TCTAACCAATTCGCCCTCTAAATATCTTCTCAATCAAGGACACAAAAGAGAAGTGGCTAAA  
 5400 ATGCTCGCTTTTGTCCCTAGCACATAAATAGGGGCGTTTTTATCTTTTACTTGTGCTTGATC  
 5520 TCTCTAAGCTAGAGCGCTCGCTGTGTGATGCCACAATCAATAATTCATCTGGTGGGT  
 5640 CCATAAGGCACCTAGCCCGTATCGCCATAATAGATGATTTTCATCAAAATTTGCGCTTTTAA  
 5760 ACACCTTTTTTAAATTTAATGGGATTAAATAGGGAATTTTATTTTTCATTCATTAAAGTTTAAAT  
 5880

FIG. 4F

ERSATZBLATT

12 / 14

10 30 50  
AAGCTTGCTGTCATGATCACAAAAACACTAAAAACATTATTATTAAGGATACAAAATG M  
70 90 110  
GCAAAAGAAATCAAATTTTCAGATAGTGCAGAGAAACCTTTTATTTGAAGGCGTGAGGCAA  
A K E I K F S D S A R N L L F E G V R Q  
130 150 170  
CTCCATGACGCTGTCAAAGTAACCATGGGGCCAAGAGGCAGGAATGTATTGATCCAAAAA  
L H D A V K V T M G P R G R N V L I Q K  
190 210 230  
AGCTATGGCGCTCCAAGCATCACCAAAGACGGCGTGAGCGTGGCTAAAGAGATTGAATTA  
S Y G A P S I T K D G V S V A K E I E L  
250 270 290  
AGTTGCCCAGTAGCTAACATGGGGCGCTCAACTCGTTAAAGAAGTAGCGAGCAAAACCGCT  
S C P V A N M G A Q L V K E V A S K T A  
310 330 350  
GATGCTGCCGGCGATGGCACGACCACAGCGACCGTGCTAGCTTATAGCATTTTTTAAAGAA  
D A A G D G T T T A T V L A Y S I F K E  
370 390 410  
GGTTTGAGGAATATCACGGCTGGGGCTAACCTATTGAAGTGAAACGAGGCATGGATAAA  
G L R N I T A G A N P I E V K R G M D K  
430 450 470  
GCTGCTGAAGCGATCATTAAATGAGCTTAAAAAGCGAGCAAAAAAGTAGGCGGTAAAGAA  
A A E A I I N E L K K A S K K V G G K E  
490 510 530  
GAAATCACCCAAGTGGCGACCATTTCTGCAAACCTCCGATCACAATATCGGGAAACTCATC  
E I T Q V A T I S A N S D H N I G K L I  
550 570 590  
GCTGACGCTATGGAAAAAGTGGGTAAAGACGGCGTGATCACCGTTGAGGAAGCTAAGGGC  
A D A M E K V G K D G V I T V E E A K G  
610 630 650  
ATTGAAGATGAATTGGATGTCGTAGAAGGCATGCAATTTGATAGAGGCTACCTCTCCCCT  
I E D E L D V V E G M Q F D R G Y L S P

FIG. 5A

13 / 14

670 690 710  
 TATTTTGTAACGAACGCTGAGAAAATGACCGCTCAATTGGATAATGCTTACATCCTTTTA  
 Y F V T N A E K M T A Q L D N A Y I L L  
 730 750 770  
 ACGGATAAAAAAATCTCTAGCATGAAAGACATTCTCCCGCTACTAGAAAAAACCATGAAA  
 T D K K I S S M K D I L P L L E K T M K

790 810 HindIII  
 GAGGGCAAACCGCTTTTAATCATCGCTGAAGACATTGAGGGCGAAGCTTTAACGACTCTA  
 E G K P L L I I A E D I E G E A L T T L  
 850 870 890  
 GTGGTGAATAAATTAAGAGGCGTGTGAATATCGCAGCGGTAAAGCTCCAGGCTTTGGG  
 V V N K L R G V L N I A A V K A P G F G  
 910 930 950  
 GACAGAAGAAAAGAAATGCTCAAAGACATCGCTATTTTAACCGGCGGTCAAGTCATTAGC  
 D R R K E M L K D I A I L T G G Q V I S  
 970 990 1010  
 GAAGAATTGGGCTTGAGTCTAGAAAACGCTGAAGTGGAGTTTTTAGGCAAAGCTGGAAGG  
 E E L G L S L E N A E V E F L G K A G R  
 1030 1050 1070  
 ATTGTGATTGACAAAGACAACACCACGATCGTAGATGGCAAAGGCCATAGCGATGATGTT  
 I V I D K D N T T I V D G K G H S D D V  
 1090 1110 1130  
 AAAGACAGAGTCGCGCAGATCAAAACCCAAATTGCAAGTACGACAAGCGATTATGACAAA  
 K D R V A Q I K T Q I A S T T S D Y D K  
 1150 1170 1190  
 GAAAAATTGCAAGAAAGATTGGCTAAACTCTCTGGCGGTGTGGCTGTGATTAAAGTGGGC  
 E K L Q E R L A K L S G G V A V I K V G  
 1210 1230 1250  
 GCTGCGAGTGAAGTGGAAATGAAAGAGAAAAAAGACCGGGTGGATGACGCGTTGAGCGCG  
 A A S E V E M K E K K D R V D D A L S A  
 1270 1290 1310  
 ACTAAAGCGGCGGTTGAAGAAGGCATTGTGATTGGTGGCGGTGCGGCTCTCATTGCGCGG  
 T K A A V E E G I V I G G G A A L I R A

FIG. 5B

ERSAT7RI ATT

14 / 14

1330 1350 1370  
GCTCAAAAAGTGCATTTGAATTTGCACGATGATGAAAAAGTGGGCTATGAAATCATCATG  
A Q K V H L N L H D D E K V G Y E I I M  
1390 1410 1430  
CGCGCCATTAAAGCCCCATTAGCTCAAATCGCTATCAACGCTGGTTATGATGGCGGTGTG  
R A I K A P L A Q I A I N A G Y D G G V  
1450 1470 1490  
GTCGTGAATGAAGTAGAAAAACACGAAGGGCATTTTGGTTTTAACGCTAGCAATGGCAAG  
V V N E V E K H E G H F G F N A S N G K  
1510 1530 1550  
TATGTGGATATGTTTAAAGAAGGCATTATTGACCCCTTAAAGTAGAAAGGATCGCTCTA  
Y V D M F K E G I I D P L K V E R I A L  
1570 1590 1610  
CAAAATGCGGTTTCGGTTTCAAGCCTGCTTTTAACACAGAAGCCACCGTGCATGAAATC  
Q N A V S V S S L L L T T E A T V H E I  
1630 1650 1670  
AAAGAAGAAAAAGCGACTCCGGCAATGCCTGATATGGGTGGCATGGGCGGTATGGGAGGC  
K E E K A T P A M P D M G G M G G M G G  
1690 1710 1730  
ATGGGCGGCATGATGTAAGCCCGCTTGCTTTTTAGTATAATCTGCTTTTAAATCCCTTC  
M G G M M \*  
1750 1770 1790  
TCTAAATCCCCCCTTTCTAAAATCTCTTTTTTGGGGGGGTGCTTTGATAAACCGCTCG  
  
1810 1830  
CTTGTA AAAACATGCAACAAAAAATCTCTGTTAAGCTT

FIG. 5C



DECLARATION FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

HELICOBACTER PYLORI PROTEINS USEFUL FOR VACCINES AND DIAGNOSTICS

the specification of which (check one)    is attached hereto   x   was filed on March 2, 1993 as PCT/EP93/00472 and was amended on    (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56(a).

=====

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s) Number	Country	Day/Month/Year Filed	Priority Claimed	
			Yes	No
FI92 A 000052	IT	02 03 92	x	
PCT/EP93/00158	EP	25 01 93	x	

=====

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application Serial No.	Filing Date	Status
		Patented, Pending, Abandoned
EP 93/00472	03/02/93	Pending

=====

I hereby declare that all statements herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements and the like so made are punishable by fine or imprisonment or both, under Section 1001 of Title 18 of the United States code and that such

willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor: ANTONELLO COVACCI


Inventor's signature:  Date: 6.10.94

Residence: Vc. Provenzano, 8  
53100, Siena  
ITALY

Citizenship: ITALY

Post Office Address: Same as above

Full name of second inventor: MASSIMO BUGNOLI

Inventor's signature:  Date: 6.10.94

Residence: V. del Pozzo, 38  
53035, Monteriggioni  
ITALY

Citizenship: ITALY

Post Office Address: Same as above

Full name third inventor: JOHN TELFORD

Inventor's signature:  Date: 6 Oct 1994

Residence: Via S. Ambro, 43  
53010, Monteriggioni  
ITALY

Citizenship: ITALY

Post Office Address: Same as above

Full name of fourth inventor: GIOVANNI MACCHIA

Inventor's signature: Giovanni Macchia Date: October 14<sup>th</sup> 1994

Residence: Via Monte Velino 57  
67051 Avezzano (AQ)  
ITALY

Citizenship: ITALY

Post Office Address: Same as above

Full name of fifth inventor: RINO RAPPUOLI

Inventor's signature: [Signature] Date: 7/10/94

Residence: Via Calamandrei, 39  
53010 Quercegrossa (SI)  
ITALY

Citizenship: ITALY

Post Office Address: Same as above

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

## In Re Application of:

Antonello Covacci, Massimo Bugnoli, John  
Telford, Rini Rappuoli and Giovanni Macchia

**Group Art Unit:** Unassigned

**Examiner:** Unassigned

**For:** Helicobacter Pylori CAI Antigen Proteins  
Useful for Vaccines and Diagnostics

## DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name; and

I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a

☒ Utility Patent      ☐ Design Patent

is sought on the invention, whose title appears above, the specification of which:

- ☒ is attached hereto.
- ☐ was filed on \_\_\_\_\_ as Serial No. \_\_\_\_\_.
- ☒ said application having been amended by Preliminary Amendment.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to be material to the patentability of this application in accordance with 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a-d) of any **foreign**

**application(s)** for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of any application on which priority is claimed:

Priority Claimed (If X'd)	Country	Serial Number	Date Filed
<input checked="" type="checkbox"/>	Italy	FI92A 000052	March 2, 1992
<input checked="" type="checkbox"/>	PCT	EP93/00472	March 2, 1993
<input checked="" type="checkbox"/>	PCT	EP93/00158	January 25, 1993
<input type="checkbox"/>			

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to be material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Serial Number	Date Filed	Patented/Pending/Abandoned
08/471,491	June 6, 1995	
08/256,848	October 21, 1994	

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below:

Serial Number	Date Filed
---------------	------------

\_\_\_\_\_  
\_\_\_\_\_

I hereby appoint the following persons as attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

<u>Robert P. Blackburn</u>	Reg. No. <u>30,447</u>
<u>Kenneth M. Goldman</u>	Reg. No. <u>34,174</u>
<u>Alisa A. Harbin</u>	Reg. No. <u>33,895</u>
<u>Francis A. Paintin</u>	Reg. No. <u>19,386</u>
<u>Doreen Y. Trujillo</u>	Reg. No. <u>35,719</u>

Address all correspondence to:

Alisa A. Harbin, Esq.  
**CHIRON CORPORATION**  
Intellectual Property  
P.O. Box 8097  
Emeryville, CA 94662-8097  
Telephone No.: **(510) 923-2700**  
Facsimile No.: **(510) 655-3542**

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

<b>Name: Antonello Covacci</b>	
<b>Mailing Address:</b> Vc. Provenzano, 8 53100, Siena, Italy	<b>Signature</b>  <b>Date of Signature:</b> _____
<b>City/State of Actual Residence:</b> Siena, Italy	<b>Citizenship:</b> <u>Italy</u>

<b>Name: Massimo Bugnoli</b>	
<b>Mailing Address:</b> V. del Pozzo, 38 53035, Monteriggioni, Italy	<b>Signature</b>  <b>Date of Signature:</b> _____
<b>City/State of Actual Residence:</b> Monteriggioni, Italy	<b>Citizenship:</b> <u>Italy</u>

<b>Name: John Telford</b>	
<b>Mailing Address:</b> Via Sambuco, 43 53010, Monteriggioni, Italy	<b>Signature</b>  <b>Date of Signature:</b> _____
<b>City/State of Actual Residence:</b> Monteriggioni, Italy	<b>Citizenship:</b> <u>Italy</u>

<b>Name: Rino Rappuoli</b>	
<b>Mailing Address:</b> <b>Via Calamandrei</b> <b>53010 Quercegrossa (SI), Italy</b>	<b>Signature</b>
<b>City/State of Actual Residence:</b> Sienna, Italy	<b>Date of Signature:</b> _____ <b>Citizenship:</b> <u>Italy</u>

<b>Name: Giovanni Macchia</b>	
<b>Mailing Address:</b> Parkweg 31 2271 AD Voorburg (NL), Netherlands	<b>Signature</b>
<b>City/State of Actual Residence:</b> Voorburg, Netherlands	<b>Date of Signature:</b> _____ <b>Citizenship:</b> <u>Italy</u>



## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

- (i) APPLICANT: Covacci, Antonello  
Bugnoli, Massimo  
Telford, John  
Macchia, Giovanni  
Rappuoli, Rino
- (ii) TITLE OF INVENTION: Helicobacter Pylori Proteins Useful  
for Vaccines and Diagnostics
- (iii) NUMBER OF SEQUENCES: 7
- (iv) CORRESPONDENCE ADDRESS:
  - (A) ADDRESSEE: Chiron Corporation
  - (B) STREET: 4560 Horton Street
  - (C) CITY: Emeryville
  - (D) STATE: California
  - (E) COUNTRY: USA
  - (F) ZIP: 94608-2916
- (v) COMPUTER READABLE FORM:
  - (A) MEDIUM TYPE: Floppy disk
  - (B) COMPUTER: IBM PC compatible
  - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
  - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
  - (A) APPLICATION NUMBER: 08/471,491
  - (B) FILING DATE: 06-JUNE-1995
  - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
  - (A) NAME: McClung, Barbara G.
  - (B) REGISTRATION NUMBER: 33,113
  - (C) REFERENCE/DOCKET NUMBER: 0316.003
- (ix) TELECOMMUNICATION INFORMATION:
  - (A) TELEPHONE: (510) 601-2708
  - (B) TELEFAX: (510) 655-3542

## (2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 27 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GCAAGCTTAT CGATGTCGAC TCGAGCT

27

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 3960 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

AAAAAGAAAG GAAGAAAATG GAAATACAAC AAACACACCG CAAAATCAAT CGCCCTCTGG	60
TTTCTCTCGC TTTAGTAGGA GCATTAGTCA GCATCACACC GCAACAAAGT CATGCCGCCT	120
TTTTCACAAC CGTGATCATT CCAGCCATTG TTGGGGGTAT CGCTACAGGC ACCGCTGTAG	180
GAACGGTCTC AGGGCTTCTT AGCTGGGGGC TCAAACAAGC CGAAGAAGCC AATAAAACCC	240
CAGATAAACC CGATAAAGTT TGGCGCATTC AAGCAGGAAA AGGCTTTAAT GAATTCCCTA	300
ACAAGGAATA CGACTTATAC AGATCCCTTT TATCCAGTAA GATTGATGGA GGTTGGGATT	360
GGGGGAATGC CGCTAGGCAT TATTGGGTCA AAGGCGGGCA ACAGAATAAG CTTGAAGTGG	420
ATATGAAAGA CGCTGTAGGG ACTTATACCT TATCAGGGCT TAGAACTTT ACTGGTGGGG	480
ATTTAGATGT CAATATGCAA AAAGCCACTT TACGCTTGGG CCAATTCAAT GGCAATTCTT	540
TTACAAGCTA TAAGGATAGT GCTGATCGCA CCACGAGAGT GGATTTCAAC GCTAAAAATA	600
TCTCAATTGA TAATTTTGTA GAAATCAACA ATCGTGTGGG TTCTGGAGCC GGGAGGAAAG	660
CCAGCTCTAC GGTTTTGACT TTGCAAGCTT CAGAAGGGAT CACTAGCGAT AAAAACGCTG	720
AAATTTCTCT TTATGATGGT GCCACGCTCA ATTTGGCTTC AAGCAGCGTT AAATTAATGG	780
GTAATGTGTG GATGGGCCGT TTGCAATACG TGGGAGCGTA TTTGGCCCCT TCATACAGCA	840
CGATAAACAC TTCAAAAGTA ACAGGGGAAG TGAATTTTAA CCACCTCACT GTTGGCGATA	900

AAAACGCCGC TCAAGCGGGC ATTATCGCTA ATAAAAAGAC TAATATTGGC AACTTGGATT	960
TGTGGCAAAG CGCCGGGTTA AACATTATCG CTCCTCCAGA AGGTGGCTAT AAGGATAAAC	1020
CCAATAATAC CCCTTCTCAA AGTGGTGCTA AAAACGACAA AAATGAAAGC GCTAAAAACG	1080
ACAAACAAGA GAGCAGTCAA AATAATAGTA AACTCAGGT CATTAACCCA CCAATAGTG	1140
CGCAAAAAAC AGAAGTTCAA CCCACGCAAG TCATTGATGG GCCTTTTGCG GCGGCAAAG	1200
ACACGGTTGT CAATATCAAC CGCATCAACA CTAACGCTGA TGGCACGATT AGAGTGGGAG	1260
GGTTTAAAGC TTCTCTTACC ACCAATGCGG CTCATTTGCA TATCGGCAAA GCGGGTGTCA	1320
ATCTGTCCAA TCAAGCGAGC GGGCGCTCTC TTATAGTGGA AAATCTAACT GGAATATCA	1380
CGTTGATGG GCCTTTAAGA GTGAATAATC AAGTGGGTGG CTATGCTTTG GCAGGATCAA	1440
GCGCGAATTT TGAGTTTAAG GCTGGTACGG ATACCAAAAA CGGCACAGCC ACTTTTAATA	1500
ACGATATTAG TCTGGGAAGA TTTGTGAATT TAAAGGTGGA TGCTCATACA GCTAATTTTA	1560
AAGGTATTGA TACGGGTAAT GGTGGTTTCA ACACCTTAGA TTTTAGTGGC GTTACAGACA	1620
AAGTCAATAT CAACAAGCTC ATTACGGCTT CCACTAATGT GGCCGTTAAA AACTTCAACA	1680
TTAATGAATT GATTGTTAAA ACCAATGGGA TAAGTGTGGG GGAATATACT CATTTTAGCG	1740
AAGATATAGG CAGTCAATCG CGCATCAATA CCGTGCCTTT GGAAACTGGC ACTAGGTCAC	1800
TTTCTCTGCG GGGTGTTAAA TTTAAAGGTG GCGAAAAATT GGTTATAGAT GAGTTTACT	1860
ATAGCCCTTG GAATTATTTT GACGCTAGAA ATATTAAAAA TGTTGAAATC ACCAATAAAC	1920
TTGCTTTTGG ACCTCAAGGA AGTCCTTGGG GCACATCAAA ACTTATGTTC AATAATCTAA	1980
CCCTAGGTCA AAATGCGGTC ATGGATTATA GCCAATTTTC AAATTTAACC ATTCAAGGGG	2040
ATTCATCAA CAATCAAGGC ACTATCAACT ATCTGGTCCG AGGTGGGAAA GTGGCAACCT	2100
TAAGCGTAGG CAATGCAGCA GCTATGATGT TTAATAATGA TATAGACAGC GCGACCGGAT	2160
TTTACAAACC GCTCATCAAG ATTAACAGCG CTCAAGATCT CATTAAAAAT ACAGAACATG	2220
TTTTATTGAA AGCGAAAATC ATTGGTTATG GTAATGTTTC TACAGGTACC AATGGCATT	2280
GTAATGTAA TCTAGAAGAG CAATTCAAAG AGCGCCTAGC CCTTTATAAC AACAATAACC	2340
GCATGGATAC TTGTGTGGTG CGAAATACTG ATGACATTAA AGCATGCGGT ATGGCTATCG	2400
GCGATCAAAG CATGGTGAAC AACCCTGACA ATTACAAGTA TCTTATCGGT AAGGCATGGA	2460

AAAATATAGG GATCAGCAAA ACAGCTAATG GCTCTAAAAT TTCGGTGTAT TATTTAGGCA	2520
ATTCTACGCC TACTGAGAAT GGTGGCAATA CCACAAATTT ACCCACAAAC ACCACTAGCA	2580
ATGCACGTTT TGCCAACAAC GCCCTTGCAC AAAACGCTCC TTTCGCTCAA CCTAGTGCTA	2640
CTCCTAATTT AGTCGCTATC AATCAGCATG ATTTTGGCAC TATTGAAAGC GTGTTTGAAT	2700
TGGCTAACCG CTCTAAAGAT ATTGACACGC TTTATGCTAA CTCAGGCGCT CAAGGCAGGG	2760
ATCTCTTACA AACCTTATTG ATTGATAGCC ATGATGCGGG TTATGCCAGA AAAATGATTG	2820
ATGCTACAAG CGCTAATGAA ATCACCAAGC AATTGAATAC GGCCACTACC ACTTTAAACA	2880
ACATAGCCAG TTTAGAGCAT AAAACCAGCG GCTTACAAAC TTTGAGCTTG AGTAATGCGA	2940
TGATTTTAAA TTCTCGTTTA GTCAATCTCT CCAGGAGACA CACCAACCAT ATTGACTCGT	3000
TGCCCCAACG CTTACAAGCT TTAAAAGACC AAAAATTTCG TTCTTTAGAA AGCGCGGCAG	3060
AAGTGTGTGA TCAATTTGCC CCTAAATATG AAAACCTAC CAATGTTTGG GCTAACGCTA	3120
TGGGGGAAC GAGCTTGAAT AATGGCTCTA ACGCTTCATT GTATGGCACA AGCGCGGGCG	3180
TAGACGCTTA CCTTAACGGG CAAGTGGAAG CCATTGTGGG CGGTTTTGGA AGCTATGGTT	3240
ATAGCTCTTT TAATAATCGT GCGAACTCCC TTAACCTCTG GGCCAATAAC ACTAATTTTG	3300
GCGTGTATAG CCGTATTTTT GCCAACCAGC ATGAATTTGA CTTTGAAGCT CAAGGGGCAC	3360
TAGGGAGCGA TCAATCAAGC TTGAATTTCA AAAGCGCTCT ATTACAAGAT TTGAATCAAA	3420
GCTATCATTA CTTAGCCTAT AGCGCTGCAA CAAGAGCGAG CTATGGTTAT GACTTCGCGT	3480
TTTTTAGGAA CGCTTTAGTG TTAAAACCAA GCGTGGGTGT GAGCTATAAC CATTTAGGTT	3540
CAACCAACTT TAAAAGCAAC AGCACCAATC AAGTGGCTTT GAAAAATGGC TCTAGCAGTC	3600
AGCATTTATT CAACGCTAGC GCTAATGTGG AAGCGCGCTA TTATTATGGG GACACTTCAT	3660
ACTTCTACAT GAATGCTGGA GTTTTACAAG AGTTCGCTCA TGTTGGCTCT AATAACGCCG	3720
CGTCTTTAAA CACCTTTAAA GTGAATGCCG CTCGCAACCC TTAAATACC CATGCCAGAG	3780
TGATGATGGG TGGGGAATTA AAATTAGCTA AAGAAGTGTT TTTGAATTTG GGC GTTGT	3840
ATTGACACAA TTTGATTTCC AATATAGGCC ATTTGCTTC CAATTTAGGA ATGAGGTATA	3900
GTTTCTAAAT ACCGCTCTTA AACCCATGCT CAAAGCATGG GTTTGAAATC TTACAAAACA	3960

(2) INFORMATION FOR SEQ ID NO:3:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1296 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

```

Met Glu Ile Gln Gln Thr His Arg Lys Ile Asn Arg Pro Leu Val Ser
1           5           10           15
Leu Ala Leu Val Gly Ala Leu Val Ser Ile Thr Pro Gln Gln Ser His
20           25           30
Ala Ala Phe Phe Thr Thr Val Ile Ile Pro Ala Ile Val Gly Gly Ile
35           40           45
Ala Thr Gly Thr Ala Val Gly Thr Val Ser Gly Leu Leu Ser Trp Gly
50           55           60
Leu Lys Gln Ala Glu Glu Ala Asn Lys Thr Pro Asp Lys Pro Asp Lys
65           70           75           80
Val Trp Arg Ile Gln Ala Gly Lys Gly Phe Asn Glu Phe Pro Asn Lys
85           90           95
Glu Tyr Asp Leu Tyr Arg Ser Leu Leu Ser Ser Lys Ile Asp Gly Gly
100          105          110
Trp Asp Trp Gly Asn Ala Ala Arg His Tyr Trp Val Lys Gly Gly Gln
115          120          125
Gln Asn Lys Leu Glu Val Asp Met Lys Asp Ala Val Gly Thr Tyr Thr
130          135          140
Leu Ser Gly Leu Arg Asn Phe Thr Gly Gly Asp Leu Asp Val Asn Met
145          150          155          160
Gln Lys Ala Thr Leu Arg Leu Gly Gln Phe Asn Gly Asn Ser Phe Thr
165          170          175
Ser Tyr Lys Asp Ser Ala Asp Arg Thr Thr Arg Val Asp Phe Asn Ala
180          185          190
Lys Asn Ile Ser Ile Asp Asn Phe Val Glu Ile Asn Asn Arg Val Gly
195          200          205
Ser Gly Ala Gly Arg Lys Ala Ser Ser Thr Val Leu Thr Leu Gln Ala

```

210	215	220
Ser Glu Gly Ile Thr 225	Ser Asp Lys Asn Ala 230	Glu Ile Ser Leu Tyr Asp 235 240
Gly Ala Thr Leu Asn 245	Leu Ala Ser Ser Ser 250	Val Lys Leu Met Gly Asn 255
Val Trp Met Gly Arg 260	Leu Gln Tyr Val Gly 265	Ala Tyr Leu Ala Pro Ser 270
Tyr Ser Thr Ile Asn 275	Thr Ser Lys Val Thr 280	Gly Glu Val Asn Phe Asn 285
His Leu Thr Val Gly 290	Asp Lys Asn Ala Ala 295	Gln Ala Gly Ile Ile Ala 300
Asn Lys Lys Thr Asn 305	Ile Gly Thr Leu Asp 310	Leu Trp Gln Ser Ala Gly 315 320
Leu Asn Ile Ile Ala 325	Pro Pro Glu Gly Gly 330	Tyr Lys Asp Lys Pro Asn 335
Asn Thr Pro Ser Gln 340	Ser Gly Ala Lys Asn 345	Asp Lys Asn Glu Ser Ala 350
Lys Asn Asp Lys Gln 355	Glu Ser Ser Gln Asn 360	Asn Ser Asn Thr Gln Val 365
Ile Asn Pro Pro Asn 370	Ser Ala Gln Lys Thr 375	Glu Val Gln Pro Thr Gln 380
Val Ile Asp Gly Pro 385	Phe Ala Gly Gly Lys 390	Asp Thr Val Val Asn Ile 395 400
Asn Arg Ile Asn Thr 405	Asn Ala Asp Gly Thr 410	Ile Arg Val Gly Gly Phe 415
Lys Ala Ser Leu Thr 420	Thr Asn Ala Ala His 425	Leu His Ile Gly Lys Gly 430
Gly Val Asn Leu Ser 435	Asn Gln Ala Ser Gly 440	Arg Ser Leu Ile Val Glu 445
Asn Leu Thr Gly Asn 450	Ile Thr Val Asp Gly 455	Pro Leu Arg Val Asn Asn 460
Gln Val Gly Gly Tyr 465	Ala Leu Ala Gly Ser 470	Ser Ala Asn Phe Glu Phe 475 480
Lys Ala Gly Thr Asp 485	Thr Lys Asn Gly Thr 490	Ala Thr Phe Asn Asn Asp 495

Ile Ser Leu Gly Arg Phe Val Asn Leu Lys Val Asp Ala His Thr Ala  
 500 505 510  
 Asn Phe Lys Gly Ile Asp Thr Gly Asn Gly Gly Phe Asn Thr Leu Asp  
 515 520 525  
 Phe Ser Gly Val Thr Asp Lys Val Asn Ile Asn Lys Leu Ile Thr Ala  
 530 535 540  
 Ser Thr Asn Val Ala Val Lys Asn Phe Asn Ile Asn Glu Leu Ile Val  
 545 550 555 560  
 Lys Thr Asn Gly Ile Ser Val Gly Glu Tyr Thr His Phe Ser Glu Asp  
 565 570 575  
 Ile Gly Ser Gln Ser Arg Ile Asn Thr Val Arg Leu Glu Thr Gly Thr  
 580 585 590  
 Arg Ser Leu Phe Ser Gly Gly Val Lys Phe Lys Gly Gly Glu Lys Leu  
 595 600 605  
 Val Ile Asp Glu Phe Tyr Tyr Ser Pro Trp Asn Tyr Phe Asp Ala Arg  
 610 615 620  
 Asn Ile Lys Asn Val Glu Ile Thr Asn Lys Leu Ala Phe Gly Pro Gln  
 625 630 635 640  
 Gly Ser Pro Trp Gly Thr Ser Lys Leu Met Phe Asn Asn Leu Thr Leu  
 645 650 655  
 Gly Gln Asn Ala Val Met Asp Tyr Ser Gln Phe Ser Asn Leu Thr Ile  
 660 665 670  
 Gln Gly Asp Phe Ile Asn Asn Gln Gly Thr Ile Asn Tyr Leu Val Arg  
 675 680 685  
 Gly Gly Lys Val Ala Thr Leu Ser Val Gly Asn Ala Ala Ala Met Met  
 690 695 700  
 Phe Asn Asn Asp Ile Asp Ser Ala Thr Gly Phe Tyr Lys Pro Leu Ile  
 705 710 715 720  
 Lys Ile Asn Ser Ala Gln Asp Leu Ile Lys Asn Thr Glu His Val Leu  
 725 730 735  
 Leu Lys Ala Lys Ile Ile Gly Tyr Gly Asn Val Ser Thr Gly Thr Asn  
 740 745 750  
 Gly Ile Ser Asn Val Asn Leu Glu Glu Gln Phe Lys Glu Arg Leu Ala  
 755 760 765  
 Leu Tyr Asn Asn Asn Asn Arg Met Asp Thr Cys Val Val Arg Asn Thr  
 770 775 780 785 790 795

770					775					780					
Asp	Asp	Ile	Lys	Ala	Cys	Gly	Met	Ala	Ile	Gly	Asp	Gln	Ser	Met	Val
785					790					795					800
Asn	Asn	Pro	Asp	Asn	Tyr	Lys	Tyr	Leu	Ile	Gly	Lys	Ala	Trp	Lys	Asn
				805					810					815	
Ile	Gly	Ile	Ser	Lys	Thr	Ala	Asn	Gly	Ser	Lys	Ile	Ser	Val	Tyr	Tyr
			820					825					830		
Leu	Gly	Asn	Ser	Thr	Pro	Thr	Glu	Asn	Gly	Gly	Asn	Thr	Thr	Asn	Leu
		835					840					845			
Pro	Thr	Asn	Thr	Thr	Ser	Asn	Ala	Arg	Ser	Ala	Asn	Asn	Ala	Leu	Ala
	850					855					860				
Gln	Asn	Ala	Pro	Phe	Ala	Gln	Pro	Ser	Ala	Thr	Pro	Asn	Leu	Val	Ala
865					870					875					880
Ile	Asn	Gln	His	Asp	Phe	Gly	Thr	Ile	Glu	Ser	Val	Phe	Glu	Leu	Ala
				885					890					895	
Asn	Arg	Ser	Lys	Asp	Ile	Asp	Thr	Leu	Tyr	Ala	Asn	Ser	Gly	Ala	Gln
			900					905					910		
Gly	Arg	Asp	Leu	Leu	Gln	Thr	Leu	Leu	Ile	Asp	Ser	His	Asp	Ala	Gly
		915					920					925			
Tyr	Ala	Arg	Lys	Met	Ile	Asp	Ala	Thr	Ser	Ala	Asn	Glu	Ile	Thr	Lys
	930					935					940				
Gln	Leu	Asn	Thr	Ala	Thr	Thr	Thr	Leu	Asn	Asn	Ile	Ala	Ser	Leu	Glu
945					950					955					960
His	Lys	Thr	Ser	Gly	Leu	Gln	Thr	Leu	Ser	Leu	Ser	Asn	Ala	Met	Ile
				965					970					975	
Leu	Asn	Ser	Arg	Leu	Val	Asn	Leu	Ser	Arg	Arg	His	Thr	Asn	His	Ile
			980					985					990		
Asp	Ser	Phe	Ala	Lys	Arg	Leu	Gln	Ala	Leu	Lys	Asp	Gln	Lys	Phe	Ala
		995					1000					1005			
Ser	Leu	Glu	Ser	Ala	Ala	Glu	Val	Leu	Tyr	Gln	Phe	Ala	Pro	Lys	Tyr
	1010					1015					1020				
Glu	Lys	Pro	Thr	Asn	Val	Trp	Ala	Asn	Ala	Ile	Gly	Gly	Thr	Ser	Leu
1025					1030					1035					1040
Asn	Asn	Gly	Ser	Asn	Ala	Ser	Leu	Tyr	Gly	Thr	Ser	Ala	Gly	Val	Asp
				1045					1050					1055	



Ala Tyr Leu Asn Gly Gln Val Glu Ala Ile Val Gly Gly Phe Gly Ser  
                   1060                                  1065                                  1070  
 Tyr Gly Tyr Ser Ser Phe Asn Asn Arg Ala Asn Ser Leu Asn Ser Gly  
                   1075                                  1080                                  1085  
 Ala Asn Asn Thr Asn Phe Gly Val Tyr Ser Arg Ile Phe Ala Asn Gln  
                   1090                                  1095                                  1100  
 His Glu Phe Asp Phe Glu Ala Gln Gly Ala Leu Gly Ser Asp Gln Ser  
  1105                                  1110                                  1115                                  1120  
 Ser Leu Asn Phe Lys Ser Ala Leu Leu Gln Asp Leu Asn Gln Ser Tyr  
                                   1125                                  1130                                  1135  
 His Tyr Leu Ala Tyr Ser Ala Ala Thr Arg Ala Ser Tyr Gly Tyr Asp  
                                   1140                                  1145                                  1150  
 Phe Ala Phe Phe Arg Asn Ala Leu Val Leu Lys Pro Ser Val Gly Val  
                   1155                                  1160                                  1165  
 Ser Tyr Asn His Leu Gly Ser Thr Asn Phe Lys Ser Asn Ser Thr Asn  
                   1170                                  1175                                  1180  
 Gln Val Ala Leu Lys Asn Gly Ser Ser Ser Gln His Leu Phe Asn Ala  
  1185                                  1190                                  1195                                  1200  
 Ser Ala Asn Val Glu Ala Arg Tyr Tyr Tyr Gly Asp Thr Ser Tyr Phe  
                                   1205                                  1210                                  1215  
 Tyr Met Asn Ala Gly Val Leu Gln Glu Phe Ala His Val Gly Ser Asn  
                   1220                                  1225                                  1230  
 Asn Ala Ala Ser Leu Asn Thr Phe Lys Val Asn Ala Ala Arg Asn Pro  
                   1235                                  1240                                  1245  
 Leu Asn Thr His Ala Arg Val Met Met Gly Gly Glu Leu Lys Leu Ala  
  1250                                  1255                                  1260  
 Lys Glu Val Phe Leu Asn Leu Gly Val Val Tyr Leu His Asn Leu Ile  
  1265                                  1270                                  1275                                  1280  
 Ser Asn Ile Gly His Phe Ala Ser Asn Leu Gly Met Arg Tyr Ser Phe  
                                   1285                                  1290                                  1295

## (2) INFORMATION FOR SEQ ID NO:4:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 5925 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

CTCCATTTTA AGCAACTCCA TAGACCACTA AAGAACTTT TTTTGAGGCT ATCTTTGAAA	60
ATCTGTCCTA TTGATTTGTT TTCCATTTTG TTTCCCATGT GGATCTTG TG GATCACAAAC	120
GCTTAATTAT ACATGCTATA GTAAGCATGA CACACAAACC AACTATTTT TAGAACGCTT	180
CATGTGCTCA CCTTGACTAA CCATTTCTCC AACCATACTT TAGCGTTGCA TTTGATTTCT	240
TCAAAAAGAT TCATTTCTTA TTTCTTGTTT TTATTAAAGT TCTTTCATTT TAGCAAATTT	300
TTGTTAATTG TGGGTAAAAA TGTGAATCGT CCTAGCCTTT AGACGCCTGC AACGATCGGG	360
CTTTTTTCAA TATTAATAAT GATTAATGAA AAAAAAAAAA AATGCTTGAT ATTGTTGTAT	420
AATGAGAATG TTCAAAGACA TGAATTGACT ACTCAAGCGT GTAGCGATTT TTAGCAGTCT	480
TTGACACTAA CAAGATACCG ATAGGTATGA AACTAGGTAT AGTAAGGAGA AACAATGACT	540
AACGAAACCA TTGACCAACA ACCACAAACC GAAGCGGCTT TTAACCCGCA GCAATTTATC	600
AATAATCTTC AAGTAGCTTT TCTTAAAGTT GATAACGCTG TCGCTTCATA CGATCCTGAT	660
CAAAAACCAA TCGTTGATAA GAACGATAGG GATAACAGGC AAGCTTTTGA AGGAATCTCG	720
CAATTAAGGG AAGAATACTC CAATAAAGCG ATCAAAAATC CTACCAAAAA GAATCAGTAT	780
TTTTCAGACT TTATCAATAA GAGCAATGAT TTAATCAACA AAGACAATCT CATTGATGTA	840
GAATCTTCCA CAAAGAGCTT TCAGAAATTT GGGGATCAGC GTTACCGAAT TTTCAACAAGT	900
TGGGTGTCCC ATCAAAACGA TCCGTCTAAA ATCAACACCC GATCGATCCG AAATTTTATG	960
GAAAATATCA TACAACCCCC TATCCTTGAT GATAAAGAGA AAGCGGAGTT TTTGAAATCT	1020
GCCAAACAAT CTTTTGCAGG AATCATTATA GGAATCAAA TCCGAACGGA TCAAAAGTTC	1080
ATGGGCGTGT TTGATGAGTC CTTGAAAGAA AGGCAAGAAG CAGAAAAAAA TGGAGAGCCT	1140
ACTGGTGGGG ATTGGTTGGA TATTTTTCTC TCATTTATAT TTGACAAAAA ACAATCTTCT	1200
GATGTCAAAG AAGCAATCAA TCAAGAACCA GTTCCCCATG TCCAACCAGA TATAGCCACT	1260
ACCACCACCG ACATACAAGG CTTACCGCCT GAAGCTAGAG ATTTACTTGA TGAAAGGGGT	1320

AATTTTCTA	AATTCACCT	TGGCGATATG	GAAATGTTAG	ATGTTGAGGG	AGTCGCTGAC	1380
ATTGATCCCA	ATTACAAGTT	CAATCAATTA	TTGATTCACA	ATAACGCTCT	GTCTTCTGTG	1440
TTAATGGGGA	GTCATAATGG	CATAGAACCT	GAAAAAGTTT	CATTGTTGTA	TGGGGGCAAT	1500
GGTGGTCCTG	GAGCTAGGCA	TGATTGGAAC	GCCACCGTTG	GTTATAAAGA	CCAACAAGGC	1560
AACAATGTGG	CTACAATAAT	TAATGTGCAT	ATGAAAAACG	GCAGTGGCTT	AGTCATAGCA	1620
GGTGGTGAGA	AAGGGATTAA	CAACCCTAGT	TTTTATCTCT	ACAAAGAAGA	CCAACTCACA	1680
GGCTCACAAC	GAGCATTAAG	TCAAGAAGAG	ATCCAAAACA	AAATAGATTT	CATGGAATTT	1740
CTTGACAAAA	ATAATGCTAA	ATTAGACAAC	TTGAGCGAGA	AAGAGAAGGA	AAAATTCCGA	1800
ACTGAGATTA	AAGATTTCCA	AAAAGACTCT	AAGGCTTATT	TAGACGCCCT	AGGGAATGAT	1860
CGTATTGCTT	TTGTTTCTAA	AAAAGACACA	AAACATTGAG	CTTTAATTAC	TGAGTTTGGT	1920
AATGGGGATT	TGAGCTACAC	TCTCAAAGAT	TATGGGAAAA	AAGCAGATAA	AGCTTTAGAT	1980
AGGGAGAAAA	ATGTTACTCT	TCAAGGTAGC	CTAAAACATG	ATGGCGTGAT	GTTTGTTGAT	2040
TATTCTAATT	TCAAATACAC	CAACGCCTCC	AAGAATCCCA	ATAAGGGTGT	AGGCGTTACG	2100
AATGGCGTTT	CCCATTTAGA	AGTAGGCTTT	AACAAGGTAG	CTATCTTTAA	TTTGCCTGAT	2160
TTAAATAATC	TCGCTATCAC	TAGTTTCGTA	AGGCGGAATT	TAGAGGATAA	ACTAACCACT	2220
AAAGGATTGT	CCCCACAAGA	AGCTAATAAG	CTTATCAAAG	ATTTTTTGAG	CAGCAACAAA	2280
GAATTGGTTG	GAAAAACTTT	AAACTTCAAT	AAAGCTGTAG	CTGACGCTAA	AAACACAGGC	2340
AATTATGATG	AAGTGAAAAA	AGCTCAGAAA	GATCTTGAAA	AATCTCTAAG	GAAACGAGAG	2400
CATTTAGAGA	AAGAAGTAGA	GAAAAAATTG	GAGAGCAAAA	GCGGCAACAA	AAATAAAATG	2460
GAAGCAAAAG	CTCAAGCTAA	CAGCCAAAAA	GATGAGATTT	TTGCGTTGAT	CAATAAAGAG	2520
GCTAATAGAG	ACGCAAGAGC	AATCGCTTAC	GCTCAGAATC	TTAAAGGCAT	CAAAAGGGAA	2580
TTGTCTGATA	AACTTGAAAA	TGTCAACAAG	AATTTGAAAG	ACTTTGATAA	ATCTTTTGAT	2640
GAATTCAAAA	ATGGCAAAAA	TAAGGATTTT	AGCAAGGCAG	AAGAAACACT	AAAAGCCCTT	2700
AAAGGTTTCG	TGAAAGATTT	AGGTATCAAT	CCAGAATGGA	TTTCAAAAGT	TGAAAACCTT	2760
AATGCAGCTT	TGAATGAATT	CAAAAATGGC	AAAAATAAGG	ATTTCAGCAA	GGTAACGCAA	2820
GCAAAAAGCG	ACCTTGAAAA	TTCCGTTAAA	GATGTGATCA	TCAATCAAAA	GGTAACGGAT	2880

AAAGTTGATA ATCTCAATCA AGCGGTATCA GTGGCTAAAG CAACGGGTGA TTTCAGTAGG	2940
GTAGAGCAAG CGTTAGCCGA TCTCAAAAAT TTCTCAAAGG AGCAATTGGC CCAACAAGCT	3000
CAAAAAAATG AAAGTCTCAA TGCTAGAAAA AAATCTGAAA TATATCAATC CGTTAAGAAT	3060
GGTGTGAATG GAACCCTAGT CGGTAATGGG TTATCTCAAG CAGAAGCCAC AACTCTTTCT	3120
AAAAACTTTT CGGACATCAA GAAAGAGTTG AATGCAAAAC TTGGAAATTT CAATAACAAT	3180
AACAATAATG GACTCAAAAA CGAACCCATT TATGCTAAAG TTAATAAAAA GAAAGCAGGG	3240
CAAGCAGCTA GCCTTGAAGA ACCCATTTAC GCTCAAGTTG CTAAAAAGGT AAATGCAAAA	3300
ATTGACCGAC TCAATCAAAT AGCAAGTGGT TTGGGTGTTG TAGGGCAAGC AGCGGGCTTC	3360
CCTTTGAAAA GGCATGATAA AGTTGATGAT CTCAGTAAGG TAGGGCTTTC AAGGAATCAA	3420
GAATTGGCTC AGAAAATTGA CAATCTCAAT CAAGCGGTAT CAGAAGCTAA AGCAGGTTTT	3480
TTTGGCAATC TAGAGCAAAC GATAGACAAG CTCAAAGATT CTACAAAACA CAATCCCATG	3540
AATCTATGGG TTGAAAGTGC AAAAAAAGTA CCTGCTAGTT TGTGAGCGAA ACTAGACAAT	3600
TACGCTACTA ACAGCCACAT ACGCATTAAT AGCAATATCA AAAATGGAGC AATCAATGAA	3660
AAAGCGACCG GCATGCTAAC GCAAAAAAAC CCTGAGTGGC TCAAGCTCGT GAATGATAAG	3720
ATAGTTGCGC ATAATGTAGG AAGCGTTCCT TTGTCAGAGT ATGATAAAAT TGGCTTCAAC	3780
CAGAAGAATA TGAAAGATTA TTCTGATTCG TTCAAGTTTT CCACCAAGTT GAACAATGCT	3840
GTAAAAGACA CTAATTCTGG CTTTACGCAA TTTTAAACCA ATGCATTTTC TACAGCATCT	3900
TATTACTGCT TGGCGAGAGA AAATGCGGAG CATGGAATCA AGAACGTTAA TACAAAAGGT	3960
GGTTTCCAAA AATCTTAAAG GATTAAGGAA TACCAAAAAC GCAAAAACCA CCCCTTGCTA	4020
AAAGCGAGGG GTTTTTTAAT ACTCCTTAGC AGAAATCCCA ATCGTCTTTA GTATTTGGGA	4080
TGAATGCTAC CAATTCATGG TATCATATCC CCATACATTC GTATCTAGCG TAGGAAGTGT	4140
GCAAAGTTAC GCCTTTGGAG ATATGATGTG TGAGACCTGT AGGGAATGCG TTGGAGCTCA	4200
AACTCTGTAA AATCCCTATT ATAGGGACAC AGAGTGAGAA CCAAACCTCTC CCTACGGGCA	4260
ACATCAGCCT AGGAAGCCCA ATCGTCTTTA GCGGTTGGGC ACTTCACCTT AAAATATCCC	4320
GACAGACACT AACGAAAGGC TTTGTTCTTT AAAGTCTGCA TGGATATTTT CTACCCCAA	4380
AAGACTTAAC CCTTTGCTTA AAATTAAGTT TGATTGTGCT AGTGGGTTCG TGCTATAGTG	4440

CGAAAATTAA TTAAGGGTTA TAAAGAGAGC ATAAACTAGA AAAACAAGT AGCTATAACA	4500
AAGATCAAGT TCAAAAAATC ATAGAGCTTT TAGAGCAAAT TGATCGCGCT CTTAACCAAA	4560
GAAAAATCAG AAAAACCATA GGAATTATCA CACCTTATAA TGCCCAAAA AGACGCTTGC	4620
GATCAGAAGT GGAAAAATAC GGCTTCAAGA ATTTTGATGA GCTCAAATA GACACTGTGG	4680
ATGCCTTTCA AGGTGAAGAG GCAGATATTA TTATTTATTC CACCGTGAAA ACTTGTGGTA	4740
ATCTTTCTTT CTTGCTAGAT TCTAAACGCT TGAATGTGGC TATTTCTAGG GCAAAAGAAA	4800
ATCTCATTTT TGTGGGTAAA AAGTCTTTCT TTGAGAATTT ATGAAGCGAT GAGAAGAATA	4860
TCTTTAGCGC TATTTTGCAA GTCTGTAGAT AGGTAATCTT TTCCAAAGAT AATCATTAGA	4920
CATTCTTCGC TTCAAACGC TTTCATAAAT CTCTCTAAG CGCTTTATAA TCAACACAAT	4980
AGCCTTATAG TGTGAGCTAT AGCCCCTTTT TGGGAATTGA GTTATTTTGA CTTTAAATTT	5040
TTATTAGCGT TACAATTTGA GCCATTCTTT AGCTTGTTTT TCTAGCCAGA TCACATCGCC	5100
GCTCGCATGA AATCCACTT TAGGGAATGC GTGTGCATTT TTTTAAAGGG CGTATTTTTG	5160
CTGCAAATAT CCTACAATAG CATCGCCCGA ATGGATGAGT AGGGGGGGTG TTGAAAGGGC	5220
AAAATGCTCC ATAAAATAGC CCTCAATTTT TTGAGCGATT AAGGGAAAAT GCGTGCAACC	5280
TAAAATAATC ACTTCGGGAA AATCTTTAAG GGAGTGAAAT AATAACGCAT GCAAGTTTCT	5340
AACAATTTCG CCTCTAAAT ACTTTCTTCA ATCAAAGGCA CAAAAGAGA AGTGGCTAAA	5400
TGCGAAACAT TCAAATAGCC TTGTTGTTTC AGGGCATTGT CATAAGCGTT GGATTGGATC	5460
GTCGCTTTTG TCCCTAGCAC TAAAATAGGG GCGTTTTTAT CTTTACTTG TCGCTTGATC	5520
GCTAAAATGC TTGGCTCAAT CACGCCACA ATAGGGATTT TGAATGCTT TTGCATCTCT	5580
TCTAAAGCTA GAGCGCTCGC TGTGTTGCAT GCCACAATCA ATAATTCAAT CTGGTGCGGT	5640
TTGAAAAAAT CCAAAGCCTC TAAGCCAAAT TGCTTGATCG TAGTGGGGTC TTTAGTGCCA	5700
TAAGGCACTC TAGCCGTATC GCCATAATAG ATGATTTCAT CAAATAATTG CGCTTTTAAA	5760
AGGCTTTTTA AAACGCTAAA CCCTCCCACA CCGCTATCAA AAACGCCTAT TTTCATGACA	5820
CTTTTTTAAT TTAATGGGAT TAATTAGGGA TTTTATTTTT CATTCAATTA GTTTAAAAAT	5880
TCTTCATTGT CCTTAGTTTG TTGCATTTTA GAATAGACAA AGCTT	5925

(2) INFORMATION FOR SEQ ID NO:5:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1147 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

```

Met Thr Asn Glu Thr Ile Asp Gln Gln Pro Gln Thr Glu Ala Ala Phe
1      5      10      15
Asn Pro Gln Gln Phe Ile Asn Asn Leu Gln Val Ala Phe Leu Lys Val
20      25      30
Asp Asn Ala Val Ala Ser Tyr Asp Pro Asp Gln Lys Pro Ile Val Asp
35      40      45
Lys Asn Asp Arg Asp Asn Arg Gln Ala Phe Glu Gly Ile Ser Gln Leu
50      55      60
Arg Glu Glu Tyr Ser Asn Lys Ala Ile Lys Asn Pro Thr Lys Lys Asn
65      70      75      80
Gln Tyr Phe Ser Asp Phe Ile Asn Lys Ser Asn Asp Leu Ile Asn Lys
85      90      95
Asp Asn Leu Ile Asp Val Glu Ser Ser Thr Lys Ser Phe Gln Lys Phe
100     105     110
Gly Asp Gln Arg Tyr Arg Ile Phe Thr Ser Trp Val Ser His Gln Asn
115     120     125
Asp Pro Ser Lys Ile Asn Thr Arg Ser Ile Arg Asn Phe Met Glu Asn
130     135     140
Ile Ile Gln Pro Pro Ile Leu Asp Asp Lys Glu Lys Ala Glu Phe Leu
145     150     155     160
Lys Ser Ala Lys Gln Ser Phe Ala Gly Ile Ile Ile Gly Asn Gln Ile
165     170     175
Arg Thr Asp Gln Lys Phe Met Gly Val Phe Asp Glu Ser Leu Lys Glu
180     185     190
Arg Gln Glu Ala Glu Lys Asn Gly Glu Pro Thr Gly Gly Asp Trp Leu
195     200     205
Asp Ile Phe Leu Ser Phe Ile Phe Asp Lys Lys Gln Ser Ser Asp Val

```

210	215	220
Lys Glu Ala Ile Asn Gln Glu Pro Val Pro His Val Gln Pro Asp Ile 225 230 235 240		
Ala Thr Thr Thr Thr Asp Ile Gln Gly Leu Pro Pro Glu Ala Arg Asp 245 250 255		
Leu Leu Asp Glu Arg Gly Asn Phe Ser Lys Phe Thr Leu Gly Asp Met 260 265 270		
Glu Met Leu Asp Val Glu Gly Val Ala Asp Ile Asp Pro Asn Tyr Lys 275 280 285		
Phe Asn Gln Leu Leu Ile His Asn Asn Ala Leu Ser Ser Val Leu Met 290 295 300		
Gly Ser His Asn Gly Ile Glu Pro Glu Lys Val Ser Leu Leu Tyr Gly 305 310 315 320		
Gly Asn Gly Gly Pro Gly Ala Arg His Asp Trp Asn Ala Thr Val Gly 325 330 335		
Tyr Lys Asp Gln Gln Gly Asn Asn Val Ala Thr Ile Ile Asn Val His 340 345 350		
Met Lys Asn Gly Ser Gly Leu Val Ile Ala Gly Gly Glu Lys Gly Ile 355 360 365		
Asn Asn Pro Ser Phe Tyr Leu Tyr Lys Glu Asp Gln Leu Thr Gly Ser 370 375 380		
Gln Arg Ala Leu Ser Gln Glu Glu Ile Gln Asn Lys Ile Asp Phe Met 385 390 395 400		
Glu Phe Leu Ala Gln Asn Asn Ala Lys Leu Asp Asn Leu Ser Glu Lys 405 410 415		
Glu Lys Glu Lys Phe Arg Thr Glu Ile Lys Asp Phe Gln Lys Asp Ser 420 425 430		
Lys Ala Tyr Leu Asp Ala Leu Gly Asn Asp Arg Ile Ala Phe Val Ser 435 440 445		
Lys Lys Asp Thr Lys His Ser Ala Leu Ile Thr Glu Phe Gly Asn Gly 450 455 460		
Asp Leu Ser Tyr Thr Leu Lys Asp Tyr Gly Lys Lys Ala Asp Lys Ala 465 470 475 480		
Leu Asp Arg Glu Lys Asn Val Thr Leu Gln Gly Ser Leu Lys His Asp 485 490 495		

Gly	Val	Met	Phe	Val	Asp	Tyr	Ser	Asn	Phe	Lys	Tyr	Thr	Asn	Ala	Ser		
			500					505					510				
Lys	Asn	Pro	Asn	Lys	Gly	Val	Gly	Val	Thr	Asn	Gly	Val	Ser	His	Leu		
		515					520					525					
Glu	Val	Gly	Phe	Asn	Lys	Val	Ala	Ile	Phe	Asn	Leu	Pro	Asp	Leu	Asn		
	530					535					540						
Asn	Leu	Ala	Ile	Thr	Ser	Phe	Val	Arg	Arg	Asn	Leu	Glu	Asp	Lys	Leu		
545					550					555					560		
Thr	Thr	Lys	Gly	Leu	Ser	Pro	Gln	Glu	Ala	Asn	Lys	Leu	Ile	Lys	Asp		
				565					570					575			
Phe	Leu	Ser	Ser	Asn	Lys	Glu	Leu	Val	Gly	Lys	Thr	Leu	Asn	Phe	Asn		
			580					585					590				
Lys	Ala	Val	Ala	Asp	Ala	Lys	Asn	Thr	Gly	Asn	Tyr	Asp	Glu	Val	Lys		
		595					600					605					
Lys	Ala	Gln	Lys	Asp	Leu	Glu	Lys	Ser	Leu	Arg	Lys	Arg	Glu	His	Leu		
	610					615					620						
Glu	Lys	Glu	Val	Glu	Lys	Lys	Leu	Glu	Ser	Lys	Ser	Gly	Asn	Lys	Asn		
625					630					635					640		
Lys	Met	Glu	Ala	Lys	Ala	Gln	Ala	Asn	Ser	Gln	Lys	Asp	Glu	Ile	Phe		
				645				650						655			
Ala	Leu	Ile	Asn	Lys	Glu	Ala	Asn	Arg	Asp	Ala	Arg	Ala	Ile	Ala	Tyr		
			660				665						670				
Ala	Gln	Asn	Leu	Lys	Gly	Ile	Lys	Arg	Glu	Leu	Ser	Asp	Lys	Leu	Glu		
		675					680					685					
Asn	Val	Asn	Lys	Asn	Leu	Lys	Asp	Phe	Asp	Lys	Ser	Phe	Asp	Glu	Phe		
	690					695					700						
Lys	Asn	Gly	Lys	Asn	Lys	Asp	Phe	Ser	Lys	Ala	Glu	Glu	Thr	Leu	Lys		
705					710					715					720		
Ala	Leu	Lys	Gly	Ser	Val	Lys	Asp	Leu	Gly	Ile	Asn	Pro	Glu	Trp	Ile		
				725					730					735			
Ser	Lys	Val	Glu	Asn	Leu	Asn	Ala	Ala	Leu	Asn	Glu	Phe	Lys	Asn	Gly		
			740					745					750				
Lys	Asn	Lys	Asp	Phe	Ser	Lys	Val	Thr	Gln	Ala	Lys	Ser	Asp	Leu	Glu		
		755					760					765					
Asn	Ser	Val	Lys	Asp	Val	Ile	Ile	Asn	Gln	Lys	Val	Thr	Asp	Lys	Val		



770					775					780					
Asp	Asn	Leu	Asn	Gln	Ala	Val	Ser	Val	Ala	Lys	Ala	Thr	Gly	Asp	Phe
785					790					795					800
Ser	Arg	Val	Glu	Gln	Ala	Leu	Ala	Asp	Leu	Lys	Asn	Phe	Ser	Lys	Glu
			805						810					815	
Gln	Leu	Ala	Gln	Gln	Ala	Gln	Lys	Asn	Glu	Ser	Leu	Asn	Ala	Arg	Lys
			820					825					830		
Lys	Ser	Glu	Ile	Tyr	Gln	Ser	Val	Lys	Asn	Gly	Val	Asn	Gly	Thr	Leu
		835					840					845			
Val	Gly	Asn	Gly	Leu	Ser	Gln	Ala	Glu	Ala	Thr	Thr	Leu	Ser	Lys	Asn
	850					855					860				
Phe	Ser	Asp	Ile	Lys	Lys	Glu	Leu	Asn	Ala	Lys	Leu	Gly	Asn	Phe	Asn
865					870					875					880
Asn	Asn	Asn	Asn	Asn	Gly	Leu	Lys	Asn	Glu	Pro	Ile	Tyr	Ala	Lys	Val
				885					890					895	
Asn	Lys	Lys	Lys	Ala	Gly	Gln	Ala	Ala	Ser	Leu	Glu	Glu	Pro	Ile	Tyr
			900					905					910		
Ala	Gln	Val	Ala	Lys	Lys	Val	Asn	Ala	Lys	Ile	Asp	Arg	Leu	Asn	Gln
		915					920					925			
Ile	Ala	Ser	Gly	Leu	Gly	Val	Val	Gly	Gln	Ala	Ala	Gly	Phe	Pro	Leu
	930					935					940				
Lys	Arg	His	Asp	Lys	Val	Asp	Asp	Leu	Ser	Lys	Val	Gly	Leu	Ser	Arg
945					950					955					960
Asn	Gln	Glu	Leu	Ala	Gln	Lys	Ile	Asp	Asn	Leu	Asn	Gln	Ala	Val	Ser
			965						970					975	
Glu	Ala	Lys	Ala	Gly	Phe	Phe	Gly	Asn	Leu	Glu	Gln	Thr	Ile	Asp	Lys
		980						985					990		
Leu	Lys	Asp	Ser	Thr	Lys	His	Asn	Pro	Met	Asn	Leu	Trp	Val	Glu	Ser
		995					1000					1005			
Ala	Lys	Lys	Val	Pro	Ala	Ser	Leu	Ser	Ala	Lys	Leu	Asp	Asn	Tyr	Ala
	1010					1015					1020				
Thr	Asn	Ser	His	Ile	Arg	Ile	Asn	Ser	Asn	Ile	Lys	Asn	Gly	Ala	Ile
1025					1030					1035					1040
Asn	Glu	Lys	Ala	Thr	Gly	Met	Leu	Thr	Gln	Lys	Asn	Pro	Glu	Trp	Leu
			1045						1050					1055	

Lys Leu Val Asn Asp Lys Ile Val Ala His Asn Val Gly Ser Val Pro  
 1060 1065 1070

Leu Ser Glu Tyr Asp Lys Ile Gly Phe Asn Gln Lys Asn Met Lys Asp  
 1075 1080 1085

Tyr Ser Asp Ser Phe Lys Phe Ser Thr Lys Leu Asn Asn Ala Val Lys  
 1090 1095 1100

Asp Thr Asn Ser Gly Phe Thr Gln Phe Leu Thr Asn Ala Phe Ser Thr  
 1105 1110 1115 1120

Ala Ser Tyr Tyr Cys Leu Ala Arg Glu Asn Ala Glu His Gly Ile Lys  
 1125 1130 1135

Asn Val Asn Thr Lys Gly Gly Phe Gln Lys Ser  
 1140 1145

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 546 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Met Ala Lys Glu Ile Lys Phe Ser Asp Ser Ala Arg Asn Leu Leu Phe  
 1 5 10 15

Glu Gly Val Arg Gln Leu His Asp Ala Val Lys Val Thr Met Gly Pro  
 20 25 30

Arg Gly Arg Asn Val Leu Ile Gln Lys Ser Tyr Gly Ala Pro Ser Ile  
 35 40 45

Thr Lys Asp Gly Val Ser Val Ala Lys Glu Ile Glu Leu Ser Cys Pro  
 50 55 60

Val Ala Asn Met Gly Ala Gln Leu Val Lys Glu Val Ala Ser Lys Thr  
 65 70 75 80

Ala Asp Ala Ala Gly Asp Gly Thr Thr Thr Ala Thr Val Leu Ala Tyr  
 85 90 95

Ser Ile Phe Lys Glu Gly Leu Arg Asn Ile Thr Ala Gly Ala Asn Pro  
 100 105 110

Ile Glu Val Lys Arg Gly Met Asp Lys Ala Ala Glu Ala Ile Ile Asn  
 115 120 125  
 Glu Leu Lys Lys Ala Ser Lys Lys Val Gly Gly Lys Glu Glu Ile Thr  
 130 135 140  
 Gln Val Ala Thr Ile Ser Ala Asn Ser Asp His Asn Ile Gly Lys Leu  
 145 150 155 160  
 Ile Ala Asp Ala Met Glu Lys Val Gly Lys Asp Gly Val Ile Thr Val  
 165 170 175  
 Glu Glu Ala Lys Gly Ile Glu Asp Glu Leu Asp Val Val Glu Gly Met  
 180 185 190  
 Gln Phe Asp Arg Gly Tyr Leu Ser Pro Tyr Phe Val Thr Asn Ala Glu  
 195 200 205  
 Lys Met Thr Ala Gln Leu Asp Asn Ala Tyr Ile Leu Leu Thr Asp Lys  
 210 215 220  
 Lys Ile Ser Ser Met Lys Asp Ile Leu Pro Leu Leu Glu Lys Thr Met  
 225 230 235 240  
 Lys Glu Gly Lys Pro Leu Leu Ile Ile Ala Glu Asp Ile Glu Gly Glu  
 245 250 255  
 Ala Leu Thr Thr Leu Val Val Asn Lys Leu Arg Gly Val Leu Asn Ile  
 260 265 270  
 Ala Ala Val Lys Ala Pro Gly Phe Gly Asp Arg Arg Lys Glu Met Leu  
 275 280 285  
 Lys Asp Ile Ala Ile Leu Thr Gly Gly Gln Val Ile Ser Glu Glu Leu  
 290 295 300  
 Gly Leu Ser Leu Glu Asn Ala Glu Val Glu Phe Leu Gly Lys Ala Gly  
 305 310 315 320  
 Arg Ile Val Ile Asp Lys Asp Asn Thr Thr Ile Val Asp Gly Lys Gly  
 325 330 335  
 His Ser Asp Asp Val Lys Asp Arg Val Ala Gln Ile Lys Thr Gln Ile  
 340 345 350  
 Ala Ser Thr Thr Ser Asp Tyr Asp Lys Glu Lys Leu Gln Glu Arg Leu  
 355 360 365  
 Ala Lys Leu Ser Gly Gly Val Ala Val Ile Lys Val Gly Ala Ala Ser  
 370 375 380  
 Glu Val Glu Met Lys Glu Lys Lys Asp Arg Val Asp Asp Ala Leu Ser

385		390		395		400
Ala Thr Lys Ala	Ala Val Glu Glu Gly	Ile Val Ile Gly Gly Gly	Ala			
	405	410	415			
Ala Leu Ile Arg	Ala Ala Gln Lys Val	His Leu Asn Leu	His Asp Asp			
	420	425	430			
Glu Lys Val Gly Tyr	Glu Ile Ile Met Arg	Ala Ile Lys Ala	Pro Leu			
	435	440	445			
Ala Gln Ile Ala Ile	Asn Ala Gly Tyr Asp	Gly Gly Val Val	Val Asn			
	450	455	460			
Glu Val Glu Lys His	Glu Gly His Phe Gly	Phe Asn Ala Ser	Asn Gly			
	465	470	475	480		
Lys Tyr Val Asp	Met Phe Lys Glu Gly	Ile Ile Asp Pro	Leu Lys Val			
	485	490	495			
Glu Arg Ile Ala Leu	Gln Asn Ala Val Ser	Val Ser Ser Leu	Leu Leu Leu			
	500	505	510			
Thr Thr Glu Ala Thr	Val His Glu Ile Lys	Glu Glu Lys Ala	Thr Pro			
	515	520	525			
Ala Met Pro Asp Met	Gly Gly Met Gly Gly	Met Gly Gly Met	Gly Gly Met Gly Gly			
	530	535	540			
Met Met						
545						

## (2) INFORMATION FOR SEQ ID NO:7:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1838 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

AAGCTTGCTG TCATGATCAC AAAAAACACT AAAAAACATT ATTATTAAGG ATACAAAATG	60
GCAAAAGAAA TCAAATTTTC AGATAGTGCG AGAAACCTTT TATTTGAAGG CGTGAGGCAA	120
CTCCATGACG CTGTCAAAGT AACCATGGGG CCAAGAGGCA GGAATGTATT GATCCAAAAA	180

AGCTATGGCG CTCCAAGCAT CACCAAAGAC GCGGTGAGCG TGGCTAAAGA GATTGAATTA	240
AGTTGCCCAG TAGCTAACAT GGGCGCTCAA CTCGTTAAAG AAGTAGCGAG CAAAACCGCT	300
GATGCTGCCG GCGATGGCAC GACCACAGCG ACCGTGCTAG CTTATAGCAT TTTTAAAGAA	360
GGTTTGAGGA ATATCACGGC TGGGGCTAAC CCTATTGAAG TGAAACGAGG CATGGATAAA	420
GCTGCTGAAG CGATCATTA TGAGCTTAAA AAAGCGAGCA AAAAAGTAGG CGGTAAAGAA	480
GAAATCACCC AAGTGGCGAC CATTCTGCA AACTCCGATC ACAATATCGG GAAACTCATC	540
GCTGACGCTA TGGAAAAAGT GGGTAAAGAC GCGGTGATCA CCGTTGAGGA AGCTAAGGGC	600
ATTGAAGATG AATTGGATGT CGTAGAAGGC ATGCAATTTG ATAGAGGCTA CCTCTCCCCT	660
TATTTTGTAA CGAACGCTGA GAAAATGACC GCTCAATTGG ATAATGCTTA CATCCTTTTA	720
ACGGATAAAA AAATCTCTAG CATGAAAGAC ATTCTCCCGC TACTAGAAAA AACCATGAAA	780
GAGGGCAAAC CGCTTTTAAT CATCGCTGAA GACATTGAGG GCGAAGCTTT AACGACTCTA	840
GTGGTGAATA AATTAAGAGG CGTGTTGAAT ATCGCAGCGG TTAAAGCTCC AGGCTTTGGG	900
GACAGAAGAA AAGAAATGCT CAAAGACATC GCTATTTTAA CCGGCGGTCA AGTCATTAGC	960
GAAGAATTGG GCTTGAGTCT AGAAAACGCT GAAGTGGAGT TTTTAGGCAA AGCTGGAAGG	1020
ATTGTGATTG ACAAAGACAA CACCACGATC GTAGATGGCA AAGGCCATAG CGATGATGTT	1080
AAAGACAGAG TCGCGCAGAT CAAAACCCAA ATTGCAAGTA CGACAAGCGA TTATGACAAA	1140
GAAAAATTGC AAGAAAGATT GGCTAAACTC TCTGGCGGTG TGGCTGTGAT TAAAGTGGGC	1200
GCTGCGAGTG AAGTGGAAT GAAAGAGAAA AAAGACCGGG TGGATGACGC GTTGAGCGCG	1260
ACTAAAGCGG CGGTTGAAGA AGGCATTGTG ATTGGTGGCG GTGCGGCTCT CATTCGCGCG	1320
GCTCAAAAAG TGCATTTGAA TTTGCACGAT GATGAAAAAG TGGGCTATGA AATCATCATG	1380
CGCGCCATTA AAGCCCCATT AGCTCAAATC GCTATCAACG CTGGTTATGA TGGCGGTGTG	1440
GTCGTGAATG AAGTAGAAAA ACACGAAGGG CATTTTG GTT TTAACGCTAG CAATGGCAAG	1500
TATGTGGATA TGTTTAAAGA AGGCATTATT GACCCCTTAA AAGTAGAAAG GATCGCTCTA	1560
CAAAATGCGG TTTCGGTTTC AAGCCTGCTT TTAACCACAG AAGCCACCGT GCATGAAATC	1620
AAAGAAGAAA AAGCGACTCC GGCAATGCCT GATATGGGTG GCATGGGCGG TATGGGAGGC	1680
ATGGGCGGCA TGATGTAAGC CCGCTTGCTT TTAGTATAA TCTGCTTTTA AAATCCCTTC	1740

TCTAAATCCC	CCCCTTTCTA	AAATCTCTTT	TTGGGGGGG	TGCTTTGATA	AAACCGCTCG	1800
CTTGTA AAAA	CATGCAACAA	AAAATCTCTG	TTAAGCTT			1838